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Abstract 
Joceline Clare Triner 
 
Defining neurochemical properties and functions of primary sensory neurons 
in the rat trigeminal ganglion 
 
The trigeminal ganglion (TG) is a complex sensory structure and multiple lines of 
evidence suggest that significant differences exist in anatomical, neurochemical and 
physiological properties between it and its equivalent structure in the somatosensory 
system, the dorsal root ganglion (DRG).  This is likely to be a reflection, first on the 
unique areas of tissue innervation of the TG and second, on the unusual responses 
to injury which give rise to distinct pain symptoms such as toothache, migraine and 
temporomandibular joint disorders.  In an attempt to address this disparity in 
knowledge, we have carried out an in-depth in vivo study investigating neurochemical 
populations and cell size distributions of sensory neurons within the rat TG.  We have 
performed a detailed analysis of expression patterns for receptor components of 
important inflammatory mediators, NGF (TrkA), TNFα (p55) and IL-6 (gp130), along 
with the thermo-transducers TRPV1 and TRPM8.  For each analysis we have 
compared our findings with those of the rat DRG.   
 
We have shown a significantly larger population of NF200+ neurons within the TG 
(51%) compared to the DRG (40%), and most interestingly, the majority of NF200+ 
neurons in the TG were within the small to medium cell size range, conferring a 
nociceptive phenotype.  We have for the first time, determined expression of p55 and 
gp130 protein levels within neurochemically defined subpopulations of the TG.  We 
show that a large proportion (33%) of TG neurons, in particular 27% of NF200+ 
neurons co-express p55, and thereby have the potential to respond directly to TNFα.  
Furthermore, we have observed gp130 protein expression to be ubiquitous within the 
TG, suggesting all neurons, including non-nociceptors, could respond to IL-6. 
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In addition, we have utilised biochemical and electrophysiological techniques in vitro 
to measure the functional outcome of exposure of TG neurons to IL-6.  We have 
demonstrated that IL-6 activates the JAK/STAT signalling pathway, preferentially 
within NF200+ neurons.  Furthermore, we have shown that IL-6 sensitises the 
response of TG neurons to the TRPV1 agonist capsaicin, altering the gating 
properties and prolonging the opening time of the channel.   
Taken together, our findings support the emerging picture of a complex combinatorial 
pattern of co-expression of sensory neurochemicals, transducers and receptor 
components that help to define TG neuronal modality and function.  We would 
advocate caution in making generalisations across sensory ganglia in particular in 
extrapolating data from the DRG to the trigeminal ganglion. 
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CAPS Capsaicin 
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TN Trigeminal nerve 
TNFα Tumour necrosis factor-alpha 
TrkA Tropomyosin-related kinase A 
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TRPV1 Transient receptor potential vanilloid 1 
TRPV2 Transient receptor potential vanilloid 2 
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1.  Introduction 
1.1. Encoding senses 
The environment around us is constantly providing all our senses with a diverse 
range of stimuli and the question of how this information is integrated and interpreted 
has long been a fascination to many scientific disciplines.  Our ability to sense stimuli 
from the surrounding environment as well as to monitor internal parameters is 
fundamentally important to our survival (Lechner and Siemens, 2011).  Selective 
evolutionary pressure has therefore driven the acuity of the sensory nervous system 
towards accurately discriminating between diverse types of sensation (see Frings, 
2009).  This has led to the existence of phenotypically and functionally specialised 
sensory neurons which are finely tuned to respond to specific sensory modalities 
(Frings, 2009, Lallemend and Ernfors, 2012). 
Over the past 130 years, two main theories have been proposed to explain how the 
sensory nervous system encodes environmental stimuli into a final perceived 
sensation.  In the late 19th century three scientists, Magnus Blix, Alfred Goldscheider 
and Henry Donaldson put forward their specificity theory suggesting a direct 
relationship between the stimulus, receptor, afferent nerve and the percept, with each 
sensory modality being processed along specific labelled lines (see Norrsell et al., 
1999).  Secondly, the pattern theory, as exemplified in the gate control theory of pain, 
proposed that afferent fibres respond to a host of stimulus modalities and that the 
final percept depends upon the summation of inputs from various primary sensory 
afferents together with the brains interpretation and modulation of these patterns of 
activity (Melzack and Wall, 1962, 1965).   
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Over the past few decades, great progress has been made in understanding how 
distinct modalities are encoded.  The theory of population coding is now emerging 
which encompasses elements from both the specificity and pattern theories (Ma, 
2010).  The population coding theory hypothesises that different modalities are 
selectively processed along specific labelled lines, but in addition, that crosstalk, 
which can often be antagonistic, occurs between labelled lines within the CNS (Craig, 
2003, Ma, 2010, Prescott and Ratté, 2012).  Moreover, an important feature of this 
theory is that activation of a nerve fibre by a particular stimulus may not necessarily 
correlate with the sensation perceived (see Ma, 2010).  This paradox between 
stimulus and percept is exemplified during the processing of nociceptive information, 
as outlined below, and gives weight to the theory of population coding.  
1.2. Nociception and pain 
The term nociception was first used at the beginning of the 20th century by Charles 
Sherrington (1906) who suggested that any stimuli capable of injuring tissue be 
labelled ‘noxious’ and devised the terms ‘nociception’ and ‘nociceptor’ to define 
unique activity by selective afferents (see Perl, 2011).   Since this time, the 
nociceptive system  has been recognised as a discrete system responsible for the 
processing of noxious information and for the perception of pain (see Norrsell et al., 
1999).  However, to this day, pain perception remains an enigma, differing from the 
other senses, not only due to the particularly labile nature of the nociceptive system, 
but also as a result of the emotional component involved in the processing of 
nociceptive information (Craig, 2003, Colvin, 2006).   
Under normal circumstances, the sensory experience of pain is the expected 
outcome following activation of nociceptors by high threshold mechanical and 
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thermal stimuli and by algesic chemical modulators.  The experience of pain under 
normal conditions serves a useful biological function.  Short term sensitisation of 
nociceptors may result in physiological enhancement of pain perception enabling the 
injured part to be protected and allowing time for the healing process (Colvin, 2006).  
However, if sensitisation is prolonged, the plasticity of the nociceptive system can 
lead to pathological chronic pain conditions offering no biological advantage, and 
increasing suffering (see Woolf and Mannion, 1999(b)).  Furthermore, mechanisms 
distinguishing the transition from acute to chronic pain are presently poorly 
understood.  Currently chronic pain is often diagnosed based on temporal cut-offs, 
however, clinical experience suggests the transition is more accurately defined by an 
uncoupling between the observed pathology and the perceived pain, and decreased 
responsiveness to acute pain therapy (see Reichling and Levine, 2009).  One of the 
central goals in the study of pain mechanisms therefore is to understand how chronic 
pain is maintained or persists (see Costigan and Woolf, 2000).  
Following injury, the inflammatory process produces profound changes to the 
chemical milieu surrounding the peripheral terminals of nociceptors.  Inflammatory 
mediators such as cytokines, chemokines, kinins, purines, protons and neurotrophins 
are released from injured tissue, activated nociceptors or non-neural cells such as 
immune cells and keratinocytes.  Nociceptors express transducer proteins at their 
peripheral terminals which are gated by specific noxious temperatures, chemicals or 
mechanical forces.   Inflammatory mediators can act either directly or indirectly to 
sensitise nociceptors via these transducer proteins (see Basbaum et al., 2009). 
Sensitisation may occur via reductions in the threshold for activation of membrane 
transducers resulting in an increase in the excitability of the terminal membrane or by 
the increased expression of transducer proteins or both (see Basbaum et al., 2009).  
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Subsequent to sensitisation, nociceptors change from being exclusive detectors of 
noxious stimuli to being detectors of innocuous stimuli (see Woolf and Ma, 2007).  
Furthermore, activity evoked by nociceptors can induce a state of central 
sensitisation within the spinal cord whereby aberrant processing of sensory 
information can underlie such clinical states as hyperalgesia (an exaggerated or 
prolonged response, disproportionate to the noxious stimuli), and allodynia (pain in 
response to a previously innocuous stimuli) (see Coutaux et al., 2005).  These key 
mechanisms of neuronal plasticity in response to tissue damage are now well 
established and have been extensively reviewed over the past 20 years (Woolf and 
Costigan, 1999(a), Hill, 2001, Lewin et al., 2004, Woolf, 2004, Coutaux et al., 2005, 
Woolf and Ma, 2007, Basbaum et al., 2009, Ringkamp and Meyer, 2009, Woolf, 
2011, Sandkühler and Gruber-Schoffnegger, 2012).   
In summary, the schematic in Figure 1-1 illustrates the key mechanisms of peripheral 
and central sensitisation as follows: (A) Peripheral sensitisation (PS) – (1) Injury to 
and inflammation of tissue results in profound changes to the chemical milieu 
surrounding the peripheral terminals of nociceptors.  Inflammatory mediators such as 
NGF, TNFα and IL-6, are released from injured and inflammatory cells and bind to 
their cognate receptors on the peripheral terminals of nociceptors.  (2) Inflammatory 
mediator-initiated signalling leads to post-translational changes to pre-existing 
transducer proteins and ion channels on the nociceptor terminal.  For example, 
activation of TrkA by NGF activates the PLC/PKC signalling pathway resulting in the 
phosphorylation and sensitisation of TRPV1 to subsequent stimuli.  In addition, 
activation of TrkA leads to an increase in TRPV1 expression via the PI3K/PKC 
signalling pathway.  (3)  The sensitisation and increased expression of TRPV1 
augments the inward sodium current in the nociceptor terminal such that a 
depolarising stimulus produces greater excitation, thereby lowering the activation 
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threshold of these neurons.   (3)  These changes produce a state of heightened 
sensitivity within the nociceptor terminal such that further noxious or innocuous 
stimuli now produce exaggerated or prolonged responses.  (4)  PS manifests as 
hyperalgesia at the site of injury (primary hyperalgesia). 
(B) Central sensitisation (CS): (1) Afferent peripheral sensory neurons terminate on 
wide dynamic range cells (WDRC) within the CNS.  Following PS, WDRCs receive 
enhanced input from sensitised nociceptors.  (2)  Enhanced nociceptor input triggers 
the recruitment of ionotropic N-methyl-D-aspartate (NMDA) receptors, leading to 
temporal summation and the phenomenon of windup within the WDRC.  This results 
in a progressively increasing output during the course of a train of identical stimuli.  In 
addition, enhanced nociceptor input increases α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor conductance and enhances levels of AMPA 
receptor expression.  These modifications result in an increase in synaptic efficacy 
lasting long after the end of the conditioning stimuli (long term potentiation (LTP)).  
(3) Inflammatory mediator-initiated signalling results in an elevated release of 
synaptic modulators such as neuropeptides, which contribute to the sustained 
depolarisation of WDRCs.  (4, 5)  The majority of synaptic input to neurons is sub-
threshold, acting subliminally either because the synaptic input is too weak or that 
membrane excitability is controlled by inhibitory inputs.  However, following PS and 
CS, the increase in membrane excitability of WDRCs means that normally sub-
threshold inputs can be brought to threshold, such that previously innocuous, light 
touch, input from Aβ-fibers is now perceived as pain.  (6)  CS manifests as secondary 
hyperalgesia (hyperalgesia at the site of injury and outside of the site of injury) and 
allodynia.   
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Hypersensitivity may not always resolve itself, and pain may continue to be intense 
and often unremitting, becoming physiologically and psychologically debilitating.  
Under these circumstances, pain, as an acute warning and protective mechanism, 
has outlived its usefulness (see Basbaum et al., 2009).  A recent review by Tracey et 
al. (2009) used neuroimaging studies to investigate chronic pain.  Not only do they 
highlight the huge financial burden to society due to chronic pain, estimated at over 
€200 billion per annum in Europe and $150 billion per annum in the USA, but also 
suggest that chronic pain could be a disease state in its own right.  White et al. 
(2005) suggest that chronic pain is one of the most intractable and widespread 
conditions in addition to having a low treatment success.  Furthermore, they highlight 
the role of cytokines and chemokines involved in the inflammatory process as an 
important mechanism in the development of chronic pain.   
The vital role of inflammatory mediators in establishing many chronic pain conditions 
has also been recognised in recent epigenetic studies.  Histone deacetylase (HDAC) 
inhibitors have been shown to significantly improve symptoms of certain inflammatory 
diseases (Chung et al., 2003, Leoni et al., 2005, Glauben et al., 2006).  The effects of 
these inhibitors are believed to be mediated through suppression of crucial pro-
inflammatory cytokines such as TNFα (Leoni et al., 2002).  Indeed, the levels of 
inflammatory mediators such as TNFα, have been found to correlate with pain 
severity in patients with chronic pain conditions (see Reichling and Levine, 2009), 
and TNFα has been linked to neuropathic pain (Moalem and Tracey, 2006, Calvo et 
al., 2012).  Interestingly, the constitutively expressed TNFα receptor, p55, was 
demonstrated to have a major role in the development of chronic hyperalgesia 
(Sommer et al., 1998).   In addition, patients suffering from complex regional pain 
syndrome are shown to have significantly increased levels of both TNFα and IL-6 in 
blister fluid from affected areas (Heijmans-Antonissen et al., 2006).  Moreover, IL-6 
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has been shown to contribute significantly towards the pathogenesis of chronic pain 
(Zanjani et al., 2010). 
Another important inflammatory mediator is now known to be nerve growth factor 
(NGF) and its mode of action typifies the mechanism of sensitisation of peripheral 
nociceptor terminals.  NGF is a member of the neurotrophin family of proteins, 
originally identified as promoters of neuronal development and survival (Reichardt, 
2006).  However, NGF expression continues into adulthood and is now thought to 
contribute to the expression of a normal neuronal phenotype (Ritter et al., 1991).  In 
addition, it is considered to have a direct role as a mediator of peripheral sensitisation 
in chronic inflammatory states (Dmitrieva and McMahon, 1996) and an indirect role 
via mast cell degranulation (De Simone et al., 1990).  The interest in NGF as a key 
inflammatory mediator has grown.  Several studies have demonstrated increased 
levels of NGF upon inflammation and its contribution to inflammatory pain (Woolf et 
al., 1994, Lowe et al., 1997, Halliday et al., 1998, Kasai et al., 1998, Oddiah et al., 
1998).   
Furthermore, disruption within the central nervous system (CNS) such as deficiencies 
in noradrenergic inhibitory pathways have been linked with pain chronicity (Baron et 
al., 2012), along with the activation of microglia, suggested to be the driving force of 
chronic pain (see Guo and Schluesener, 2007).  Indeed, the important role of non-
neuronal cells in pain processing within the CNS is becoming widely recognised.  For 
instance, activated microglia release inflammatory mediators such as TNFα and IL-6, 
which induce a state of hyperexcitability within the CNS pain signalling pathways 
(see McMahon and Malcangio, 2009).  However, the importance of ongoing 
peripheral input to the maintenance of chronic pain is also widely recognised (see 
Gold and Gebhart, 2010), hence the continuing emphasis on the peripheral nervous 
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system for the development of drug strategies (Liu et al., 2011a).  Nevertheless, 
evidence suggests that peripheral and central mechanisms of persistent pain are 
intrinsically linked.  For instance, in a model of masseter muscle inflammation, 
activation of NMDA receptors on central terminals of TG neurons and resultant 
hyperalgesia, was dependent on glial cell activation and subsequent release of pro-
inflammatory cytokines (Guo et al., 2007).  Since NMDA receptors are fundamental 
to activity-dependent synaptic plasticity and persistent pain (see Thompson, 2009), 
this would suggest that both peripheral and central mechanisms are required for the 
maintenance of chronic pain.  Furthermore, the labile nature of the nociceptive 
system highlights the complication of attempting to apply theories of encoding to 
sensory neurons.  Under normal conditions, a line-labelled system may well function, 
however the diverse responses by sensory neurons to inflammatory mediators, 
would negate the idea of a line-labelled system, and offer support to the theory of 
population coding (Craig, 2003, Ma, 2010). 
Much of our understanding on the mechanism of pain has been derived from studies 
on somatic nociceptors whose somata lie within the dorsal root ganglia (DRG).  
Therefore, an extremely well established characterisation of the neuronal phenotype 
within the DRG now exists (see Basbaum et al., 2009).  Nociceptive information from 
the face and oral tissues is relayed to the central nervous system via sensory 
neurons within the trigeminal ganglia (TG).  In contrast to the somatosensory system, 
there is relatively less information regarding sensory neuron properties and their 
responses within the trigeminal system (Sessle, 2005).  This relative lack of 
knowledge has been exacerbated by the fact that chronic craniofacial pain models 
have been slow to appear (Sessle, 2005).  However, although there are similarities 
between the DRG and the TG, emerging evidence appears to be highlighting 
differences in anatomical, physiological and neurochemical properties.   
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Moreover the orofacial region is the site of some of the most common pains in the 
body and is also an area with special emotional and psychological meaning to the 
patient, making effective treatment of pain difficult (Sessle, 2000).  Furthermore, 
there are particular structures within the oral cavity, such as the tooth pulp, that have 
unique developmental and innervation properties (Sessle, 2005).  In addition there 
are a number of painful chronic oral conditions such as atypical trigeminal neuralgia, 
malignant neoplasms and burning mouth syndrome (Scully, 2008).  These relatively 
common conditions, with a population prevalence reported to be between 4.5% - 
15% (Bergdahl and Bergdahl, 1999; LeResche and Drangsholt, 2008), can only be 
effectively treated once the mechanisms underlying orofacial pain are fully 
understood (Woolf et al., 1998).   
1.3. Classification of sensory neurons 
In an attempt to specify a line-labelling system of primary afferent neurons, it has 
been the tradition in the field of sensory neurobiology to classify sensory neurons into 
functional sub-populations by the use of certain phenotypic, neurochemical and 
physiological characteristics (Priestley, 2009).  Various attributes such as extent of 
myelination, cell body size, conduction velocity (CV), electrophysiological responses, 
neurochemical phenotype and neurotrophin receptor expression have been used to 
describe functionally distinct subpopulations of sensory neurons (Zotterman, 1939, 
Harper and Lawson, 1985, Lawson and Waddell, 1991, Mense, 2009, Ringkamp and 
Meyer, 2009).  More recent advances in molecular studies and transgenic technology 
have provided further data that strongly support the presence of modality-specific 
sets of sensory neurons (see Liu et al., 2011a).  Axon diameter and extent of 
myelination was first recognised as being of physiological importance in the early 
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1930’s when it was found that nerve fibres fell into size groups and displayed 
different physiological characteristics (see Duncan, 1934).  It is now known that the 
extent of myelination determines the nerve’s CV (see McGlone and Reilly, 2010) and 
several classes of sensory afferent nerves are now recognised.  These are (in rat): 
Aα fibres which are thickly myelinated (20 µm diameter) and have the fastest CV (70-
120 m/s); Aβ fibres which are less thickly myelinated (10 µm diameter) and have a 
fast CV (35-75 m/s); Aδ fibres which are thinly myelinated (2.5 µm diameter) and 
have an intermediate CV (4-30 m/s); and C fibres which are unmyelinated (1 µm 
diameter) and have a slow CV (0.3-1.5) (Coutaux et al., 2005) (see Table 1-1).     
With the use of additional anatomical, physiological and neurochemical data, four 
general functional sub-populations of sensory neurons within the DRG have now 
been described.  Approximately 40% of the DRG neurons conduct in the Aα/β range, 
are thickly myelinated, with the majority having medium to large sized cell bodies 
(>500 µm²), and have been physiologically classified as low threshold 
mechanoreceptors or proprioceptors.  These neurons are neurochemically 
distinguished by their expression of the phosphorylated heavy chain (200kDa) 
neurofilament (NF200) (Michael and Priestley, 1999).  A further 40% of DRG neurons 
constitutively express neuropeptides and are identified by their expression of 
calcitonin gene-related peptide (CGRP).  The majority of these have small cell body 
size (<500 µm²), are mostly unmyelinated C fibre nociceptors and are termed 
peptidergic nociceptors (Price and Flores, 2007).   A group of neurons overlap with 
the previous two groups with regard to their neurofilament and neuropeptide 
properties.   These neurons express NF200 and CGRP, are thinly myelinated with 
small-to-medium sized cell bodies (<1100 µm²), and are mostly Aδ high threshold 
mechanoreceptors (see McMahon and Priestley, 2005).  A final 30% of DRG neurons 
are identified for their binding of isolectin-B4 (IB4) from the plant Griffonia 
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simplicifolia.  The majority do not express neuropeptides, have small cell body size 
and are mostly unmyelinated C fibre nociceptors, termed non-peptidergic nociceptors 
(Fang et al., 2006).  However, approximately 10% of this group overlaps that of the 
peptidergic nociceptors by expressing low levels of neuropeptides (McMahon and 
Priestley, 2005).   
  
Further distinction can be made when examining the expression of neurotrophin 
receptors and transducer proteins.  For instance, neurotrophin receptor expression 
within peptidergic and non-peptidergic populations is strikingly different.  The majority 
of peptidergic neurons express trkA, the receptor for NGF, and approximately 20% of 
these also express NF200 and are thought to correspond to the population of Aδ high 
threshold mechanoreceptors.  Non-peptidergic neurons however, respond to glial cell 
line-derived neurotrophic factor (GDNF) by the expression of its receptor components 
GFRα1 and GFRα2 along with its co-receptor molecule Ret (McMahon and Priestley, 
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2005).   Expression of one or more of the thermo-sensitive family of transient 
receptor potential ion channels (TRPV1, TRPV2, TRPA1) may also confer certain 
functional distinctions to neuronal populations.  TRPV1 is gated in response to 
noxious heat (>43°C), capsaicin and protons (Caterina and Julius, 2001), and TRPA1 
by noxious cold (<18°C) and pungent isothiocyanate compounds (Huang et al., 
2006b).  TRPA1 is frequently co-expressed with TRPV1 in both peptidergic and non-
peptidergic nociceptors (Guo et al., 1999, Michael and Priestley, 1999, Kobayashi et 
al., 2005) conferring a polymodal function to these nociceptors.  Such co-expression 
may explain the paradoxical burning sensation of extreme cold (Tominaga and 
Caterina, 2004, Huang et al., 2006b).  The high threshold vanilloid receptor 
homologue (TRPV2) gated by temperatures above 52°C, is expressed on a 
population of Aδ high threshold mechanoreceptors co-expressing NF200, CGRP and 
trkA (Caterina et al., 1999) again conferring a polymodal function to this population of 
nociceptors.      
However, using such classifications as a way of conferring modality specificity to 
neuronal sub-populations is now becoming recognised as a considerable 
oversimplification.  For instance, in the rat, about 20% of fibres conducting in the 
Aα/Aβ range are nociceptors (Djouhri and Lawson, 2004).  Conversely, cutaneous 
non-nociceptors conduct across all CV ranges (Perl, 1992, Lawson, 2002).  Indeed, 
in studies on rat DRG, 19% and 12% of cells conducting in the Aδ and C ranges 
respectively were non-nociceptors (Fang et al., 2005).  The use of cell body size 
alone as an indicator of function can also be misleading.  Although small cell size 
indicates a higher probability of nociceptive function, some neurons within the large 
cell size range are nociceptive (Harper and Lawson, 1985).  A significant number of 
C-fibres have been found to express markers for both peptidergic and non-
peptidergic populations and are responsive to NGF and GDNF (Bennett et al., 
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1998(b), Michael and Priestley, 1999, Fang et al., 2006).  Furthermore, a large 
number of so-called non-peptidergic sensory neurons identified by their binding of 
IB4, express trkA and neuropeptides (Kashiba et al., 2001).   
TRPA1, which was originally described as being only present in TRPV1 expressing 
neurons, is now accepted as being more widely distributed with 40% of total rat DRG 
profiles showing expression of TRPA1 (Kobayashi et al., 2005).  However, with only 
7-25% of neurons responding to temperatures below the activation threshold for this 
transducer, it has been suggested that additional mechanisms may be involved in the 
transduction of cold stimuli including the possibility of inhibitory modulation (Reid and 
Flonta, 2001).  Alternatively, there may be a requirement for the combinatorial co-
expression of ion channels and transducers, in order for response to cold stimuli to 
occur (see Belmonte and Viana, 2008).   
TRPM8 belongs to the thermo-sensitive family of transient receptor potential ion 
channels and is activated by cooling (<25°C).  TRPM8 and TRPA1 are purported to 
be major ion channels sensing cool and cold temperatures respectively (Huang et al., 
2006b).  The controversy over the expression of TRPA1 has raised the question of 
organ-specific differences in TRP-mediated detection of cold, with the suggestion 
that TRPM8 is responsible for this function within the somatosensory system, whilst 
the vagal system uses TRPA1 to report cold temperatures (see Lechner and 
Siemens, 2011).  The role of TRPA1 in cold sensation has been further questioned in 
a study using selective blockade of TRPA1 channels (Chen et al., 2011).  They found 
that noxious cold sensation was unaffected under normal conditions and suggest 
distinct roles for TRPA1 in physiological and pathological states.  This confirms the 
findings of a previous study that suggested TRPA1 is a mediator of cold 
hypersensitivity only under pathological conditions (del Camino et al., 2010). 
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What appears to be emerging from the literature is that the perception of a single 
stimulus may require the expression of several transduction mechanisms or the 
combinatorial co-expression of receptors, transducers and ion channels, which 
together confer specificity (see Belmonte and Viana, 2008, Liu et al., 2011a).   A 
common feature found in sensory neurons of different modalities is the formation of a 
transduction complex by the co-assembly of a large number of transducer proteins.  
These transduction complexes confer considerable plasticity to the sensory neuron 
which may contribute towards differences seen in adaptation and response 
mechanisms depending on target innervation (see Frings, 2009).  Indeed, an 
hypothesis is now emerging, that of peripheral regulation of neuronal phenotype (see 
Hargreaves, 2011).  This is supported by recent studies identifying phenotypic 
differences in sensory neurons depending on their target tissue (see Frings, 2009, 
Kiasalari et al., 2010, Hargreaves, 2011).  Finally, a new concept is developing 
regarding the role of epithelial cells in sensory transduction and whether their 
expression of TRP channels can contribute towards the transduction of physical 
stimuli (Lumpkin and Caterina, 2007).  
A further point to consider when applying generalisations regarding functional 
modalities to neuronal populations and their ultimate extension to human studies, is 
the variation between species in levels of expression and co-expression of molecules 
and transducer proteins.  For example, in rats a large proportion of both peptidergic 
and non-peptidergic neurons express TRPV1, whilst in mice, only a minority of non-
peptidergic neurons are found to express TRPV1 (see Ringkamp and Meyer, 2009).  
Furthermore, in mice, the distinction between peptidergic and non-peptidergic 
neurons is clear, whereas in rats, this distinction is more complex (Price and Flores, 
2007).  In studies examining the proportion of nociceptors conducting in the Aβ fibre 
range, values ranged from 18% - 65% depending on the species being investigated 
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(cat, guinea pig, monkey, mouse, rat) (see Lawson, 2002, Djouhri and Lawson, 
2004).  Expression of certain transducer proteins also appear to be different between 
species.  For instance, expression of TRPA1 and TRPM8 mRNA in rat DRG was 
shown to be 30% and 23% respectively (Kobayashi et al., 2005), however in mice 
DRG, it was 4% and 5-10% respectively (Peier et al., 2002, Story et al., 2003).  
Different methodologies can also lead to variations in results between studies.  Of 
particular interest are the findings of one study investigating the variations in 
expression of glutaminase, TRPV1 and the voltage-gated sodium channel Nav1.8 in 
rat DRG.  Their results showed that increasing the concentration of fixative from 
0.25% - 4%, significantly reduced the levels of expression in all three markers.  In 
addition, increasing antibody incubation times from 2 h to 192 h significantly 
increased levels of expression in all three markers (Hoffman et al., 2010).  A criticism 
has also been made on the explosion of nucleic acid studies, focussing on mRNA 
expression, which often ignore the fact that sensory neurons are primarily made of 
protein and that the main method of communication is via electrical impulses 
(Costigan, 2012).  The promise of quantitative peptide analysis en masse using mass 
spectrometry however, should hopefully provide us with a clearer picture of the in 
vivo state (Costigan, 2012). 
It is clear from the above, that the functional classification of sensory neurons is a far 
more complex and perplexing process than originally thought.  Much of our 
understanding of transduction and encoding of stimuli within the sensory nervous 
system is derived from studies on populations of somatosensory neurons.  However, 
the trigeminal nervous system displays distinct organisational characteristics and 
unique areas of innervation which may confer distinct response mechanisms.  
Moreover, a more complex picture is emerging with regard to the functional 
classification of sensory neurons, that of a characteristic combinatorial expression 
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pattern of a number of receptors, transducers and ion channels, which together 
confer modality specificity (Belmonte and Viana, 2008).  In light of these 
considerations, the necessity for further molecular studies on sensory neurons within 
the trigeminal nervous system is even greater. 
1.4. Trigeminal nerve anatomy 
The trigeminal nerve is the largest and most extensively distributed of the cranial 
nerves.  It is a mixed sensory-motor nerve, transmitting sensory information from the 
orofacial region and motor innervation to the muscles of mastication (Norrsell et al., 
1999).  The trigeminal nerve projects to three sensory nuclei and from one motor 
nucleus which extend through much of the brainstem.  Central processes of the 
trigeminal nerve carrying sensory information enter the brainstem, synapsing on 
second-order neurons within the trigeminal brainstem sensory nuclear complex 
(VBSNC).  The VBSNC extends from the midbrain to medulla with the mesencephalic 
nucleus within the midbrain, main sensory nucleus within the pons and spinal tract 
nucleus within the medulla.  The spinal tract nucleus is further split into three sub-
nuclei, namely oralis, interporalis and caudalis (Sessle, 1986, Lumpkin and Caterina, 
2007).  The main sensory nucleus mediates the tactile sensation of light touch and 
pressure.  The mesencephalic nucleus mediates proprioceptive information 
controlling the strength of the bite and the spinal tract nucleus conveys sensation of 
pain and temperature (Colvin, 2006).  The smaller motor root of the trigeminal nerve 
originates from cell bodies within the motor nucleus located in the upper pons, medial 
to the main sensory nucleus which receives sensory proprioceptive input from the 
mesencephalic nucleus (Lumpkin and Caterina, 2007, Mense, 2009, Fernandes et 
al., 2012).  Afferent fibres of the mesencephalic nucleus convey proprioceptive 
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information from the teeth, palate and temporomandibular joint to motor neurons 
within the motor nucleus which convey impulses to control bite force and mastication 
(Lechner and Siemens, 2011).     
Sensory neurons throughout the VBSNC project to higher CNS centres such as the 
thalamus, cerebellum, superior colliculus, periaqueductal grey, reticular formation 
and pontine parabrachial nucleus (Sessle et al., 2008).  More specifically, 
proprioceptive and low threshold sensory information is carried to the ventral 
posteromedial nucleus of the thalamus via the trigeminal lemniscus, whereas 
nociceptive sensory information reaches the intralaminar nuclei (mediodorsalis, 
centralis lateralis and parafascicularis nuclei) of the contralateral thalamus via the 
trigeminothalamic tract.   From the thalamus, trigeminal sensory information travels 
via the posterior limb of the internal capsule to the lateral region of the postcentral 
gyrus of the primary sensory cortex (Belmonte et al., 1996).   
Extra-cranially, the sensory component of the trigeminal nerve trunk expands forming 
the trigeminal ganglion (TG) which contains the cell bodies of the trigeminal sensory 
first-order neurons with the exception of proprioceptive afferents.  Cell bodies of 
proprioceptive afferents are contained within the mesencephalic nucleus and are 
considered to be primary sensory neurons which have been retained within the 
central nervous system (Melzack and Wall, 1965, Siemionow et al., 2011, Liu and 
Ma, 2011b, Fernandes et al., 2012).  Indeed, the mesencephalic nucleus is the only 
known nucleus within the CNS that contains the cell bodies of primary afferent 
neurons (Michael and Doufexi, 2000, Benarroch, 2011).  Distal to the TG, the 
trigeminal nerve trifurcates to form three main branches, ophthalmic (V1), maxillary 
(V2) and mandibular (V3).  The motor root of the trigeminal nerve bypasses the TG 
then re-unites with the sensory component of V3.  The three main branches split to 
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form smaller branches as follows:  V1 divides forming the frontal, lacrimal, 
nasociliary, tentorial and dural nerves innervating the eye, nose, paranasal sinuses 
and upper face; V2 divides forming the infraorbital, zygomatic, greater and lesser 
palatine, posterior superior alveolar and meningeal nerves innervating the middle 
third of the face and upper teeth; V3 divides forming five sensory branches, 
meningeal, lingual, auriculotemporal, inferior alveolar and buccal and five motor 
branches, masseteric, deep temporal, medial pterygoid, lateral pterygoid and 
mylohyoid.  Sensory V3 nerves innervate the lower third of the face, tongue, jaw and 
lower teeth while motor V3 nerves innervate muscles of mastication (Norrsell et al., 
1999, Colvin, 2006, Lumpkin and Caterina, 2007, Lechner and Siemens, 2011, Liu 
and Ma, 2011b, Fernandes et al., 2012).  The schematic in Figure 1-2 illustrates 
areas of peripheral innervation, branches and central projections of the trigeminal 
nerve. 
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1.5. Trigeminal sensory neurons 
Despite awareness of the functional complexity of the trigeminal nervous system in 
comparison to spinal nerves (Kruger and Young, 1981), our understanding of 
trigeminal pain mechanisms has often relied on analogies from the spinal sensory 
system.   There are however, a number of considerations why such mechanisms 
should not be extrapolated directly to the orofacial sensory system.  For instance, the 
trigeminal nervous system displays some distinct embryonic origins and 
organisational characteristics along with several unique areas of innervation which 
will be discussed in more detail below (Bereiter et al., 2009).  In addition, there is 
growing evidence that the properties of TG nociceptors and their responses to 
peripheral injury are distinct from those of the DRG (Sessle, 2005, Hargreaves, 
2011).  Previous studies for example have suggested that the cell-size correlation 
(Matsuo et al., 2001, Price and Flores, 2007) and expression of certain nociceptive-
specific markers (Mosconi et al., 2001, Kobayashi et al., 2005, Price and Flores, 
2007) observed in DRG nociceptors, may not be reflected in TG nociceptor 
populations. 
The development of the sensory ganglia involves migration of precursor cells to the 
site of ganglion formation and differentiation of sensory neurons.  There is a 
significant difference however, between the development of sensory neurons in DRG 
compared to TG.  DRG sensory neurons are derived from neural crest cells whilst the 
majority of TG sensory neurons are derived from the neurogenic placodes (D'Amico-
Martel and Noden, 1983, Lazarov, 2002).  A further distinction is the lack of 
progenitor cells within the forming TG.  Progenitor cells are found within developing 
DRGs allowing them to retain a degree of plasticity, however, TG progenitor cells 
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differentiate during migration and enter the forming TG as post-mitotic neurons 
(Blentic et al., 2010).  Furthermore, the TG as opposed to the DRG shows distinct 
somatotopic organisation whereby cell bodies of the mandibular nerve are located in 
the postero-lateral part of the ganglion, those of the ophthalmic nerve antero-
medially, and those of the maxillary nerve between these two locations (Shellhammer 
et al., 1984). 
Nociceptors from the DRG terminate within the dorsal horn of the spinal cord.  
Peptidergic C fibres terminate superficially within lamina I and II outer.  Non-
peptidergic C fibres terminate within Lamina II inner, and finely myelinated Aδ fibres 
terminate within lamina I, lamina II outer and lamina V (see Basbaum et al., 2009).  
TG nociceptors terminate within the brainstem in the VBSNC, more particularly within 
the most caudal region of the Vc, as previously described.  The Vc is a laminated 
structure which resembles the dorsal horn, with nociceptor terminals most densely 
located within laminae I and II (see Sessle, 2000).  However, the clear laminar 
delineations of terminals seen within the DRG are less well defined within the TG.  
The Vc displays a broader density of non-peptidergic C fibres which cross laminae I, 
II outer and II inner and overlap the terminal regions of peptidergic C fibres (see 
Bereiter et al., 2000).  Furthermore, there are unique structures within the VBSNC 
where nociceptor terminals have been located, namely the paratrigeminal islands.  
These are small nuclei located within the dorsal lateral medullary spinal trigeminal 
tract.  These, paratrigeminal terminating nociceptors have been implicated in 
inflammation induced pain (Yamazaki et al., 2008).  A further inconsistency exists 
between the DRG and TG in that nociceptors also terminate within the Vi/Vc 
transition region, which is not a laminated structure and which has been implicated 
as a critical region for the processing of craniofacial pain (Bereiter et al., 2000).  
Furthermore, a distinctive feature of the trigeminal system is the dual representation 
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of specialised craniofacial tissues innervated by the ophthalmic division of the 
trigeminal nerve.  Such tissues are represented discontinuously within the Vi/Vc 
transition zone and Vc, in contrast to spinal nerves which project to a dominant 
segment (Molander and Grant, 1990, Bullitt, 1991, Bereiter et al., 2000).  It has been 
suggested that dual representation allows for parallel or redundant processing and 
may ensure the faithful encoding of critical sensory information. 
Perhaps most importantly, the orofacial region has specialised peripheral structures 
such as meningeal membranes, oral mucosal tissues, cornea and tooth pulp.  These 
structures are densely innervated by small diameter trigeminal afferents and show a 
marked sensitivity to chemical irritants (see Bereiter et al., 2000, Sessle, 2005).  
Furthermore, the face has been reported to be the area with the highest distribution 
of sensory neurons with free nerve endings (Kawakami et al., 2001).  Pain is the 
predominant sensation evoked by stimuli to tooth pulp, an area richly innervated by 
Aδ- and C-fibre afferents most of which are deemed to be polymodal.  Being within a 
highly vascular area, they would be very susceptible to sensitisation via inflammatory 
mediators (see Sessle, 2005).  Paradoxically, although tooth pulp is richly innervated 
by nociceptors, stimulation can be either extremely intense, or pulpal inflammation 
can proceed to total necrosis without any painful symptoms being present (Narhi et 
al., 1994).  
1.6. Aim of research 
Chronic orofacial pain conditions are among the commonest in the Western world 
(Sessle, 2000), with a prevelance in the UK of around 7% (Zakrezewska, 2010).  In 
order to better manage orofacial pain conditions, it is important to more fully 
understand mechanisms of sensitisation and hyperalgesia within the trigeminal 
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system.  Full clarification of neurochemically defined populations of TG neurons 
together with the pattern of distribution of inflammatory mediator receptors that form 
key components of the sensitisation pathway is a priority in order that defined 
physiological roles are ascribed to these cells. 
1.7. Research objectives 
 Using indirect fluorescence immunohistochemistry, to perform an in-depth 
analysis of neuronal populations within the TG in naïve rat using the 
neurochemical markers NF200, CGRP and IB4.    
 Using indirect fluorescence immunohistochemistry, to perform an in-depth 
analysis of cell size distributions across the entire TG and within each 
neurochemical population in naïve rat. 
 Using indirect fluorescence immunohistochemistry to perform a detailed 
analysis of the expression patterns of receptor components for several 
important inflammatory mediators, namely, NGF, TNFα and IL-6 across the 
entire TG in naïve rat.  We will analyse the combinatorial co-expression of these 
receptor components within each neurochemical population in TG. 
 Using indirect fluorescence immunohistochemistry to perform a detailed 
analysis of the expression patterns of the thermo-transducers, TRPV1 and 
TRPM8 across the entire TG in naïve rat.  We will analyse the combinatorial co-
expression of these thermo-transducers within each neurochemical population 
in TG. 
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 For each analysis we will make direct equivalent comparison with the naïve rat 
DRG. 
 To perform in vitro analysis of the functional competency of the IL-6 receptor 
component gp130 in cultured rat TG neuronal cells by investigating the 
activation and phosphorylation of the downstream signalling molecule STAT3.   
 Using immunocytochemistry, to examine the activation status of STAT3 in TG 
neuronal cells following exposure to IL-6.   
 To quantify any changes in STAT3 phosphorylation in TG neuronal cells 
following exposure to IL-6 by Western blot analysis. 
 To determine whether IL-6 was preferentially activating a specific 
neurochemical sub-population of TG neuronal cells. 
 Using biochemical and electrophysiological outcomes we will explore 
mechanisms by which activation of gp130 by IL-6 might lead to the sensitisation 
of the thermo-transducer TRPV1 in vitro in rat TG neuronal cells. 
 Using a CGRP-release enzyme immunoassay, to determine whether exposure 
of TG neuronal cells to IL-6 resulted in a change in CAPS-evoked CGRP 
release. 
 Using whole-cell patch-clamp electrophysiological analysis to determine 
whether exposure of TG neuronal cells to IL-6 resulted in any change to CAPS-
evoked responses.  
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2. Molecular biology of the trigeminal 
ganglion  
Part 1: Neurochemistry 
2.1. Introduction 
Understanding the mechanisms involved in encoding somatosensory stimuli has long 
been a major goal in the field of neurobiology.  To this end, many studies have been 
undertaken on sensory neurons whose somata lie within the DRG, to the extent that 
a well-established characterisation of neuronal phenotype now exists within this 
system (see Basbaum et al., 2009).  Traditionally, neurons have been divided into 
subpopulations based on their anatomy, neurochemistry and physiology as a way of 
assigning a specific function to a population of sensory neurons and to aid 
understanding of response mechanisms and the subsequent encoding of specific 
stimuli (see Priestley, 2009).   
The neurochemical marker NF200 (phosphorylated heavy chain (200 kDa) 
neurofilament), has been traditionally used to identify sensory neurons which are 
thickly myelinated and conduct in the Aα/β fibre range with a non-nociceptive 
phenotype.  A further neurochemical marker, CGRP (calcitonin gene-related peptide) 
has been used to identify sensory neurons with a nociceptive phenotype and which 
are classed as peptidergic and conduct within the Aδ/C fibre range.  Binding of IB4 
(isolectin-B4 from the plant Griffonia simplicifolia) identifies a third population of 
sensory neurons as non-peptidergic nociceptors, conducting within the C fibre range 
(McMahon and Priestley, 2005).  In addition to these neurochemical markers, soma 
size has been used as a means of identification of neuronal subpopulations, such 
that in rat, neurons considered to have a nociceptive function generally have small 
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(<500 µm²) to medium (500-1100 µm²) sized cell bodies, and those with a large 
(>1100 µm²) soma size are generally considered to have a non-nociceptive function 
(Wotherspoon and Priestley, 1999).     
Using these conventions of classification, it is now widely accepted that cell size 
distribution of DRG neurons ranges from approximately 75 µm² to 4,500-5,500 µm² 
(Pover et al., 1992, Bosco et al., 2010).  Around 40% of DRG neurons are low-
threshold, Aα/β fibre non-nociceptive proprioceptors or mechanoreceptors (Michael 
and Priestley, 1999) and a further 40% are high-threshold peptidergic Aδ/C fibre 
nociceptors (Price and Flores, 2007).  Approximately 10% of DRG neurons co-
express both NF200 and CGRP and are classified as mostly Aδ fibre high threshold 
mechanoreceptors (see McMahon and Priestley, 2005).  A final 30% are classified as 
non-peptidergic nociceptors, although there is some degree of overlap with 
peptidergic nociceptors by the expression of low levels of neuropeptides (McMahon 
and Priestley, 2005). 
As mentioned in Chapter 1, in contrast to the somatosensory system, there is 
relatively less information regarding the properties of sensory neurons and their 
response mechanisms within the TG (Sessle, 2005).  Indeed, much of our 
understanding on TG sensory mechanisms has relied on extrapolating data from 
studies on the DRG.  However, although there are similarities between the two 
systems, growing evidence suggests there are distinct properties and response 
mechanisms within the trigeminal sensory system (Sessle, 2005, Price and Flores, 
2007, Hargreaves, 2011).   Studies on the TG investigating phenotypic and cell size 
populations have been unsuccessful in agreeing with the established data for the 
DRG, moreover many researchers have shown contrasting results when comparing 
their outcomes to similar studies on the TG.   
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For instance, in their study on rat TG, Cho et al. (2009a) showed that 58.2% of TG 
neurons were NF200+, with CGRP+ and/or IB4+ neurons making up a smaller 
population of 37.2%.  This was compared to their results on the DRG where 40% 
were NF200+ and 58% were CGRP+ and/or IB4+, in line with the accepted 
proportions mentioned previously.  With regard to expression of CGRP in TG 
neurons, previous studies have shown widely differing data.  For example, 
populations of CGRP+ neurons in rat TG have been reported as 16% (Price and 
Flores, 2007), 22% (Nagamine et al., 2006) and 44% (Lennerz et al., 2008) across 
the entire TG; whilst studies investigating specific subpopulations within the rat TG 
have reported 5% (Mosconi et al., 2001), 33% (Yang et al., 2006), 40% (Mori et al., 
1990) and 72% (Ichikawa et al., 2006) in tooth pulp; 40% (Mori et al., 1990) in buccal 
mucosa; 50% (Ichikawa et al., 2006) in facial skin and 40% (Nagamine et al., 2006) 
within the TG maxillary region.   Furthermore, populations of IB4+ rat TG neurons 
have been reported as approximately 19% (Cho et al., 2009a) and 23% (Price and 
Flores, 2007).  These data are summarised in Table 2-1. 
Cell size data for TG neurons has also proved inconsistent.  For example, cell size 
distribution over the entire rat TG has been reported to range from 75-2800 µm² 
(Wotherspoon and Priestley, 1999), ~50-1800 µm² (Paik et al., 2009) and 75-2550 
µm² (Lennerz et al., 2008); with peak frequencies between 200-400 µm² (Ichikawa et 
al., 2006), 400-500 µm² (Wotherspoon and Priestley, 1999), 200-300 µm² (Paik et al., 
2009) or 314-491 µm² (Lennerz et al., 2008) (see Table 2-1).  Furthermore, cell size 
distributions for neurons innervating sub-populations of rat TG range widely and are 
summarised in Table 2-1 (Sugimoto et al., 1988, Mori et al., 1990, Wotherspoon and 
Priestley, 1999, Mosconi et al., 2001, Fristad et al., 2006, Ichikawa et al., 2006, 
Nagamine et al., 2006, Yang et al., 2006, Price and Flores, 2007, Lennerz et al., 
2008, Cho et al., 2009a, Paik et al., 2009).   
 44 
Therefore, in order to better understand sensory mechanisms within the trigeminal 
nervous system, we have conducted an in-depth study adopting conventional 
methods to classify neurons first of all on the basis of neurochemistry.  Results on 
DRG from our study have concurred with the generally accepted proportions showing 
approximately 40% NF200+, 32% CGRP+ and 40% IB4+ neurons.  We have also 
examined co-expression of these factors and compared our findings to established 
functional subgroupings within the DRG.  In addition, we have determined cell size 
distribution profiles for all neurons within the TG and have determined neurochemical 
phenotypic distribution across these size distribution ranges, comparing our findings 
to established distribution profiles in DRG.  Here again, our results on the DRG 
concur with those established findings.  Of particular note is that our study has found 
significant differences in the proportions of these neuronal subpopulations and in cell 
size distributions within the TG compared to the DRG. 
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2.2. Methods 
2.2.1. Animals 
Experiments were conducted on eight adult naive male Sprague Dawley rats ranging 
from 220-250 g body weight (Charles River, Margate, UK).  All procedures were 
conducted in accordance with the UK 1986 Animals (Scientific Procedures) Act.  
Animals were housed in a temperature controlled room on a 12:12 h light/dark cycle, 
food and water was available ad libitum.  Following Schedule 1 killing, animals were 
transcardially perfused with 0.01 M phosphate-buffered saline (PBS, pH 7.4), 
followed by fixation with 4% paraformaldehyde in 0.2 M phosphate buffer (pH 7.4).   
TG and DRG (lumbar 4 and 5) were rapidly dissected and postfixed for 2 h in  4% 
paraformaldehyde in 0.2 M phosphate buffer (pH 7.4), followed by overnight 
cryoprotection in 20% sucrose.  Tissues were blocked in OCT mounting media 
(Tissue-Tek), snap-frozen in liquid nitrogen and stored at -80°C until required.  The 
tissue was then cut into 8 µm sections on a Leica cryostat (CM1100), sequentially 
thaw-mounted onto SuperFrost Plus slides (VWR) and stored at -20°C in 
cryoprotection solution (30% sucrose, 30% ethylene glycol, PBS) until use.  
Sequential sectioning was carried out in order to eliminate biasing of counts and to 
ensure that sections from across the entire ganglion were represented on each slide.  
Figure 2-1 illustrates the process as follows:  slides are labelled from 1 – 18.  Section 
one is thaw-mounted onto slide 1, section two is thaw-mounted onto slide 2 etc. until 
slide 18 is reached.  Section 19 is then thaw-mounted onto slide 1 and the process is 
repeated until slide 18.  Therefore, once all sections have been cut from the TG or 
DRG, the sections on each slide represent areas throughout the entire ganglia.   
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2.2.2. Antibody characterisation 
Table 2-2 describes the primary and secondary antibodies used in this study.  The 
NF200, CGRP and IB4 antibodies used have been widely characterised in a number 
of previous studies (Wotherspoon and Priestley, 1999, Hwang et al., 2005, Eftekhari 
et al., 2010, Kiasalari et al., 2010).  Specificity for secondary antibodies was 
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confirmed by omitting primary antibodies from immunohistochemical protocols.  No 
labelling was observed under these conditions.  
2.2.3. Immunohistochemistry 
Indirect dual immunofluorescence was performed using NF200, CGRP and IB4 to 
determine levels of expression and co-expression of these neurochemical phenotypic 
markers.  The sources, characteristics and dilutions of the primary and secondary 
antibodies used are listed in Table 2-2.  All antibodies were made up in 5% donkey 
serum (Sigma (#D9663)) in 0.01 M PBS (Sigma (#P4417)) / 0.2% Triton X-100 
(Sigma (#T8787)) / 0.1% Azide (Sigma (#S2002)).  All experiments were carried out 
in at least 3 animals, and were duplicated concurrently under identical conditions in 
both TG and DRG.  The slides were placed in a Coplin jar on an orbital shaker and 
washed 3 X 10 min in PBS.  A well was formed around tissue sections using a PAP 
pen (Sigma (#Z377821)).  Slides were then placed in a humidity chamber at room 
temperature and blocked for 1 h in 10% donkey serum (in 0.01 M PBS/0.2% Triton X-
100/0.1% Azide).  The slides were washed 3 X 10 min in PBS, placed in a humidity 
chamber, incubated with primary antibodies and left overnight at room temperature.  
Following this, the slides were again washed 3 X 10 min in PBS, placed in a humidity 
chamber, incubated with secondary antibodies and left for 3 h at room temperature.  
Slides were then washed 3 X 10 min in PBS, placed in a humidity chamber and 
stained with DAPI (Sigma (#32670)) (100 ng/ml, in 0.01 M PBS) for 1 h at room 
temperature in order to stain nuclei.  The slides were washed 1 X 10 min in PBS then 
coverslipped with the use of FluorSave mounting media (Calbiochem, VWR 
(#345789-20)) and left in dark to dry overnight.  The slides were then sealed using 
nail varnish and stored at 4°C. 
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2.2.4. Image acquisition and analysis 
Images were acquired with the use of a Nikon Eclipse 80i epifluorescence 
microscope equipped with a Nikon DS-Qi1Mc camera using NIS-Elements Software 
(BR 3.0, Nikon).  All images were taken at X20 magnification.  For expression levels, 
3 images were taken from each of the eight sections per slide from TG and DRG and 
from at least three animals.  For cell size distribution, images were taken covering the 
entire eight sections on each slide from TG and DRG from three animals.  Counting 
and measuring were carried out using NIS elements Software including only those 
neuronal profiles with visible nuclei DAPI staining.  Profile area values were binned to 
create neuron size frequency profiles.  Expression and co-expression data are 
expressed as mean ± SEM.  Statistical differences in proportions of cells expressing 
markers or cells within size ranges between TG and DRG were assessed on raw 
data using a 2-sample T-test.  Significance was set at p=<0.05.  * p=<0.05; ** 
p=<0.01; *** p=<0.001. 
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2.3. Results 
2.3.1. Expression of phenotypic markers in TG and comparison 
with expression patterns in DRG 
In order to determine proportions of functional sub-populations of neurons within TG 
and DRG, the technique of indirect dual immunofluorescence was used to detect a 
range of neurochemical phenotypic markers considered indicative of functional sub-
groups.  In order to avoid bias, expression levels were determined using sections 
from throughout the entire TG and DRG.   Expression of the phosphorylated heavy 
chain (200kDa) neurofilament (NF200) was used to distinguish a sub-population of 
low threshold Aβ-fibre mechanoreceptors.  Expression of the neuropeptide calcitonin 
gene-related peptide (CGRP) and binding of the lectin Griffonia simplicifolia IB4 were 
used to distinguish sub-populations of Aδ- or C-fibre peptidergic and non-peptidergic 
nociceptors respectively (see Priestley, 2009).  Figure 2-2 shows photomicrographs 
of immunoreactivity (‘+’) for NF200, CGRP and IB4, expressed by sensory neurons in 
transverse sections of the TG.   
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The proportion of neuronal profiles which were NF200+, CGRP+ and IB4+ within the 
TG compared to the DRG was 50.78±0.7% (n=5) vs. 40.08±0.9% (n=5); 18.65±1.1% 
(n=5) vs. 31.64±1.9% (n=5) and 26.25±1.2% (n=6) vs. 39.61±1.2% (n=6) respectively 
(Figure 2-3, Table 2-3 A).  These data indicate a significantly higher proportion of 
neuronal profiles are NF200+ in TG compared to DRG (p=<0.001 t-test) and a 
significantly lower proportion of neuronal profiles are CGRP+ (p=<0.01 t-test) and 
IB4+ (p=<0.001 t-test) in TG compared to DRG (Figure 2-4, Table 2-3 A). 
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Previous data from the DRG has also shown a small degree of co-expression of 
these standard neurochemical markers.  We have therefore assessed percentage 
co-expression within the TG.  Within the TG, 6.27±2.0% (n=5) of NF200+ neuronal 
profiles were CGRP+ compared to 18.17±2.8% (n=4) within the DRG.  Co-expression 
of these two markers has previously been suggested to constitute a population of Aδ 
TRPV2+ nociceptors (high threshold mechanoreceptors) (Priestley, 2009).  Our data 
show a significantly lower proportion of NF200+ neuronal profiles co-expressing 
CGRP in TG compared to DRG (p=<0.001 t-test) which would suggest a significantly 
smaller population of Aδ TRPV2+ nociceptors are present within the TG.  Within the 
TG 1.07±0.4% (n=3) of NF200+ neuronal profiles were IB4+ compared to 1.08±0.5% 
(n=3) within the DRG.  No significant difference was found between these values 
(Table 2-3 B).   
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Within the TG, 18.14±4.36% (n=4) of CGRP+ neuronal profiles were NF200+ 
compared to 19.24±4.38% within the DRG.  Within the TG, 29.79±2.76% (n=3) of 
CGRP+ neuronal profiles were IB4+ compared to 28.12±2.19% (n=3) within the 
DRG.    These data were not significantly different between TG compared to DRG 
(Table 2-3 B).  Within the TG, 3.01±1.15% (n=3) of IB4+ neuronal profiles were 
NF200+ compared to 1.47±0.78% (n=3) within the DRG.  Within the TG, 
23.82±0.54% (n=3) of IB4+ neuronal profiles were CGRP+ compared to 
24.21±0.06% within the DRG.  These data show a significantly higher proportion of 
IB4+ neuronal profiles co-expressing NF200 in TG compared to DRG (p=<0.05 t-test) 
(Table 2-3 B).  
These data can also be expressed as a percentage of total neuronal profiles across 
the entire TG and DRG, representing 3.2% of TG and 7.3% of DRG are 
NF200+/CGRP+, 0.5% of TG and 0.4% of DRG are NF200+/IB4+ and 5.56% of TG 
and 8.9% of DRG are CGRP+/IB4+ (Figure 2-3). 
Overall, these data show a much larger proportion of the TG is made up of NF200+ 
neurons with correspondingly smaller populations of CGRP+ and IB4+ neurons when 
compared to the DRG.  However, despite the larger population of NF200+ neurons 
within the TG, a smaller proportion of this population appear to co-express CGRP in 
comparison to the DRG.  In addition, although the TG appears to have a much 
smaller population of IB4+ neurons, a larger proportion of this population appear to 
co-express NF200 than in the DRG.  
In addition, it is noteworthy that our results for expression levels within the DRG 
concur with those from research undertaken over the past few decades (for review 
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see Priestley, 2009), and can therefore serve as a further mechanism of control for 
interpreting our results from the TG.  
 
2.3.2. Cell size distribution 
Within the somatic distribution of the somatosensory system, it is generally accepted 
that somal size is an indicator of functional modality.  Under these circumstances 
somal size is considered directly proportional to axon calibre, myelination status, 
conduction velocity and ultimately functional modality (Duncan, 1934, Mense, 2009).  
Within the DRG, neurons considered to have a nociceptive function generally have a 
mean neuronal cross-sectional profile area <1100 µm² and are classified as small (< 
500 µm²) or medium (500 – 1100 µm²) sized cells.  Those cell profiles with a cross-
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sectional profile area >1100 µm² are classified as large and generally considered to 
have a non-nociceptive function (Wotherspoon and Priestley, 1999).   
A total of 3,700 (TG) and 1,756 (DRG) neuronal profiles were measured across 
entire sections taken from throughout the TG and DRG from three animals.  Neuronal 
profiles were manually outlined and areas calculated.  Only profiles containing visible 
nuclei were included.  Values ranged from 79.17 - 2,703.96 µm² for TG (median 
value 1,164.39 µm²; 3,700 profiles) and 85.39 - 4,596.07 µm² for DRG (median value 
589.01 µm²; 1,756 profiles).  The proportional distribution for all neuronal profiles in 
both TG and DRG are shown in Figure 2-5A represented as proportions within each 
cell size bin.  DRG profile distribution shows a bi-modal distribution with peaks at 500 
µm² and 1,700 µm².  The TG profile distribution shows a uni-modal distribution with a 
single peak at 400 µm².  These data show that the TG has a relative absence of 
larger neuronal profiles ranging above 1,800 µm² and a relative increase in neuronal 
profiles in the region 700 – 1,300 µm².  These data show a significant difference 
between mean values for overall neuronal profile distributions in TG compared with 
DRG (p=<0.001 t-test). 
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As mentioned previously, cells were divided into 3 size groups (small, medium, large) 
according to criteria of Wotherspoon and Priestley (1999).  Over the whole ganglia 
neuronal profiles were distributed within cell size groups in TG and DRG as follows: 
small 41.07% vs. 34.3%, medium 45.56% vs. 36.36%, large 13.36% vs. 29.39% 
respectively (Figure 2-5 B).  These data show a significantly lower proportion of cells 
within the large size group in TG compared to DRG (p=<0.05 t-test). 
Previous studies within the DRG have shown differential expression of 
neurochemical markers across all cell size groups.  Hence the majority of NF200+ 
neurons are generally considered to fall within the large cell size group, give rise to 
axons of large calibre with fast conduction velocities.  In contrast, the majority of 
CGRP+ and IB4+ neurons are considered to lie within the small/medium cell size 
groups, give rise to axons of small calibre with low conduction velocities.  We have 
further analysed the cell size distribution of neuronal profiles from each 
neurochemical sub-population within the TG and compared these to the DRG from 
the same animals. 
In TG, the overall cell size distribution for NF200+ neuronal profiles ranged from 300 
– 2,200 µm² (median value of 913 µm²; 2,508 profiles) with a peak value of 900 µm².  
In DRG, cell size range was 300 – 3,600 µm² (median value 1,437 µm²; 1,766 
profiles) with a peak value of 1,500 µm² (Figure 2-6 A-B).  There was a significant 
difference between mean cell size values for NF200+ profiles in TG and DRG 
(p=<0.001 t-test).  These data indicate a mean smaller overall size of NF200+ 
neurons in TG compared to DRG.  Furthermore, NF200+ profiles were distributed 
within cell size groups in TG and DRG as follows: small 5.98% vs. 1.96%, medium 
64.27% vs. 26.43%, large 29.75% vs. 71.61% respectively (Figure 2-7 A).  These 
data confirm our overall findings and show that for NF200+ profiles there were a 
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significantly higher proportion in the small and medium cell size groups (p=<0.05 and 
p=<0.001 t-test) and a significantly lower proportion in the large cell size group in TG 
compared to DRG (p=<0.001 t-test) (Figure 2-7 A).  
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In TG, the overall cell size distribution for CGRP+ neuronal profiles ranged from 200 
– 1,600 µm² (median value 416.68 µm²; 1,708 profiles) with a peak value of 300 µm².  
In DRG, cell size range was 200 – 3,300 µm² (median value 568.78 µm²; 1,383 
profiles) with a peak value of 500 µm² (Figure 2-6 C-D).  There was a significant 
difference between mean cell size values for CGRP+ profiles in TG and DRG 
(p=<0.001 t-test).   CGRP+ profiles were distributed within cell size groups in TG and 
DRG as follows: small 60.54% vs. 39.8%, medium 34.36% vs. 40.62%, large 5.09% 
vs. 19.58% respectively (Figure 2-7 B).  These data show that for CGRP+ profiles 
there was a significantly higher proportion in the small cell size group (p=<0.01 t-test) 
and a significantly lower proportion in the large cell size group in TG compared to 
DRG (p=<0.05 t-test) (Figure 2-7 B). 
In TG, the overall cell size distribution for IB4+ neuronal profiles ranged from 200 – 
1,300 µm² (median value 393 µm²; 1,350 profiles) with a peak value of 400 µm².  In 
DRG, cell size range was 200 – 1,300 µm² (median value 531 µm²; 1,206 profiles) 
with a peak value of 500 µm² (Figure 2-6 E-F).  There was a significant difference 
between mean cell size values for IB4+ profiles in TG and DRG (p=<0.001 t-test).  
IB4+ profiles were distributed within cell size groups in TG and DRG as follows: small 
74.99% vs. 41.9%, medium 24.19% vs. 57.7%, large 0.82% vs. 0.44% respectively 
(Figure 2-7 C).   These data show that for IB4+ profiles there was a significantly 
higher proportion in the small cell size group (p=<0.01 t-test) and a significantly lower 
proportion in the medium cell size group in TG compared to DRG (p=<0.01 t-test) 
(Figure 2-7 C).  Data for cell size distributions are summarised in Table 2-4. 
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2.3.3. Summary of results 
 There was a significantly larger population of NF200+ neurons in TG and 
significantly smaller populations of CGRP+ and IB4+ neurons in TG compared to 
DRG (Figures 2-3 and 2-4, Table 2-3 A). 
 Levels of NF200/CGRP co-expression were significantly lower in TG compared to 
DRG.  Furthermore, a significantly larger proportion of IB4+ neurons co-express 
NF200 in TG compared to DRG (Table 2-3 B). 
 The overall cell size distribution within the TG is significantly skewed towards the 
smaller size ranges with results showing a distinct lack of large cells in TG 
compared to DRG (Figure 2-5 A-B, Table 2-4). 
 The majority of NF200+ neurons were within the small and medium cell size 
groups in TG whereas in the DRG, the majority of NF200+ neurons are within the 
large cell size group (Figure 2-7 A, Table 2-4).   
 The majority of CGRP+ neurons were within the small cell size group in TG 
whereas CGRP+ neurons in the DRG are more evenly distributed across all cell 
size groups (Figure 2-7 B, Table 2-4). 
 The majority of IB4+ neurons were within the small cell size group in TG whereas 
IB4+ neurons in the DRG are evenly distributed across the small and medium cell 
size groups (Figure 2-7 C, Table 2-4). 
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2.4. Discussion 
A major goal in the field of neurobiology has been to understand the mechanisms 
involved in encoding sensory information from afferent neurons within the peripheral 
nervous system.  With the use of certain anatomical, neurochemical and 
physiological markers, neurons in the DRG have been classified into well-established 
functional subpopulations.  It is now widely accepted that around 40% of DRG 
neurons are Aα/β fibre non-nociceptors, having large sized cell bodies and identified 
by their expression of NF200  (see Michael and Priestley, 1999).  Neurons with small-
medium sized cell bodies have generally been divided into two main subgroups of 
which around 50% are Aδ/C fibre peptidergic nociceptors, identified by their 
expression of CGRP, and approximately 50% are C fibre non-peptidergic 
nociceptors, identified by their binding of IB4, with some degree of overlap between 
these three populations (see McMahon and Priestley, 2005).  More recently, these 
two main subgroups of nociceptors have been further sub-divided using the co-
expression of additional markers as a means of classification.  Consequently, CGRP 
expressing nociceptors have been further sub-divided into those co-expressing 
NF200 and TRPV2 making up a smaller population of Aδ fibre nociceptors, and a 
larger population of C fibre nociceptors co-expressing TRPV1, TRPA1 and TrkA.  
The majority of the C fibre IB4 expressing neurons are believed to co-express 
TRPV1, TRPA1, and the purinoceptor, P2X3 (see Priestley, 2009). 
In contrast to the DRG, there is relatively less information regarding the properties of 
sensory neurons within the TG (Sessle, 2005).  Indeed, prudence has been 
suggested when extrapolating data from studies on the DRG and applying these to 
the TG, as there is growing evidence for distinct properties and response 
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mechanisms within the trigeminal sensory system (Sessle, 2005, Price and Flores, 
2007, Hargreaves, 2011).  Therefore, in order to better understand sensory 
mechanisms within the trigeminal nervous system we have performed an in-depth 
study making direct comparisons between TG and DRG using established 
neurochemical markers and cell size distributions to determine functional sub-
populations of neurons within the TG. 
2.4.1. Expression of neurochemical markers and cell size 
distribution: a direct comparison between TG and DRG 
In the current study, we have adopted traditional conventions to classify neurons on 
the basis of neurochemistry.  It is noteworthy that our results for neurochemical 
populations within the DRG concur with the well-established and accepted 
proportions mentioned previously.  We found approximately 40% of DRG neurons 
were NF200+, 32% CGRP+ and 40% IB4+.  Levels of co-expression are also within 
accepted limits such that approximately 7% of DRG neurons were NF200+/CGRP+, 
9% were CGRP+/IB4+ and 0.4% NF200+/IB4+ (Figures 2-3 and 2-4, Table 2-3) (see 
also Priestley, 2009).  Our results for the TG were significantly different for all three 
neurochemical populations.  We found a significantly higher proportion of NF200+ 
neurons (51%, p=<0.001) along with significantly lower proportions of both CGRP+ 
(19%, p=<0.01) and IB4+ (26%, p=<0.001) in TG compared to DRG.  In addition, we 
found discrepancy in the levels of co-expression of markers between ganglia, with a 
larger population of IB4+/NF200+ neurons and smaller population of NF200+/CGRP+ 
neurons in the TG (Figures 2-3 and 2-4, Table 2-3).  As far as we are aware, only 
one other study to date has carried out a similar direct comparison between rat TG 
and DRG using standard neurochemical markers to determine expression over the 
entire ganglia (Cho et al., 2009b).  Unfortunately in this study, the same secondary 
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antibody chromophore was used for both CGRP+ and IB4+ neurons, hence the 
authors were unable to distinguish between these two cell populations.  However, our 
results concur with their study in that they found a significantly larger population of 
NF200+ neurons in TG along with a smaller population of CGRP+ and/or IB4+ 
neurons when compared to their data on DRG.   
As mentioned earlier, there are a number of studies which have examined 
expression of one or more neurochemical markers in TG only, without a direct 
comparison being carried out with the DRG.  These studies however, have produced 
inconsistent results for example, levels of CGRP expression have ranged from 16% 
to 44% across the entire TG (Nagamine et al., 2006, Price and Flores, 2007, Lennerz 
et al., 2008) and from 5% to 72% in sub-populations of TG neurons (Mori et al., 1990, 
Mosconi et al., 2001, Ichikawa et al., 2006, Nagamine et al., 2006, Yang et al., 2006).  
Due to the lack of direct comparison to the DRG in previous research and for reasons 
of variability amongst studies mentioned in Chapter 1, it is difficult to use these data 
to make a valid comparison between earlier data and the results from our study. 
Using data generated within this study therefore, there are several important 
functional implications that can be drawn.  Traditionally, the marker NF200 has been 
used to define a population of neurons with a non-nociceptive function that conduct in 
the Aα/β fibre range and have large sized cell bodies (Michael and Priestley, 1999).  
Our data show that there are significantly more NF200+ neurons in the TG than 
DRG.  These data are surprising at a number of levels.  First, considering the lack of 
proprioceptive neurons within the TG, whose cell bodies are located within the 
mesencephalic nucleus (see Bereiter et al., 2009), we would have expected to see 
significantly fewer NF200+ neurons in the TG than the DRG.  Second, our data 
showed these NF200+ neurons to be enriched within the small to medium cell size 
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range with an almost complete absence of larger neuronal cells  >1800 µm² in the 
TG.  Whilst this is in line with the lack of proprioceptive neurons and in agreement 
with several previous studies (Wotherspoon and Priestley, 1999, Ichikawa et al., 
2004, Ichikawa et al., 2006) the implication may be that many of these small to 
medium NF200 expressing neurons could be nociceptors.  This hypothesis could 
possibly be supported by our finding of an increase in the frequency of cells within 
the 700 – 1,300 µm² range within the TG, possibly Aδ fibre, nociceptors.  The 
hypothesis could be that these may account for the larger population of NF200 
expressing neurons.  In order to test this, we carried out further analysis of cell size 
distribution within each neurochemical population.   
As mentioned earlier, there was a significant shift towards the smaller cell sizes in the 
TG for all three neurochemical populations compared to the DRG.  Again, this would 
be somewhat expected, due to the lack of proprioceptors in the TG (Figure 2-6, Table 
2-4).   To further quantify these findings, the cells were divided into 3 size groups, 
small (<500 µm²), medium (500-1100 µm²) and large (>1100 µm²).  With the small-
medium sizes assuming to be a nociceptive phenotype and large, a non-nociceptive 
phenotype (Harper and Lawson, 1985, Lawson and Waddell, 1991).  Of particular 
interest were the results for NF200+ neurons.  Here we found significantly larger 
NF200+ populations in the small and medium size groups in TG compared to DRG, 
and most interestingly, the majority (64%) of NF200+ TG neurons were in the 
medium cell size group, whereas the majority (72%) of NF200+ DRG neurons were 
in the large cell size group (Figure 2-7, Table 2-4).  These data therefore, initially 
suggest that the TG contains significantly more neurons than the DRG which fall 
within the small to medium cell size range and which are NF200+.  The functional 
implication here is that the TG is potentially enriched with small diameter, NF200+ 
nociceptors. 
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These data however, need to be viewed alongside that from further analysis of the 
other neurochemical markers.  In the TG, the majority of CGRP+ and IB4+ cells fell 
within the small size group, whereas in the DRG, both groups were more evenly 
distributed across all cell size groups (see Figure 2-7, Table 2-4).  These data do 
agree with previous studies for the TG whereby CGRP and IB4 expression was 
found predominantly within the small cell size group.  For instance, CGRP+ rat TG 
neurons showed peak frequency between 314-491 µm² (Lennerz et al., 2008) and a 
mean soma size of 325 µm² (Price and Flores, 2007).  In addition, the mean soma 
size for IB4+ rat TG neurons has been reported as 366 µm², significantly smaller than 
corresponding cells within the DRG (Price and Flores, 2007).    
From our previous assertion that because the TG appears to be enriched with NF200 
expressing neurons within the smaller cell size ranges and may therefore be 
nociceptors, it follows that we may find higher levels of co-expression of NF200 with 
either CGRP or IB4 within these size brackets in the TG compared to the DRG.  This 
could possibly support the hypothesis that these small NF200+ neurons were 
nociceptors.  However, our data showed significantly less co-expression of NF200 
and CGRP within the TG compared to the DRG, which would imply that these smaller 
NF200+ TG neurons are not the CGRP/NF200/TRPV2 expressing nociceptor 
population as described earlier.  Nonetheless, our data did show significantly higher 
co-expression of NF200 within the IB4+ population of neurons in the TG compared to 
the DRG.  Although only accounting for a small proportion of the total neuronal 
populations in both ganglia, our data appear to describe a novel neuronal population 
of IB4/NF200/P2X3 expressing nociceptors which are enriched within the TG.  The 
function of IB4 expressing neurons is largely unknown and it has been suggested 
that they signal different types of pain to those expressing CGRP (see Priestley, 
2009).   Indeed, IB4+ DRG neurons have been shown to terminate less superficially 
 68 
(within lamina II inner), than those expressing CGRP (within lamina 1 and II outer), 
and are believed to be responsible for mediating acute thermal and mechanical 
nociception (Vulchanova et al., 2001, Zylka et al., 2005).  Of particular interest is the 
suggestion that non-peptidergic nociceptors may innervate different central pathways 
to those of peptidergic nociceptors and are primarily responsible for conveying the 
affective rather than sensory component of pain (see Priestley, 2009).  Thus, this 
small, but enriched population of neurons within the TG may help to explain the 
difficulties encountered in treating pain within the orofacial region due to its being an 
area with special emotional and psychological meaning to patients (see Sessle, 
2000). 
Since pain is the predominant sensation evoked by pulpal stimuli, and tooth pulp is 
rich in unmyelinated nerve fibres, it has generally been accepted that these pulpal 
fibres give rise to small diameter nociceptive neurons that conduct in the C fibre 
range (Brashear, 1935, Anderson et al., 1970, Mumford and Bowsher, 1976, 
Johnsen and Johns, 1978, McGrath et al., 1983, Sessle, 1986, Narhi et al., 1994, 
Nair, 1995, Orchardson and Cadden, 2001, Narhi, 2005).  However, studies are now 
suggesting that many of the unmyelinated axons within tooth pulp originate from 
myelinated parent axons which have tapered terminal segments within the pulp 
(Orchardson and Cadden, 2001).  For instance, Ichikawa et al. (2006) found that 
tooth pulp neurons had larger cell bodies than those of cutaneous TG neurons.  
Sugimoto et al. (1988) showed that the majority (64%) of pulpal neurons had cell 
bodies over 500 µm², namely within the medium cell size range.  A more recent study 
concurs with these findings, where the majority of parent axons innervating tooth pulp 
were found to be small myelinated fibres, namely Aδ fibres with correspondingly 
medium size cell bodies (Paik et al., 2009).  In agreement with these studies, 
physiological experiments have also showed that pulpal axons increase their 
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conduction velocity as they leave the pulp and enter the alveolar nerve (for reviews 
see Hildebrand et al., 1995, Lazarov, 2002, Fried et al., 2011).  As fibre type would 
strongly influence the characteristic quality of the pain perceived following activation 
of pulpal nociceptors, it is therefore important to determine the relative contribution of 
pulpal innervation from sensory neurons that give rise to either unmyelinated or 
myelinated parent axons (Henry et al., 2012).   
The dense innervation of the tooth pulp, and the fact that these neurons are being 
shown to have myelinated parent axons, may help to explain our results. We know 
that the TG lacks proprioceptors, therefore the lack of large cells is somewhat 
expected.  In addition, we found an over-representation of NF200+ neurons, the 
majority of which had medium sized cell bodies.  These neurons may possibly 
contribute towards the population of Aδ fibre, tapering neurons that innervate the 
tooth pulp.  Furthermore, the current study has demonstrated some key differences 
between the neurochemical and cell size distribution patterns in the TG compared to 
the DRG, which likely reflect functional differences in response mechanisms between 
the ganglia.  In addition, we have identified populations of TG neurons with unusual 
phenotypes, and would therefore agree with previous researchers who dictate 
prudence when extrapolating data from the DRG and applying it to the TG.  
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3. Molecular biology of the trigeminal 
ganglion Part 2: Neurotrophin receptor, 
cytokine receptor and thermo-transducer 
protein expression 
3.1. Introduction 
An understanding of the sensory processes responsible for pain and the factors that 
can modify these response mechanisms is important for the effective management of 
orofacial pain (Cadden and Orchardson, 2001).  Moreover, treatment of orofacial 
pain is more complex owing to a lack of discrimination making it difficult for some 
patients to locate the exact source of intraoral pain conditions (Weigelt et al., 2010).  
Inflammatory mediators, such as neurotrophins and cytokines, released following 
injury, form what is more commonly referred to as the “inflammatory soup” and have 
the effect of profoundly changing the chemical milieu surrounding the peripheral 
terminals of sensory neurons (see Basbaum et al., 2009).    By expression of specific 
receptor components on the terminals of sensory neurons, these inflammatory 
mediators can have a direct effect on neuronal response mechanisms. In addition, 
sensory neurons express transducer proteins, which can be sensitised indirectly via 
post-translational mechanisms initiated by inflammatory mediators.  The resulting 
sensitisation of sensory neurons, leads to such states as thermal and mechanical 
hyperalgesia (as explained in Chapter 1).  Furthermore, this form of hypersensitivity 
may be unresolved, resulting in chronic and debilitating pain conditions (see 
Basbaum et al., 2009). 
Clinical biopsy studies and pre-clinical animal studies have shown that some of the 
most potent mediators present within the inflammatory milieu are nerve growth factor 
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(NGF) (see Pezet and McMahon, 2006), tumour necrosis factor alpha (TNFα) (Miller 
et al., 2009) and interleukin 6 (IL-6) (Andratsch et al., 2009).  NGF activates cells by 
binding to a high affinity tropomyosin-related kinase receptor, TrkA.  In the 
somatosensory system TrkA is specifically expressed by populations of nociceptor-
specific neurons expressing CGRP or co-expressing NF200 (Lewin and Mendell, 
1993, Averill et al., 1995).  Activation of TrkA on these sensory neurons underlies 
nociceptor activation and sensitisation to algogenic stimuli such as heat and noxious 
chemicals and is considered a major mechanism underlying some persistent 
inflammatory pain states (Dmitrieva and McMahon, 1996, Lowe et al., 1997, Halliday 
et al., 1998, Gould et al., 2000, Pezet and McMahon, 2006).  Indeed, the use of 
antibodies to sequester NGF has given effective and sustained relief from clinical 
pain (Lane et al., 2010).  Furthermore, it has been suggested that local availability of 
NGF may be a crucial factor in altering nociceptor phenotype and lowering threshold 
levels (Bennett et al., 1998(a), Obreja et al., 2011).   
Overall expression of TrkA in DRG is generally accepted to be around 40-45% 
(Averill et al., 1995, Kobayashi et al., 2005, McMahon and Priestley, 2005).  There is 
extensive overlap between TrkA expressing cells and those expressing CGRP 
(McMahon, 1996), indeed, Averill et al. (1995) showed that 90% of peptidergic 
nociceptors co-expressed TrkA in DRG.  Furthermore, approximately 25% of NF200+ 
neurons co-express TrkA (McMahon and Priestley, 2005) and around 6-12% of IB4+ 
neurons co-express TrkA (Averill et al., 1995, McMahon, 1996) in DRG.  Reported 
expression levels of TrkA in rat TG have varied greatly from 38% to 78% between 
studies and depending on the type of tissue innervated (Wetmore and Olson, 1995, 
Jacobs and Miller, 1999, Pan et al., 2000, Yang et al., 2006, Gaspersic et al., 2007, 
Svensson et al., 2010).  These previous studies highlight a discrepancy between the 
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DRG and TG in relation to the potential for TG cells to respond to an important 
inflammatory mediator. 
TNFα is a potent pro-inflammatory cytokine which is rapidly produced by a wide 
range of immune cells in response to inflammatory stimuli (Verri et al., 2006a).  TNFα 
interacts with target cells through two structurally related high-affinity receptors p55 
(TNFR1, CD120a) and p75 (TNFR2, CD120b) both able to activate pro-inflammatory 
signalling pathways (Caminero et al., 2011).  Within the DRG, the proportion of 
neurons which display p55 protein expression have been reported as 13% (Sakuma 
et al., 2007) and 15%, mainly in C fibres (Xu et al., 2006).  Increased levels of TNFα 
have been correlated with a number of painful inflammatory conditions (Lindenlaub 
and Sommer, 2003), complex regional pain syndrome (see Calvo et al., 2012) 
rheumatoid arthritis, Crohn’s disease (see Coutaux et al., 2005) and 
neurodegenerative disorders (see Mc Guire et al., 2011).  Furthermore, TNFα 
produces ectopic activity and sensitisation of nociceptors (Sorkin et al., 1997, 
Sabsovich et al., 2008, Schäfers et al., 2008) and plays a pivotal role in the 
development of inflammatory hyperalgesia (Cunha, 1992, Cunha et al., 2008).  Of 
particular interest is that the constitutively expressed receptor p55 has been 
demonstrated to be key in the development of hyperalgesia and allodynia (Sommer 
et al., 1998, Moalem and Tracey, 2006, Schäfers et al., 2008).  In addition, TNFα has 
been shown to enhance capsaicin sensitivity and increase levels of TRPV1 
expression (Nicol et al., 1997, Khan et al., 2008, Spicarova and Palecek, 2010) thus 
demonstrating a link between TNFα signalling and TRPV1 sensitisation.  
Studies on rat TG have again shown equivocal results.  For example, it is known that 
TNFα enhances capsaicin sensitivity and significantly increases TRPV1 expression 
(Khan et al., 2008).  Of interest here was their finding that >90% of TRPV1+ neurons 
 73 
co-expressed p55.  In contrast however, Zhang et al. (2011) found increased TNFα 
plasma levels during migraine attacks, but were unable to locate p55 on neuronal 
cells and only observed expression on non-neuronal dural endothelial vascular cells 
and macrophages.  Bowen et al. (2005) observed p55 expression almost exclusively 
on CGRP+ neuronal cells, and Hakim et al. (2009) found that 29% of masseter 
neuronal cells were positive for p55.  We will attempt a further detailed analysis of the 
expression of p55 in sensory neurons under normal conditions in the rat TG. 
TNFα has been shown to activate sensory neurons directly initiating a cascade of 
inflammatory reactions and resulting in production of further cytokines such as IL-6 
(see Dray, 2005).  IL-6 is a predominantly pro-inflammatory cytokine released by a 
variety of cell types including immune, neuronal and glial cells (Verri et al., 2006a, 
Austin and Moalem-Taylor, 2010).  IL-6 is a member of the neuropoietic cytokine 
family which share the transmembrane signal transducing receptor component gp130 
(see Scheller et al., 2011(b)).  Elevated levels of IL-6 have been linked to several 
chronic inflammatory diseases such as rheumatoid arthritis and burning mouth 
syndrome (see Gadient and Patterson, 1999, Suh et al., 2009).  Indeed it is now 
being recognised that IL-6 may contribute to the development and progression of 
certain chronic inflammatory conditions (see Gadient and Patterson, 1999, Rincon, 
2012) along with having a key role in the development of hyperalgesia (see Verri et 
al., 2006a), mechanical allodynia (Anderson and Rao, 2001) and chronic neuropathic 
pain (Arruda et al., 1998).  For instance, patients with complex regional pain 
syndrome have displayed elevated levels of both IL-6 and TNFα (Heijmans-
Antonissen et al., 2006) whilst upregulation of IL-6 has been shown in patients with 
temporomandibular disorder (Wang et al., 2009b).  Moreover, injury-induced 
upregulation of IL-6 has been positively correlated to pain intensity and the onset of 
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acute inflammatory pain (Wang et al., 2009c).  In addition, IL-6 has been linked to the 
pathogenesis of migraine headache (Yan et al., 2012). 
Gp130 has previously been reported to be expressed on neuronal cells, albeit in 
MAH cells (immortalised sympathoadrenal progenitor cell line) (Ip et al., 1992), and 
within the CNS in rat brain, including the trigeminal sensory nuclei (Watanabe et al., 
1996).  However, a more recent study on the somatosensory system has 
demonstrated ubiquitous expression of gp130 on DRG neurons (Gardiner et al., 
2002).  Of particular interest was a study by Quarta et al. (2011) who termed gp130 a 
‘chronification factor’ and found it to be essential for the long-term potentiation of 
mechanical hypersensitivity associated with inflammation, cancer and nerve injury.  
To date, only one other study has examined localisation of gp130 within the 
trigeminal nervous system, where gp130 mRNA was shown to be expressed in >90% 
of trigeminal neurons (Mizuno et al., 1997).  Therefore, as far as we are aware, ours 
is the first study to demonstrate localisation of gp130 protein within the TG. 
Major sensitisation effects within DRG sensory neurons occur through local 
signalling, leading to post-translational changes to pre-existing proteins.  One such 
important substrate protein is TRPV1 (transient receptor potential vanilloid 1) 
(Nicholas et al., 1999, Shu and Mendell, 1999, 2001, Bonnington and McNaughton, 
2003b, Amaya et al., 2004, Lewin et al., 2004, Zhang et al., 2005, Huang et al., 
2006a, Zhu and Oxford, 2007).  TRPV1 is a polymodal transducer channel, gated in 
response to noxious heat, capsaicin and protons and is a member of the thermo-TRP 
subfamily of the TRP superfamily (Caterina and Julius, 2001).  Whilst debate remains 
over the role of TRPV1 in transducing acute thermal stimuli there is now a consensus 
regarding its central role in mediating thermal hyperalgesia (Rueff and Mendell, 1996, 
Bennett et al., 1998(a), Caterina et al., 2000, Shu and Mendell, 2001, Bonnington 
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and McNaughton, 2003b, Lewin et al., 2004, Woodbury et al., 2004, Pogatzki-Zahn 
et al., 2005, Zhang et al., 2005, Yu et al., 2008, Walder et al., 2012, Barcena de 
Arellano et al., 2013).  Within the TG, a significant increase in NGF levels and 
subsequent increase in TRPV1 expression has been found in patients with burning 
mouth syndrome (BMS) (Yilmaz et al., 2007, Jääskeläinen, 2011).  In addition, NGF-
mediated TRPV1 sensitisation has been linked to ectopic orofacial pain (Shinoda et 
al., 2011).   
In the DRG around 50% of neurons are TRPV1+ (Guo et al., 1999, Kobayashi et al., 
2005, Kiasalari et al., 2010).  Approximately 65% of peptidergic nociceptors and 75% 
of non-peptidergic nociceptors co-express TRPV1 (see Guo et al., 1999, McMahon 
and Priestley, 2005) and only 3% of NF200+ neurons co-express TRPV1 (see 
Priestley et al., 2002).  Previous data have estimated the proportion of TRPV1 
expressing neurons in the TG to be between 16% to 50% (Ichikawa and Sugimoto, 
2001, Bae et al., 2004, Kobayashi et al., 2005, Tanimoto et al., 2005, Nagamine et 
al., 2006, Simonetti et al., 2006, Pei et al., 2007, Price and Flores, 2007, Kiasalari et 
al., 2010, Gibbs et al., 2011).  Moreover, studies investigating sub-populations of rat 
TG neurons have also varied from 8% to 35% depending on the target tissue being 
innervated (Ichikawa and Sugimoto, 2001, Stenholm et al., 2002, Murata and 
Masuko, 2006, Gibbs et al., 2011, Saloman et al., 2013).  We have therefore further 
analysed TRPV1 expression in TG neurons. 
TRPM8 (transient receptor potential melastatin 8) was first reported around a decade 
ago as a specific marker for prostate cancer (Knowlton and McKemy, 2011) and is 
now known to be activated by gentle cooling, menthol, eucalyptol and icilin (see 
Latorre et al., 2007).  Interestingly, TRPM8 can be activated by both innocuous and 
noxious temperatures ranging from 28 to <5 °C (McKemy et al., 2002, Knowlton and 
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McKemy, 2011) and may likely be involved in thermal nociception (Tominaga and 
Caterina, 2004).  The sensory discrimination between innocuous and noxious cold by 
TRPM8 may be due to its co-expression with either tetrodotoxin-sensitive (TTXs) or 
TTX-resistant (TTXr) voltage gated Na+ channels, with TTXs inferring a non-
nociceptive phenotype, and TTXr a nociceptive phenotype  (Sarria et al., 2012).  The 
role of TRPM8 in inflammatory pain is still under debate, although functional 
modulation of TRPM8 by pro-inflammatory mediators such as NGF has been 
reported (see Babes et al., 2011).  Indeed a recent study using TRPM8-ablated and 
knockout mice showed significant attenuation of cold pain associated with 
inflammation and nerve injury (Knowlton et al., 2013).  Studies on rat DRG have 
reported the proportion of neurons expressing TRPM8 to be between 6% and 23% 
and in rat TG between 12% and 35% (Peier et al., 2002, Abe et al., 2005, Kobayashi 
et al., 2005, Su et al., 2011).   
Since the trigeminal system plays a major role in the detection of noxious chemicals 
via transducer channels located on nociceptor terminals within the oral and nasal 
mucosa (Gerhold and Bautista, 2009), and given the role played by many of these 
underlying neuronal sensitisation, elucidating expression patterns and proportions of 
transducer channels within the TG would appear to be a priority.  Moreover, 
commensal microbiota, which is abundant within the oral mucosa, has been shown to 
enhance the development of inflammatory hyperalgesia (Amaral et al., 2008).  In 
addition, the successful development of novel analgesics is contingent upon the 
correct target molecule being selected which can only happen once we have a 
thorough understanding of transducer receptor distribution and mechanisms of 
sensitisation (Hughes et al., 2012). 
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To provide greater insight into the functional roles of TG neurons we have made a 
detailed examination of the distribution of key receptor and transducer molecules 
known to be important for the induction of peripheral sensitisation or as potential 
downstream targets for post-translational modifications.  We have examined the 
distribution of the high affinity NGF receptor, TrkA, along with receptor components 
for two further major inflammatory mediators TNFα and IL6 (p55 and gp130 
respectively).  In addition, we have examined patterns of expression for the thermo-
transducer proteins TRPV1 and TRPM8 and compared our findings for all markers to 
patterns of expression within the DRG, in order to establish a basis for dynamic 
plasticity of the TG nociceptive system.  Furthermore, we have compared co-
localisation of each of these receptor components and transducer proteins with 
standard neurochemical markers in both TG and DRG.  Finally, we have determined 
the neuronal cell size profile distributions for each molecular marker and compared 
distributions between TG and DRG. 
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3.2. Methods 
3.2.1. Animals 
Experiments were conducted on adult naive male Sprague Dawley rats ranging from 
220-250 g body weight (Charles River, Margate, UK).  All procedures were 
conducted in accordance with the UK 1986 Animals (Scientific Procedures) Act.  
Animals were housed in a temperature controlled room on a 12:12 h light/dark cycle, 
food and water was available ad libitum.  Following Schedule 1 killing, animals were 
transcardially perfused, dissected and the tissue was snap-frozen and stored at -
80°C.  The tissue was cut into 8 µm sections and thaw-mounted onto SuperFrost 
Plus slides as previously described in Chapter 2. 
3.2.2. Antibody characterisation 
Table 3-1 describes the primary and secondary antibodies used in this study.  The 
NF200, CGRP and IB4 antibodies used have been widely characterised as described 
in Chapter 2.  Antibodies for markers of interest have previously been characterised 
as follows: TrkA (Drummond et al., 2006), p55 (Xu et al., 2006), gp130 (Gardiner et 
al., 2002), TRPV1 (Kiasalari et al., 2010, Harrington et al., 2011) and TRPM8 
(Harrington et al., 2011).   Specificity for secondary antibodies was confirmed by 
omitting primary antibodies from immunohistochemical protocols.  No labelling was 
observed under these conditions. 
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3.2.3. Immunohistochemistry 
Indirect dual immunofluorescence was performed on naïve adult rat TG and DRG as 
described in Chapter 2.  Briefly, slides were blocked for 1 h in 10% donkey serum 
(0.01 M PBS/0.2% Triton X/0.1% Azide) then incubated with primary antibodies 
overnight at room temperature.  Slides were then incubated with secondary 
antibodies and left for 3 h at room temperature (for TrkA staining, secondary 
antibodies were left on for 5 h).  The slides were stained with DAPI (100 ng/ml, in 
0.01 M PBS) for 1 h at room temperature in order to stain nuclei, coverslipped with 
the use of FluorSave mounting media (Calbiochem), dried overnight and sealed. 
3.2.4. Image acquisition and analysis 
As described in Chapter 2, Images were acquired with the use of a Nikon Eclipse 80i 
epifluorescence microscope.  Counting and measuring were carried out including 
only those neuronal profiles with visible nuclei DAPI staining.  High-expressing 
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TRPV1+ profiles were readily discernible by eye although a fluorescence intensity 
measurement was used to confirm visual identification.  Profile area values were 
binned to create neuron size frequency profiles.  Expression and co-expression data 
are expressed as mean ± SEM.  Statistical differences in proportions of cells 
expressing markers or cells within size ranges between TG and DRG were assessed 
on raw data using a 2-sample T-test.  Significance was set at p=<0.05.  * p=<0.05; ** 
p=<0.01; *** p=<0.001. 
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3.3. Results 
3.3.1. TrkA – Expression, co-expression and cell size distribution 
Indirect dual immunofluorescence was used to define the proportion of neurons 
expressing the high affinity receptor for NGF, TrkA, within the TG and DRG and to 
observe the degree of co-localisation with the neurochemical markers NF200, CGRP 
and IB4.  The total proportion of neuronal profiles which were TrkA+ in the TG 
compared to the DRG was, 24.2±0.82% (n=6) vs. 27.87±1.94% (n=6) respectively 
(Figure 3-1, Table 3-2 A).  There was no significant difference between these values.  
Within the TG, TrkA was co-localised as follows: NF200+/TrkA+, 16.52±1.25% (n=3); 
CGRP+/TrkA+, 60.63±3.76% (n=5); IB4+/TrkA+, 11.32±1.59% (n=3).  Corresponding 
values within the DRG were: NF200+/TrkA+, 22.80±6.53% (n=3); CGRP+/TrkA+, 
78.54±2.5% (n=5); IB4+/TrkA+, 11.22±1.09% (n=3) (Figure 3-1 J-O, Table 3-2 B-D).  
Although overall levels of TrkA expression were not significantly different between 
TG and DRG, our data appear to show that TrkA was differentially distributed across 
neurochemical populations with significantly lower CGRP/TrkA co-localisation 
(p=<0.01) along with a trend towards lower NF200/TrkA co-localisation in TG 
compared to DRG (Figure 3-1, Table 3-2).  
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In TG, the overall cell size distribution for TrkA+ profiles ranged from 100 – 2,000 µm² 
(median value 530 µm²; 1,884 profiles) with a peak at 400 µm² (Figure 3-2 A).  In 
DRG, cell size range was 200 – 3,300 µm² (median value 641 µm²; 1,014 profiles) 
with a peak at 400 µm² (Figure 3-2 B).  There was a significant difference between 
mean values for overall cell size distributions of TrkA+ profiles in TG compared to 
DRG (p=<0.001 t-test) (Figure 3-2 A-B, Table 3-3). Cells were further analysed as 
per distribution within small, medium and large size ranges (see section 2.3.2).  
TrkA+ profiles were distributed within cell size groups in TG and DRG as follows: 
small 44.41% vs. 38.02%, medium 44.88% vs. 37.56%, large 10.71% vs. 24.42% 
respectively (Figure 3-2 C).  These data show that there was a significantly higher 
proportion of TrkA+ profiles in the medium cell size group in TG (p=<0.05 t-test) and 
a significantly lower proportion of TrkA+ profiles in the large cell size group in TG 
compared to DRG (p=<0.01 t-test) (Figure 3-2 C, Table 3-3). 
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3.3.2. P55 – Expression, co-expression and cell size distribution 
Indirect dual immunofluorescence was used to define the proportion of neurons 
expressing the receptor for TNFα, p55, within the TG and DRG to observe the 
degree of co-localisation with NF200, CGRP and IB4.   The total proportion of 
neuronal profiles which were p55+ in the TG compared to the DRG was 
33.01±4.21% (n=4) vs. 38.05±2.85% (n=3) respectively (Figure 3-3, Table 3-2 A).  
There was no significant difference between these values.  Within the TG, p55 was 
co-localised as follows: NF200+/p55+, 26.53±2.15% (n=3); CGRP+/p55+, 
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38.45±3.11% (n=3); IB4+/p55+, 60.82±1.52% (n=3).  Corresponding values within 
the DRG were: NF200+/p55+, 29.76±7.02% (n=3); CGRP+/p55+, 32.56±1.42% 
(n=3); IB4+/p55+, 88.83±1.41% (n=3) (Figure 3-3 J-O, Table 3-2 B-D).  Although 
there was no significant difference in overall expression levels between TG and DRG 
these data show differential distribution of p55 across neurochemical populations 
with significantly lower IB4/p55 co-localisation (p=<0.01 t-test) within the TG along 
with trends towards higher levels of CGRP/p55 co-localisation and lower levels of 
NF200/p55 co-localisation in TG compared to DRG (Figure 3-3, Table 3-2). 
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In TG, the overall cell size distribution for p55+ profiles ranged from 200 – 2,200 µm² 
(median value 530 µm²; 816 profiles) with a peak at 400 µm² (Figure 3-4 A).   In 
DRG, cell size range was 200 – 2,600 µm² (median value 636 µm²; 773 profiles) with 
a peak at 600 µm² (Figure 3-4 B).  There was a significant difference between mean 
values for overall cell size distributions of p55+ profiles in TG compared to DRG 
(p=<0.001 t-test) (Figure 3-4 A-B, Table 3-3).  P55+ profiles were distributed within 
cell size groups in TG and DRG as follows: small 46.84% vs. 28.57%, medium 
43.14% vs. 51.24%, large 10.02% vs. 20.2% respectively (Figure 3-4 C).  These data 
show that p55 was preferentially and significantly distributed within the small cell size 
group in TG compared to DRG (p=<0.05 t-test) (Figure 3-4 C, Table 3-3). 
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3.3.3. Gp130 – Expression, co-expression and cell size distribution 
Indirect dual immunofluorescence was used to define the proportion of neurons 
expressing the IL-6 family receptor, gp130, within the TG and DRG and to observe 
the degree of co-localisation with standard neurochemical markers.  The proportion 
of neuronal profiles which were gp130+ in the TG and DRG was 99.29±0.42% vs. 
100% respectively (n=3).  These data were not significantly different between TG 
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compared to DRG.  Examination of co-expression of gp130 with NF200 revealed 
virtual complete co-localisation in both TG and DRG (Figure 3-5). 
 Gp130 was found to be ubiquitously expressed throughout both the TG and DRG.  
Therefore, cell size distribution for gp130 matches our results for the entire TG and 
DRG presented in Chapter 2, section 2.3.2. 
3.3.4. TRPV1 – Expression, co-expression and cell size 
distribution 
Indirect dual immunofluorescence was used to define the proportion of neurons 
expressing the transducer protein TRPV1, within the TG and DRG and to observe 
the degree of co-localisation with NF200, CGRP and IB4 (Figure 3-6).  Previous work 
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(Michael and Doufexi, 2000) has identified small sub-populations of DRG and TG 
neurons expressing high levels of TRPV1.  Furthermore, these neurons do not 
express the markers normally associated with nociceptors and appear to express a 
unique repertoire of neurotrophic factor receptors (Michael and Doufexi, 2000, 
Kiasalari et al., 2010).  When examining expression levels for TRPV1 across the 
entire TG or DRG we have therefore distinguished a separate population of high-
expressing TRPV1 neuronal profiles (HE-TRPV1+) from normal expressing TRPV1 
neurons (TRPV1+).  As described earlier, distinction between levels of expression for 
HE-TRPV1+ and normal TRPV1+ neurons was made by visual examination and by 
using a threshold measurement of fluorescence intensity.   
The proportion of profiles which were HE-TRPV1+ in the TG compared to the DRG 
was, 0.25±0.03% (n=5) vs. 0.89±0.14% (n=5) respectively (Table 3-2 A).  The 
proportion of profiles which were TRPV1+ in the TG compared to the DRG was, 
26.73±1.3% (n=5) vs. 33.12±1.8% (n=5) respectively (Table 3-2 A).  Within the TG, 
TRPV1 was co-localised as follows: NF200+/TRPV1+, 3.13±0.33% (n=3); 
CGRP+/TRPV1+, 68.5±4.0% (n=3); IB4+/TRPV1+, 61.67±5.3% (n=3).  
Corresponding values within the DRG were: NF200+/TRPV1+, 5.23±0.28% (n=3); 
CGRP+/TRPV1+, 48.93±5.6% (n=3); IB4+/TRPV1+, 52.9±6.6% (n=3) (Figure 3-6 J-
O, Table 3-2 B-D).  Overall levels of both HE-TRPV1 and TRPV1 were significantly 
lower in TG compared to DRG (p=<0.05, p=<0.05 respectively).  Similarly, there was 
significantly less co-localisation of NF200/TRPV1 in TG compared to DRG (p=<0.05).  
Moreover, there were trends towards higher levels of CGRP/TRPV1 and IB4/TRPV1 
co-localisation in TG compared to DRG (Figure 3-6, Table 3-2). 
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In TG, the overall cell size distribution for TRPV1+ profiles ranged from 200 – 1,800 
µm² (median value 440 µm²; 1851 profiles) with a peak at 400 µm² (Figure 3-7 A).   In 
DRG, cell size range was 200 – 1,900 µm² (median value 595 µm²; 1463 profiles) 
with a peak at 700 µm² (Figure 3-7 B).  There was a significant difference between 
mean values for overall cell size distributions of TRPV1+ profiles in TG compared to 
DRG (p=<0.001 t-test) (Figure 3-7 A-B, Table 3-3).  TRPV1+ profiles were distributed 
within cell size groups in TG and DRG as follows: small 59.81% vs. 33.04%, medium 
37.19% vs. 64.98%, large 2.1% vs. 1.98% respectively (Figure 3-7 C).  These data 
show that TRPV1 was significantly enriched in the small cell size group in TG 
(p=<0.01 t-test) whilst being significantly lower in the medium cell size group in TG 
compared to DRG (p=<0.01 t-test) (Figure 3-7 C, Table 3-3). 
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3.3.5. TRPM8 – Expression, co-expression and cell size 
distribution 
Indirect dual immunofluorescence was used to define the proportion of neurons 
expressing the transducer protein TRPM8 within the TG and DRG and to observe the 
degree of co-localisation with NF200, CGRP and IB4 (Figure 3-8).   The proportion of 
total profiles which were TRPM8+ in the TG compared to the DRG was, 10.89±1.3% 
(n=3) vs. 6.24±0.3% (n=3) respectively (Table 3-2 A).  There was no significant 
difference between these values.  Expression of TRPM8 was found to be completely 
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exclusive of all standard neurochemical markers (NF200, CGRP or IB4) in both TG 
and DRG (Figure 3-8, Table 3-2). 
 
In TG, the overall cell size distribution for TRPM8+ profiles ranged from 100 – 800 
µm² (median value 327 µm²; 752 profiles) with a peak at 400 µm² (Figure 3-9 A).   In 
DRG, cell size range was 100 – 900 µm² (median value 224 µm²; 333 profiles) with a 
peak at 200 µm² (Figure 3-9 B).  There was a significant difference between mean 
values for overall cell size distributions of TRPM8+ profiles in TG compared to DRG 
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(p=<0.001 t-test) (Figure 3-9 A-B, Table 3-3).  TRPM8+ profiles were distributed 
within cell size groups in TG and DRG as follows: small 90.06% vs. 91.05%, medium 
9.94% vs. 8.95% respectively (Figure 3-9 C).  No neuronal profiles in either TG or 
DRG were found within the large cell size group (Figure 3-9 A-C, Table 3-3).  The 
significant difference in mean values for overall cell size distribution indicates that 
although the majority of cells in both TG and DRG are within the small cell size 
group, the cells from each ganglion are differentially distributed within this size range. 
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3.3.6. Summary of results 
 There are significantly lower levels of CGRP/TrkA co-localisation in TG, along 
with a trend towards lower levels of NF200/TrkA co-localisation in TG compared 
to DRG (Figure 3-1, Table 3-2).  There are significantly more TrkA+ cells within 
the medium cell size range and significantly fewer within the large cell size range 
in TG, along with a trend towards a higher number of TrkA+ cells within the small 
cell size range in TG compared to DRG (Figure 3-2, Table 3-3). 
 There are significantly lower levels of IB4/p55 co-localisation in TG, along with 
trends towards less NF200/p55 co-localisation and more CGRP/p55 co-
localisation in TG compared to DRG (Figure 3-3, Table 3-2).  There are 
significantly more p55+ cells within the small cell size range, along with trends 
towards a lower number of p55+ cells within both medium and large cell size 
ranges in TG compared to DRG (Figure 3-4, Table 3-3). 
 Gp130 was found to be constitutively expressed in all cells in both TG and DRG, 
thus gp130+ cells are present throughout all cell size ranges (Figure 3-5).   
 Overall there are significantly lower levels of both HE-TRPV1 and TRPV1 
expression in TG compared to DRG.  Furthermore, there are significantly lower 
levels of NF200/TRPV1 co-localisation, along with trends towards higher levels of 
CGRP/TRPV1 and IB4/TRPV1 co-localisation in TG compared to DRG (Figure 3-
6, Table 3-2).  There are significantly more TRPV1+ cells within the small cell size 
range and significantly less within the medium cell size range in TG compared to 
DRG (Figure 3-7, Table 3-3). 
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 Overall, there was a trend towards higher levels of TRPM8 expression in TG 
compared to DRG.  No co-localisation of TRPM8 was found with NF200, CGRP 
or IB4 in either TG or DRG (Figure 3-8, Table 3-2).  There was no difference 
between proportions of TRPM8+ cells within cell size groups in TG compared to 
DRG (Figure 3-9, Table 3-3). 
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3.4. Discussion 
Approximately 95% of chronic orofacial pain arises from diseases of the teeth or 
periodontal region (Scully, 2008).  In addition, around 7% of the UK population suffer 
from chronic orofacial pain of a non-dental origin (Zakrzewska, 2007).  Furthermore, 
the aetiology of syndromes with significant non-dental contributions such as burning 
mouth syndrome (BMS), a relatively common condition, atypical facial pain and 
trigeminal neuralgia are poorly understood (Scully, 2008).  It is likely that many of 
these syndromes may have precipitating factors that involve activation of TG neurons 
by injury-induced inflammatory mediators.  In order to understand the interaction of 
such mediators within the TG system, we have determined expression patterns and 
cell size distributions for several markers conferring a nociceptive phenotype and 
compared our results with those in the DRG. 
Previous clinical and animal studies have concluded that the some of the most potent 
inflammatory mediators present during chronic inflammatory states are NGF, TNFα 
and IL-6 (Pezet and McMahon, 2006, Andratsch et al., 2009, Miller et al., 2009).  We 
have therefore made a detailed study on expression levels of receptor components 
for these inflammatory mediators in TG and DRG, namely TrkA, p55 and gp130.  In 
addition we have investigated expression of two thermal transducer proteins, TRPV1 
and TRPM8, both of which have been linked to inflammatory pain (Patapoutian et al., 
2009, Babes et al., 2011).   
A summary of expression and cell size data from previous research studies 
investigating the markers of interest to this study, can be found in Table 3-4, in 
addition to a more detailed analysis below.   
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3.4.1. Expression of cytokine receptors and transducers: a direct 
comparison between TG and DRG 
In the somatosensory system TrkA is traditionally thought to be a marker of 
nociceptive function, being almost exclusively co-expressed by CGRP+ neurons 
within DRG (Priestley, 2009).  TrkA expression in the TG was found to correspond 
with levels in the DRG by Gaspersic et al. (2007), who showed that approximately 
40% of neurons within  the rat TG expressed TrkA.  Their results also showed that 
90% of TrkA-expressing neurons were small to medium in size, suggesting that most 
TG TrkA-expressing neurons were nociceptors.  Of interest were their findings that 
70% of TG neurons innervating the gingivomucosa were TrkA-expressing.  Thus this 
unique orofacial region appears to be predominately innervated by nociceptors and 
would therefore be highly susceptible to NGF released within the inflammatory soup.  
Furthermore, a study investigating expression of rat TrkA mRNA in TG and DRG 
found levels to be the same in both ganglia at 45% (Wetmore and Olson, 1995).   
There is evidence however, that the accepted levels of TrkA expression in the DRG 
may not directly transpose to the TG.  One study observed TrkA expression of 
around 68%, all within small sized neurons (<530 µm²) in rat TG (Jacobs and Miller, 
1999).  Mosconi et al. (2001) found that the relationship between TrkA expression 
and nociceptive phenotype appeared to be less clear-cut within the TG.  Their results 
on mice TG, showed that most cells expressing TrkA were medium to large in size.  
Furthermore, only 43% TrkA+ cells co-expressed CGRP, whereas in the DRG TrkA 
is expressed almost exclusively in CGRP+ cells which are mostly small to medium in 
size (<706 µm²) (Averill et al., 1995).  Another study using mice observed 53% of TG 
neuronal cells expressed TrkA mRNA, although cell size was more in line with TrkA+ 
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cells of the DRG, as these were found to be predominantly small to medium in size 
(<1300 µm²) (Krol et al., 2001).    
Further contradictory results arise when investigating subpopulations of TG neurons.  
Mosconi et al. (2001) found only 10% of neurons innervating incisor pulp in mice 
were TrkA+ and of particular interest, they demonstrated no co-expression within 
these neurons of TrkA and CGRP.  In contrast, Yang et al. (2006) showed 78% of 
neurons innervating rat molar pulp expressed TrkA with only 38% TrkA-expressing 
neurons in non-pulpal afferents, suggesting a larger proportion of nociceptors 
innervating tooth pulp than the surrounding tissues.  Moreover, when investigating 
co-expression of TrkA and CGRP, they found that all CGRP+ cells also expressed 
TrkA.  Interestingly, the majority of TrkA+ cells within the molar pulp were in the 
medium to large cell size range, peaking at around 1257-1590 µm² (Yang et al., 
2006).  These findings concur with an earlier study by Pan et al. (2000) who 
observed TrkA expression in 72% of rat molar pulp neurons and 55% in surrounding 
maxillary neurons.  Here again, pulpal neuronal cells were found to be considerably 
larger than their neighbouring cells, with the majority of pulp cells shown to be 
medium to large (>500 µm²) and the majority of neighbouring cells small (<500 µm²).  
Finally, 70% of rat TG masseter neurons were TrkA+ and expression was uniformly 
distributed among all cell size ranges (Svensson et al., 2010).  These data show that 
there is significant discrepancy between the DRG and TG in relation to the potential 
for TG cells to respond to NGF, an important inflammatory mediator. 
Over the entire ganglia, we have observed TrkA expression to be slightly lower in TG 
compared to DRG (24% and 28% respectively).  Interestingly, we have shown 
significantly less co-expression of TrkA within the CGRP+ population in TG (61%) 
compared to DRG (79%).  Expression of TrkA within the IB4+ population was similar 
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in both ganglia at 11%.   Whereas we observed a trend towards less co-expression 
of TrkA in the NF200+ population in TG compared to DRG (17% and 23% 
respectively) (Figure 3-1, Table 3-2).   
When interpreting our data, the results from a previous study by Yang et al.  (2006) 
on rat molar pulp are of particular interest.  In their study, although all CGRP+ cells 
also expressed TrkA, only 35% of TrkA+ cells co-expressed CGRP.  Furthermore, 
65% of pulpal neuronal cells co-expressed TrkA and GFRα-1, the receptor for glial 
cell line-derived neurotrophic factor (GDNF).  In the DRG, TrkA and CGRP are 
almost exclusively co-expressed and make up the peptidergic population of 
nociceptors, whereas, GFRα-1, is almost exclusively expressed on the IB4+ 
population of non-peptidergic nociceptors (McMahon and Priestley, 2005).  
Therefore, within the tooth pulp, this unusual co-expression of TrkA and GFRα-1, and 
reduced neuropeptide expression, may indicate a population of neurons with a 
unique functional phenotype.  Our data would concur with this, in that we have shown 
a significantly smaller population of CGRP+ neurons over the entire TG (see Chapter 
2) and in addition, only 48% of TrkA+ cells were CGRP+.  Conversely, 39% of 
CGRP+ cells did not express TrkA, the activation of which is known to regulate 
neuropeptide expression (Pezet and McMahon, 2006).  This could imply regulation of 
neuropeptide expression by a neurotrophin other than NGF, possibly GDNF via its 
receptor GFRα-1.   
Our study shows that a significant portion of TG neurons express the TNFα receptor, 
p55.  TNFα has been shown to activate sensory neurons directly (Schäfers et al., 
2003) and sensitise them via post-translational modification of transducer proteins 
such as TRPV1 (Nicol et al., 1997).  TNFα interacts with cells through two structurally 
related receptors, p55 and p75.  Interestingly, activation of the p55 component has 
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been shown to play a key role in the development of hyperalgesia and allodynia 
(Sommer et al., 1998, Moalem and Tracey, 2006, Schäfers et al., 2008).  Within the 
somatosensory system, p55 mRNA has been found to be constitutively expressed in 
the rat DRG (Li et al., 2004).  Protein levels however, have been observed as 13% 
and 15% in rat DRG (Xu et al., 2006, Sakuma et al., 2007).  There is a paucity of 
previous evidence for p55 expression within rat TG.  Bowen et al. (2005) showed p55 
in the majority of CGRP+ neurons, and Hakim et al. (2009) found that 29% of 
masseter nociceptors expressed p55.  Interestingly, another study was unable to 
locate p55 expression on any TG neurons and only observed expression in non-
neuronal cells (Zhang et al., 2011).  Our study has for the first time determined p55 
expression levels within neurochemically defined subpopulations of the TG.  Over the 
entire TG and DRG, we have observed p55 expression in a similar proportion of 
neurons in both ganglia (33% and 38% respectively).  In addition co-expression of 
p55 within the NF200+ populations were similar in both ganglia (27% TG vs. 30% 
DRG).  We observed a slight trend towards higher CGRP/p55 co-expression with 
levels of 39% and 33% in TG compared to DRG respectively.  Moreover, we can 
report significantly less co-expression of p55 within the IB4+ population of non-
peptidergic nociceptors in TG compared to DRG (61% and 89% respectively), 
suggesting that in the TG, a smaller proportion of these nociceptors could respond 
either directly or indirectly to TNFα.   
IL-6 is one of the most potent inflammatory mediators (Andratsch et al., 2009) and is 
upregulated in various pathological conditions such as temporomandibular joint 
disorder (Wang et al., 2009b).  Following activation of its receptor subunits, IL-6 has 
been found to be a critical mediator of increased pain and hyperalgesia experienced 
following injury (Wang et al., 2009c).  Indeed, increased levels of IL-6 and NGF are 
suggested to contribute to the development of mechanical allodynia following 
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trigeminal nerve injury (Anderson and Rao, 2001).  Expression of gp130 has been 
found to be almost ubiquitously expressed across all neurochemical sub-populations 
of the rat DRG (Gardiner et al., 2002).  Only one previous study has examined gp130 
within rat TG and their findings showed that the majority of neurons expressed gp130 
mRNA (Mizuno et al., 1997).  As far as we are aware, ours is the first study 
examining gp130 protein expression within the rat TG.  We can report that our 
findings are in agreement with Gardiner et al. (2002), as we observed almost 
complete expression of gp130 across both TG (99%) and DRG (100%) (Figure 3-5).  
Thus, within the TG and DRG, all neuronal cells, including non-nociceptors, have the 
potential to respond to and be influenced by, the potent inflammatory cytokine, IL-6.  
Indeed, since gp130 has been shown to be essential for the long-term potentiation of 
hypersensitivity (Quarta et al., 2011), these findings could have important 
implications in understanding the mechanisms underlying chronic pain conditions.       
The thermal transducer protein TRPV1, is a common target for post-translational 
modification by potent inflammatory mediators such as NGF and TNFα (Nicol et al., 
1997, Bonnington and McNaughton, 2003b).  In the DRG, previous data has shown 
that TRPV1 is expressed in around 50% of neurons, with the majority within the 
peptidergic and non-peptidergic populations of nociceptors (Guo et al., 1999, 
McMahon and Priestley, 2005).  As mentioned previously, one research group has 
identified a small sub-population of sensory neurons expressing high levels of 
TRPV1 (HE-TRPV1) and which display an unusual repertoire of receptor co-
expression (Michael and Doufexi, 2000).  Their results for HE-TRPV1 expression in 
TG and DRG (L4/5) were <1% and around 2% respectively.  Our results for HE-
TRPV1 expression are similar to this previous study, in that we observed significantly 
less expression within the TG compared to DRG (0.3% and 0.9% respectively) (Table 
3-2).   
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In contrast to the generally agreed levels of TRPV1 expression and co-expression 
within the DRG, a number of reports show a wide variation in the proportions of 
neurons expressing TRPV1 in the TG.  For instance, levels of TRPV1 expression in 
rat TG have been observed as: 50%, mostly in cells <175 µm² (Simonetti et al., 
2006); 48%, mostly in small to medium cells <800 µm² (Bae et al., 2004); 46%, 
mostly in small cells <706 µm² (Tanimoto et al., 2005, Kiasalari et al., 2010); 44% 
(Kobayashi et al., 2005); 27%, mostly in small cells <314 µm² (Nagamine et al., 
2006); 26% (Gibbs et al., 2011); 24%, mostly in small to medium cells <800 µm² (Pei 
et al., 2007); 20%, in cells with a mean area of 427 µm² (Ichikawa and Sugimoto, 
2001); 16%, in cells with a mean area of around 400 µm² (Price and Flores, 2007); 
and the proportion of rat TG neurons responding to capsaicin as: 24% (although this 
study only tested Aδ and C fibre neurons) (Lam et al., 2009). 
TRPV1 expression has also been described with reference to the innervation targets 
of the neurons.  Thus TRPV1 expression in sub-populations of rat TG have been 
reported as: 21-23% (Stenholm et al., 2002), 17% (Gibbs et al., 2011) and 8% in 
molar pulp (Ichikawa and Sugimoto, 2001); 26% in periodontal tissues (Gibbs et al., 
2011); 26% in facial skin (Ichikawa and Sugimoto, 2001); 21-26% in gingiva 
(Stenholm et al., 2002); 35% in masseter afferents (Saloman et al., 2013); 37% in 
cornea (Murata and Masuko, 2006); and that the proportion of rat TG neurons 
innervating molar pulp which respond to capsaicin as: 65% ranging across all cell 
sizes (Chaudhary et al., 2001) and 82% in cells <1,260 µm² (Kim et al., 2010).  
Furthermore, co-expression of TRPV1 with neurochemical markers in rat TG have 
also varied widely across the accepted levels within the DRG.  For instance 68% of 
CGRP+ but only 28% of IB4+ cells co-expressed TRPV1 (Price and Flores, 2007); 
53% of CGRP+ cells were TRPV1+ (Ichikawa and Sugimoto, 2001); and 44% of 
TRPV1+ cells were CGRP+ (Bae et al., 2004).  Whereas in CGRP+ subpopulations 
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of rat TG, 63% of cutaneous neurons and 20% of molar pulp neurons co-expressed 
TRPV1 (Ichikawa and Sugimoto, 2001); and 21% of TRPV1+ neurons innervating the 
dura mater were CGRP+ (Shimizu et al., 2007).   
Our data has shown there to be less expression of TRPV1 over the entire TG 
compared to DRG (27% vs. 33% respectively).  In our direct comparison of the co-
expression of TRPV1 with other neurochemical phenotypes, we note some 
significant differences between TG and DRG.  For instance, we found less co-
expression of NF200/TRPV1 in TG compared to DRG (3% vs. 5%), and marked 
trends towards higher levels of co-expression in both the CGRP+ and IB4+ 
populations in TG compared to DRG (69% vs. 49% and 62% vs. 53% respectively) 
(Figure 3-6, Table 3-2).  These results would suggest that in the TG, although there 
was slightly less TRPV1 expression over the entire ganglia, a relatively larger 
proportion of peptidergic and non-peptidergic nociceptors appear to express the 
thermotransducer TRPV1 in the TG and therefore could presumably be sensitised via 
signalling mechanisms from inflammatory mediators such as NGF and TNFα.  
There has been growing interest in the thermal transducer protein TRPM8 since it 
was first reported around a decade ago (McKemy et al., 2002) and it is now known to 
be activated by both non-noxious cool and noxious cold temperatures (Knowlton and 
McKemy, 2011).  The proportion of neurons expressing TRPM8 within the rat DRG 
have previously been reported as: 23% (mRNA) (Kobayashi et al., 2005); 5-10% 
(mRNA) in cells with a mean area of 254 µm² (Peier et al., 2002) and 6% (Su et al., 
2011); and in mouse DRG: 13%, the majority in cells <380 µm² (Takashima et al., 
2007); 7-9% (Harrington et al., 2011) and 8% (Dhaka et al., 2008).   
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The proportion of TRPM8+ neurons co-expressing other markers has been reported 
as follows, in rat DRG: 81% TRPM8/NF200+, 22% TRPM8/CGRP+, 5% 
TRPM8/IB4+, 17% TRPM8/TRPV1+ (Hayashi et al., 2009) and 8% TRPM8/TRPV1+, 
8% TRPM8/TRPA1+, 21% TRPM8/TrkA (mRNA) (Kobayashi et al., 2005); and in 
mouse DRG: 14% TRPM8/NF200+, 20% TRPM8/CGRP+, 24% TRPM8/TRPV1+ 
(Takashima et al., 2007) and 12% TRPM8/TRPV1+ (Dhaka et al., 2008) 
Similarly, within the TG, the proportion of neurons expressing TRPM8 show wide 
variation with levels in rat TG being reported as: 35% (mRNA) (Kobayashi et al., 
2005) and 12%, in cells with a mean area of 380 µm² (Abe et al., 2005); and in 
mouse TG: 13%, the majority in cells <380 µm² (Takashima et al., 2007); 10% 
(Dhaka et al., 2008), and in a study using menthol-evoked responses as a marker of 
TRPM8 expression in mouse TG, they found that 94% of low-threshold cold sensitive 
neurons and 62% of high-threshold cold sensitive neurons responded to menthol 
(Madrid et al., 2009).  The proportion of TRPM8+ neurons co-expressing other 
markers has been reported as follows in rat TG: 76% TRPM8/NF200+, 3% 
TRPM8/CGRP+, 5% TRPM8/TRPV1+ (Abe et al., 2005); and in mouse TG: 26% 
TRPM8/NF200+, 32% TRPM8/CGRP+, 39% TRPM8/TRPV1+ (Takashima et al., 
2007) and 19% TRPM8/TRPV1+ (Dhaka et al., 2008).   
Although these studies are varied, the majority show that TRPM8 is expressed within 
a relatively small population of TG and DRG neuronal cells.  However, the main 
discrepancies between studies appear to be in establishing co-expression patterns of 
TRPM8 with other markers.  For instance, as detailed above, previous research has 
reported no co-expression of TRPM8 within the NF200, CGRP or IB4 populations of 
sensory neurons (Peier et al., 2002, Dhaka et al., 2008).  Others have reported 
TRPM8 expression to be in small sub-populations of NF200 or CGRP expressing 
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neurons (Takashima et al., 2007), whilst a few studies have shown TRPM8 to be 
almost exclusively expressed with NF200 (Abe et al., 2005, Hayashi et al., 2009).  
What is clear from the above is that a definitive assessment of TRPM8 expression 
levels is lacking in the rat TG. 
Our data show a trend towards higher levels of TRPM8 expression within the TG 
compared to DRG (11% and 6% respectively).  We can also report that we found no 
co-expression of TRPM8 within any of the neurochemical populations being 
examined in both TG and DRG.  Our results, along with some of the previous 
research, seem to suggest that TRPM8+ neurons make up a distinct population of 
sensory neurons.  In TG and DRG therefore, TRPM8 appears to be expressed 
completely exclusively of all other common neurochemical markers.  It is not currently 
known what the functional correlate of this is likely to be. 
3.4.2. Cell size distributions of nociceptive markers: a direct 
comparison between TG and DRG 
Cell size distribution profiles for all markers (TrkA, p55, gp130, TRPV1 and TRPM8) 
across both ganglia were significantly different.  All markers appeared to be 
preferentially expressed on neuronal profiles towards the smaller size range in TG 
compared to DRG.   
Our results showed that the majority of TrkA+ cells within the TG and DRG were 
within the small and medium cell size groups, but there were significantly fewer 
TrkA+ cells in the large cell size group in TG compared to DRG (Figure 3-2, Table 3-
3).  Of particular interest was the significantly larger proportion of TrkA+ TG neurons 
within the medium cell size group, suggesting that within the TG, there is a larger 
number of TrkA+ Aδ fibre nociceptors.  This would concur with two previous studies 
 113 
in rat TG where the majority of TrkA+ neurons were within the medium cell size group 
(Pan et al., 2000, Yang et al., 2006). 
Our study has for the first time established a neuronal profile distribution and the 
proportions of p55+ neurons within each cell size group.  We found a significantly 
larger proportion of p55+ cells within the small cell size group in TG compared to 
DRG.  In addition, there were trends towards less p55 expression in both the medium 
and large cell size groups within the TG compared to DRG (Figure 3-4, Table 3-3).  
This would suggest that within the TG, a larger proportion of C fibre nociceptors were 
able to respond to TNFα than in the DRG. 
We have for the first time examined gp130 protein expression within the TG.  We 
showed ubiquitous expression of gp130 and can therefore report that this protein is 
expressed across all cell size ranges in both TG and DRG.  Therefore, all neurons 
including non-nociceptors have the potential to respond to its ligand, IL-6 and other 
gp130 cytokines.  
Our results showed that the majority of TRPV1+ neurons in the TG were within the 
small cell size group, whereas in the DRG, TRPV1+ neurons were mostly in the 
medium cell size group.  Furthermore, there was an almost complete lack of TRPV1 
expression within the large cell size range in both TG and DRG which is in line with 
previous research and gives credence to TRPV1 being a purported nociceptive 
marker (McMahon and Priestley, 2005) (Figure 3-7, Table 3-3).  Our results would 
also suggest that within the TG, TRPV1+ neurons were more likely to be C fibre than 
Aδ fibre nociceptors.  
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We also report that >90% of TRPM8+ neurons were within the small cell size group 
in both TG and DRG.  This would be in agreement with previous studies in rat 
showing mean cell size of TRPM8 cells to be <400 µm² (Peier et al., 2002, Abe et al., 
2005) and suggests that TRPM8 is expressed exclusively on C fibre nociceptive 
neurons.   
3.4.3. Conclusion 
In conclusion, whilst we reported earlier that there is a significantly larger proportion 
of neurons that express NF200 in the TG, there is a similar level of co-expression of 
receptors for NGF and TNFα, and the transducer proteins TRPV1 and TRPM8, with 
these NF200+ neurons in the TG compared with the DRG.  However, we can report 
for the first time, that gp130 protein is expressed throughout the TG and therefore, all 
NF200+ neurons could potentially respond to IL-6 and assume a nociceptive 
phenotype.   In addition, within the TG, the almost exclusive co-expression of TrkA 
and CGRP seen within the DRG, does not seem to occur.  Indeed only half TrkA+ 
neurons showed CGRP expression and around 40% of CGRP+ neurons did not co-
express TrkA in the TG.  This would strongly suggest that within the TG, alternative 
mechanisms and neurotrophins are potentially regulating both neuropeptide 
expression and neuronal phenotype. 
Taken together, our findings suggest significant differences in proportions of 
neurochemically defined sub-populations of neurons in TG compared to DRG in a 
manner that reflects both the unique regions of target innervation found within the TG 
and the requirement for a rapidly conducting surveillance system to monitor potential 
pathological insults to the orofacial region.   We provide definitive data relating to 
expression levels of receptor components for the potent inflammatory mediators 
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NGF, TNFα and IL-6 and for transducer proteins TRPV1 and TRPM8.  In addition, we 
report profile distributions for all markers and offer quantitative data for expression of 
these markers within cell size groups in both TG and DRG.  Notably, we provide 
evidence that significant proportions of neurons with both nociceptive and non-
nociceptive neurochemical phenotypes have the potential to respond directly to these 
potent inflammatory mediators.  Finally, our data supports the notion that the 
accepted patterns of gene expression defining nociceptors and non-nociceptors 
within the DRG, may not strictly apply within the TG.   
  
 116 
4. Cytokine receptor function and activation 
within neurochemically defined neuronal 
populations of the trigeminal ganglion 
4.1. Introduction 
IL-6 is a pleiotropic cytokine that has wide ranging biological actions on a variety of 
target cells, mainly related to the regulation of inflammatory and immune responses 
(see Verri et al., 2006a).  IL-6 has also been recognised as one of the most potent 
pro-inflammatory mediators present within the inflammatory milieu (Andratsch et al., 
2009).  Indeed, IL-6 is now thought to play a more prominent role in the cytokine 
cascade than first appreciated, as it has been shown to upregulate the production of 
other pro-inflammatory cytokines (see Austin and Moalem-Taylor, 2010).  Studies are 
increasingly showing that IL-6 is a key mediator in the development and progression 
of some chronic inflammatory conditions such as rheumatoid arthritis (Gadient and 
Patterson, 1999).  Furthermore, accumulating evidence points to IL-6 having a crucial 
role in the development of hypernociception, mechanical hyperalgesia and 
mechanical allodynia (Arruda et al., 1998, Anderson and Rao, 2001, Verri et al., 
2006a, Manjavachi et al., 2010).   
The importance of IL-6 in nociception has been further demonstrated since elevated 
levels of IL-6 have been found in patients with chronic pain conditions such as 
complex regional pain syndrome (Heijmans-Antonissen et al., 2006) and 
temporomandibular disorder (Wang et al., 2009b) with pain intensity being positively 
correlated with rising levels of IL-6 (Wang et al., 2009c).  In addition, IL-6 is thought 
to contribute to the pathogenesis of migraine headaches by increasing the excitability 
of dural afferent neurons (Yan et al., 2012).  Interestingly, it has been shown that IL-
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6-evoked signalling contributes towards abnormal pain behaviour following nerve 
injury to the sciatic nerve, but not following injury to the trigeminal nerve, suggesting 
that different mechanisms may contribute towards the development of cephalic (i.e. 
relating to the head) and extra-cephalic neuropathic pain (Latremoliere et al., 2008).   
IL-6, released from immune cells, fibroblasts, keratinocytes and endothelial cells, 
signals via a membrane complex consisting of one transmembrane α-receptor 
subunit, IL-6Rα, that binds IL-6 directly, and two transmembrane signal transducing 
components, gp130 (see Heinrich et al., 1998) known as the ‘classic’ signalling 
pathway (Chalaris et al., 2011).  IL-6 can also regulate cells via ‘trans-signalling’, 
whereby IL-6 binds to a soluble form of its receptor component (sIL-6Rα) forming a 
complex which then binds to membrane-bound gp130 signal transducing 
components (Rincon, 2012).  The soluble IL-6Rα is generated by alternative splicing 
which accounts for around 10% of sIL-6Rα, however, the majority of sIL-6Rα is 
produced by ectodomain shedding via the cleaving action of a disintegrin and 
metalloproteinase, ADAM17 (Chalaris et al., 2011).  Thus, trans-signalling allows IL-6 
to influence cells without the need for them to express IL-6Rα.  Indeed, gp130 has 
been shown to be ubiquitously expressed within the DRG (Gardiner et al., 2002), and 
as a consequence, all somatosensory neurons could be directly regulated via IL-6 
signalling mechanisms.  Interestingly, both IL-6 and sIL-6Rα have been shown to be 
upregulated during inflammatory conditions (Jones et al., 2010).  In addition, it has 
been suggested that IL-6 classic signalling responses tend to be more regenerative 
or anti-inflammatory, whereas IL-6 trans-signalling responses are pro-inflammatory 
and contribute towards the maintenance of inflammatory states (Chalaris et al., 2011, 
Scheller et al., 2011(a), Scheller et al., 2011(b), Rose-John, 2012).  
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Binding of IL-6 to IL-6Rα and association with gp130 triggers activation of the Janus 
kinase (JAK) and signal transducer and activator of transcription (STAT) signalling 
cascade, specifically, JAK1, JAK2 and Tyk2 which in turn leads to phosphorylation 
and activation of STAT3 and STAT1.  IL-6 is a potent activator of STAT3, and STAT1 
to a lesser extent.  In addition, STAT3 activation is often used as a measure of IL-6 
signalling (Zhang et al., 1995, Burton et al., 2011).  Activated STATs form homo- or 
hetero-dimers which translocate to the nucleus and regulate transcription of target 
genes involved in inflammatory and immunological responses such as acute phase 
proteins (see Akira, 1997, Heinrich et al., 1998).  In addition to the JAK/STAT 
pathway, IL-6 can initiate two further cell signalling pathways, namely the MAPK 
(mitogen-activated protein kinase) ERK1/2 pathway and the PI3K/Akt pathway.  
These two additional pathways rely on IL-6-evoked phosphorylation of the scaffolding 
adaptor protein Gab1 (see Heinrich et al., 2003).  Furthermore, ERK1/2 is an 
important mediator for the development of hypersensitivity and central sensitisation 
following peripheral inflammation (Lai et al., 2011).   
We have previously demonstrated for the first time, the ubiquitous expression of 
gp130 protein in rat TG (see previous chapter).  The question to investigate further is 
whether functional activation of these receptor signalling components occur on TG 
neurons.  We have therefore assessed signalling activation in TG neurons by 
analysing STAT3 phosphorylation following exposure to IL-6 with or without the 
presence of its soluble receptor IL-6Rα.  We have used both immunocytochemical 
analysis of STAT3 phosphorylation and Western blot analysis to further quantify the 
increase in pSTAT3 following exposure of neurons to IL-6.  Finally, we have 
determined the neurochemical phenotype of activated neurons in order to better 
understand possible response mechanisms of TG neurons to the potent inflammatory 
mediator, IL-6.   
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4.2. Methods 
4.2.1. Animals 
Experiments were conducted on adult naive male and female Sprague Dawley rats 
ranging from 220-350 g body weight (Charles River, Margate, UK).  All procedures 
were conducted in accordance with the UK 1986 Animals (Scientific Procedures) Act.  
Animals were housed in a temperature controlled room on a 12:12 h light/dark cycle, 
food and water was available ad libitum.  Following Schedule 1 killing, animals were 
transcardially perfused with ice-cold Hanks balanced salt solution (HBSS) (Fisher 
#VX14175053).  TG and DRG were swiftly removed and placed on ice in HBSS.  TG 
were cut into smaller pieces using spring scissors and ganglia were transferred into 
15 ml Falcon tubes containing 1.5 ml HBSS on ice. 
4.2.2. Cell Culture 
LabTek chamber slides (Fisher #TKT-210-916Y) were poly-D-lysine/laminin coated 
(Sigma #P6407/#L2020) as follows: 100 μl of laminin stock (1 mg laminin in 5 ml 
HBSS (without Ca2+/Mg2+, Invitrogen, #14175-053)) was added to 1.1 ml poly-D-
lysine solution (100 µl aliquot of poly-D-lysine stock (5 mg poly-D-lysine in 2.5 ml 
sterile H2O) in 10 ml HBSS).  Wells were washed X2 in sterile H2O (Sigma 
(#W3500)).  125 µl of the prepared poly-D-lysine/laminin solution was added to each 
well and the LabTek chamber slides were stored at 4°C for at least 1 h before use. 
Prior to the plating of cells, wells were washed X2 in sterile H2O.  
TG and DRG neurons were cultured using a protocol adapted from Malin et al. 
(2007) as follows.  Pre-warmed papain solution (1.5 ml HBSS, 3 µl saturated 
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NaHCO3 (Sigma #S5761), 1 mg L-Cysteine (Sigma #C7352), 60 U papain (Fisher 
#76218)) was added to tissue in Falcon tubes containing 1.5 ml HBSS and incubated 
at 37°C for 20 min.  The tissue was agitated at 10 min.  The suspension was 
centrifuged at 2000 rpm for 1 min to pellet tissue followed by careful aspiration of 
supernatant.  The pellet was re-suspended in pre-warmed collagenase/dispase 
solution (3 ml HBSS, 12 mg Collagenase Type II (Sigma #C1764), 14 mg Dispase 
Type II (Sigma #D4693)) and incubated at 37°C for 20 min.  The tissue was agitated 
at 10 min.  The equivalent volume of pre-warmed Trypsin inhibitor (1 mg/ml (Sigma 
#T6522)) was added and the suspension was centrifuged at 2000 rpm for 4 min.  
Supernatant was carefully aspirated and the pellet was re-suspended in 0.5 ml pre-
warmed L15 growth medium (Leibovitz’s L-15 medium with L-Glutamine (Fisher 
#VX11415049), 2% HEPES (1 M) (Invitrogen #15630-056), 1% 
penicillin/streptomycin (Invitrogen #15140-122)).  The tissue was triturated with a 
silicon-coated (Repelcote, VWR #632474U) flame-polished Pasteur pipette 
approximately 10 times until the solution appeared cloudy.  The cell suspension was 
gently layered over a 12.5% - 28% percoll gradient (Sigma #P4937) and centrifuged 
at 3,000 rpm for 10 min.  The upper 4.5 ml of supernatant including interface with 
debris was carefully aspirated and 4 ml of pre-warmed L15 growth medium added.  
The cells were centrifuged at 3,000 rpm for 6 min.  The pellet was resuspended in 
500 µl pre-warmed F12 culture medium (Ham’s F12 nutrient mixture with L-
Glutamine (Fisher #VX21765029), 1% penicillin/streptomycin).  The cells were then 
plated on 8-well LabTek chamber slides pre-coated with poly-D-lysine/laminin.  The 
cells were incubated at 37°C 5% CO2 for 1-2 h after which time the wells were 
flooded with pre-warmed F12 culture medium and incubated at 37°C 5% CO2 for a 
further 18 h. 
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4.2.3. Cell Viability Assays 
4.2.3.1. Trypan Blue 
The cells were cultured as previously described and 0.4% Trypan blue (Sigma 
#T8154) was added to the culture medium to a final concentration of 0.2% w/v.  Cells 
were then incubated at 37°C for 10 min.  The culture medium was aspirated then 
cells were washed in PBS and viewed on an inverted microscope to determine cell 
viability. 
4.2.3.2. Terminal deoxynucleotidyl transferase-dUTP nick end labelling 
(TUNEL) assay 
A Click-iT Tunel AF-488 imaging assay was carried out to determine cell viability 
(Invitrogen #C1-245).  Briefly, cells were fixed by adding 4% ice cold formaldehyde 
(4% w/v in double-distilled H2O, Sigma (#F15587)) and left on ice for 15 min.  The 
cells were permeabilised by adding cold methanol and left at room temperature (RT) 
for 3 min followed by washing X2 with PBS.  For the positive control, cells were 
washed with double-distilled H2O and 100 μl of DNase I solution (1 µl DNase 1/10 µl 
DNase I buffer/89 µl deionised H2O) was added to the appropriate wells.  The cells 
were incubated for 30 min at RT followed by a further wash with double-distilled H2O.  
All cells were then treated with 100 μl terminal deoxynucleotidyl transferase (TdT) 
reaction buffer and incubated for 10 min at RT.  The buffer was then aspirated and 
cells were treated with 100 μl of TdT reaction cocktail (2 µl EdUTP nucleotide 
mixture/4 µl TdT recombinant/94 µl TdT reaction buffer) and incubated for 60 min at 
37 °C.  Cells were then washed X2 with 3% donkey serum in PBS for 2 min each 
wash.   Following this, 100 μl of Click-IT reaction cocktail (2.5 µl Click-IT reaction 
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buffer additive/97.5 µl Click-IT reaction buffer containing Alexa Fluor 488) was added 
and the cells were left for 30 min at RT protected from light.  The cells were washed 
once with 3% donkey serum for 5 min.  For the antibody staining, cells were first 
blocked with 10% donkey serum for 20 min at RT followed by X2 washes in PBS.  
Primary antibody (rabbit-anti-β-Tubulin III, 1:2K, Sigma #T2200) was added and the 
cells were left for 45 min at RT followed by X2 washes in PBS.  Secondary antibody 
(DαRb-Alexa Fluor 555, 10 µg/ml, Abcam, #ab150074) was added and the cells were 
left for 30 min at RT followed by X2 washes in PBS.  DAPI (100 ng/ml, in 0.01 M 
PBS) was added, left on for 15 min at RT followed by X1 wash in PBS.  The 
chambers were removed from the slides and coverslips were added using Fluorsave 
mounting medium.  The slides were left to dry overnight at RT and sealed with nail 
varnish.  The cells were visualised using an epifluorescence microscope. 
4.2.3.3. Neurite outgrowth assay 
The cells were plated on poly-D-lysine/laminin coated 8-well LabTek chamber slides.  
The cells were incubated at 37°C 5% CO2 for 1-2 h after which time wells were 
flooded with pre-warmed F12 culture medium and incubated at 37°C 5% CO2 for a 
further 18 h.  Cells were then flooded with fresh pre-warmed F12 culture medium and 
incubated at 37°C 5% CO2 for a further 24 h.  The cells were then fixed and stained 
as described below and visualised using a Nikon Eclipse 80i epifluorescence 
microscope. 
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4.2.4. Immunocytochemistry 
4.2.4.1. Neurochemical populations within TG and DRG cell cultures 
In order to determine the proportion of viable cells within each neurochemical 
population, immunocytochemistry was carried out as follows.  Cells were cultured as 
previously described, the F12 culture medium was aspirated and cells were fixed in 
4% ice cold formaldehyde.  Cells were left on ice for 15 min.  The formaldehyde was 
aspirated and cells permeabilised by adding cold methanol for 3 min at RT.  The 
methanol was aspirated and cells were washed X2 in PBS.  Cells were blocked with 
10% donkey serum (as per Chapter 1) for 20 min at RT followed by X2 washes in 
PBS.  Primary antibodies were added for 45 min at RT as follows: rabbit-anti-β-
Tubulin III (1:2K, Sigma #T2200) with either mouse-anti-NF200 (1:8K, Sigma 
#N0142), sheep-anti-CGRP (1:600, Enzo Life Sciences #CA1137), or IB4-FITC (5 
µg/ml, Sigma #L2895).  The cells were washed X2 in PBS and secondary antibodies 
were added for 30 min at RT (DαRb-AF-488, DαRb-AF-555, DαM-AF-555, DαS-AF-
555, all at 10 µg/ml).  Cells were then washed X2 in PBS.  DAPI (100 ng/ml, in 0.01 
M PBS) was added for 15 min at RT followed by X1 wash in PBS.  Cover slips were 
then added using Fluorsave mounting medium and left to dry overnight at RT.  The 
slides were sealed with nail varnish. 
4.2.4.2. Optimisation of STAT3 activation in TG 
In order to determine the optimum treatment time for signalling activation, cells were 
cultured on four 8-well LabTek chamber slides and treated with IL-6 (20 ng/ml, R&D 
Systems #206-IL-010) ±IL-6Rα (30 ng/ml, R&D Systems #227-SR-025) for 1 min, 5 
min, 10 min or 15 min.  Using the immunocytochemistry protocol described above, 
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cells were stained with antibodies for mouse-anti-β-Tubulin III (1:2K, Sigma #T8578) 
and rabbit-anti-pSTAT3Tyr705 (1:100, New England Biolabs #9145S).  Further 
experiments were carried out to quantify STAT3 phosphorylation following treatment 
with IL-6±IL-6Rα in TG cells.   
4.2.4.3. Triple staining using Fab fragment 
In order to determine STAT3 activation within neurochemical populations the 
immunocytochemistry protocol was adapted to perform a triple stain using a Fab 
fragment as follows.  Briefly, following fixation, blocking and washing, primary 
antibodies for rabbit-anti-pSTAT3 and mouse-anti-NF200 were added for 45 min at 
RT.  The cells were washed X2 in PBS and goat-anti-mouse Fab fragment (20 µg/ml, 
(monovalent Fab fragment goat anti-mouse IgG (H+L)) Stratech Scientific #115-007-
003) was added for 45 min at RT.  The cells were washed X2 in PBS and blocked in 
10% donkey serum for 20 min at RT.  Cells were then washed X2 in PBS and 
primary antibody for mouse-β-Tubulin III added for 45 min at RT.  Following further 
washes, secondary antibodies were added (DαRb-AF-555 (10 µg/ml), DαG-AF-647 
(10 µg/ml), DαM-FITC (1:200) and the protocol was followed as previously described. 
4.2.5. Western blotting 
The cells were cultured and treated as previously described except that two animals 
were used per 8-well LabTek slide in order to increase final protein levels.  Culture 
medium was aspirated and cells flooded with ice cold PBS and kept on ice.  In order 
to lyse cells, PBS was aspirated and 25 µl of ice cold RIPA lysis buffer (RIPA buffer 
(Sigma #R0278) 5% Protease Inhibitor Cocktail (Sigma #P8340) 1% Phosphatase 
Inhibitor Cocktail 2 (Sigma #P5726)) was added to each well and left on ice for 10 
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min.  The wells were scraped and cell lysate was added to micro-centrifuge tubes.  
Cell lysate was centrifuged at 3,500 rpm at 4°C for 30 min to pellet cell debris.  The 
supernatant was carefully removed without disturbing the pellet and added to fresh 
micro-centrifuge tubes.  In order to keep our protein of interest at its optimal level for 
electrophoresis, we were reluctant to use any to carry out protein estimation assays.  
Therefore, in order to decrease variability in protein levels, equal volumes of vortexed 
supernatant was carefully added to fresh micro-centrifuge tubes before adding the 
appropriate volume of 6X Laemmli SDS-Sample buffer (Bioquote Ltd #10570021-1) 
to each tube.  Variability in protein levels were also reduced by using the 
constitutively expressed protein β-Tubulin III as a loading control.  Samples were 
vortexed then boiled for 5 min, vortexed again then cooled on ice.  Prior to loading, 
samples were centrifuged for 30 s to spin down any condensate.  Proteins were 
separated by SDS-PAGE using 12% Precise Protein Gels (Fisher #PN25202) and 
Tris-HEPES-SDS running buffer (Fisher #PN28368).  The protein samples and 
ladders (BLUeye Pre-Stained protein ladder (Geneflow #S6-0024) plus Biotinylated 
protein ladder (New England Biolabs #7727S)) were loaded onto the gel and run at 
120V for <45 min.  The proteins were blotted onto PVDF membrane (Fisher #FDR-
520-027U), pre-soaked in methanol (15 s), distilled water (2 min) and transfer buffer 
(>5 min), and run at 100V for 35 min.  The membrane was cut horizontally between 
the protein of interest band at 79-86 kDa and the loading control band at 50 kDa and 
placed in separate 50 ml Falcon tubes with protein side facing inwards.  Membranes 
were then blocked in blocking serum (5% w/v bovine serum albumin (Sigma 
(#A2153)) in TBS-Tween20 (Sigma (T9039)) (0.1% w/v)) for 1 h at RT on a roller.  
Primary antibodies were added as follows: rabbit-anti-pSTAT3Tyr705 (1:250 in blocking 
serum) or mouse-anti-β-Tubulin III (2 µg/ml in 50:50 blocking serum:TBS-Tween20 
(0.1% w/v)).  The membranes were incubated overnight on a roller at 4°C.  
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Membranes were then washed 3X 5 min in TBS-Tween20 (0.1% w/v) on a roller at 
RT.  Secondary antibody was added (1:2500, GαRb IgG or GαM IgG both Abcam 
#ab97080 #97040) and the membranes were incubated for 2 h on a roller at RT.  The 
membranes were washed 3X 5 min in TBS-Tween20 (0.1% w/v) on a roller at RT 
followed by one wash in TBS (Sigma (#T6664)) only (0.1% w/v).  The membranes 
were developed using ECL-Plus (Fisher #GZRPN2132) and visualised with an EC3 
Imaging System using VisionWorks L.S. software (both UVP Bioimaging Systems).  
Specificity of the pSTAT3 antibody was determined using a pSTAT3Tyr705 blocking 
peptide (New England Biolabs #1195S). 
4.2.6. Data Imaging and Analysis 
As described in Chapter 2, images for immunocytochemistry were acquired with the 
use of a Nikon Eclipse 80i epifluorescence microscope.  Western blots were imaged 
using an EC3 Imaging System and optical density readings for pSTAT3 were 
normalised against those for β-tubulin III (loading control) in each well to eliminate 
any variability in total protein loading.  Data are expressed as mean ± SEM.  Normal 
distribution was determined using the Anderson-Darling test.  Statistical differences 
were assessed on raw data using a 2-sample T-test.  Significance was set at 
p=<0.05.  * p=<0.05; ** p=<0.01; *** p=<0.001. 
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4.3. Results 
4.3.1. Cell Viability 
A confounding issue surrounding all in vitro assays of primary cells is the possibility 
of injury-induced cell death or preferential survival of neuronal sub-populations over 
others.  Therefore, in order to determine the ability of cells to survive axotomy and 
culturing protocols we carried out several viability assays.  Dye exclusion tests such 
as Trypan blue, are used to determine the number of viable cells present and works 
on the principle that viable cells are able to actively extrude the dye whereas dying or 
dead cells cannot extrude the dye and appear blue (Figure 4-1 A).  In the Trypan 
blue assay, 4.3±1.3% of cells were shown to be unable to extrude the dye.   
The TUNEL assay carried out incorporates fluorescent markers to fragmented DNA.  
Figure 4-1C illustrates the TUNEL positive control where all cells are nick-end 
labelled with fluorescent marker.  Healthy cells with intact DNA can be seen in Figure 
4-1D.  In the TUNEL assay, 1.7±0.4% of cells were shown to have DNA 
fragmentation.   
In a further assay, cell viability was assessed by determining the ability of neurons to 
mount a regenerative response.  Hence neurons were cultured for an additional 24 h 
period in order to allow time for neurite outgrowth in healthy cells (Figure 4-1 B).  
Following the additional 24 h culture period, 96.8±2.1% of cells appeared to display 
neurite outgrowth.   
Data from all three cell viability assays showed cell death to range from 1.7% - 4.3%. 
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4.3.2. Viability of neurochemical populations in culture 
In order to draw conclusions from our in vitro studies, it is important to demonstrate 
that similar proportions of cells are present within each neurochemical population in 
vitro compared to that found in vivo and that no preferential cell death is observed.  
We therefore carried out immunocytochemistry on TG and DRG cell cultures using 
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antibodies for NF200, CGRP and IB4.  An antibody for β-tubulin III was used to 
identify all neuronal cells within the culture, being a neuron-specific β-tubulin isotype 
(Guo et al., 2011).  The proportions of cultured TG neurons expressing NF200, 
CGRP and IB4 was similar to that observed in vivo.  DRG cell cultures also showed 
the same proportions of neurochemically identified cells as seen in vivo.   
Furthermore, the proportional discrepancies between neurochemical phenotypes 
observed in vivo between TG and DRG was also mirrored in vitro.  Therefore, in vitro 
a significantly higher proportion of TG neurons expressed NF200 compared to DRG 
(63.9±0.8% vs. 39.23±0.5%, p=<0.001).  Our findings also confirmed significantly 
lower proportions of both CGRP and IB4 populations of neuronal cells in TG than in 
DRG (34.4±0.6% vs. 50.96±1.0% (p=<0.01) and 37.55±0.9% vs. 45.49±0.4% 
(p=<0.05) respectively) (Figure 4-2).  Overall our results demonstrate that no 
significant preferential cell death was occurring during the cell culture process in 
either TG or DRG cell populations. 
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4.3.3. Activation of STAT3 following IL-6 exposure 
Downstream signalling activation in TG neurons was assessed by analysing STAT3 
phosphorylation following exposure to IL-6 with or without IL-6Rα.   Preliminary 
experiments showed that optimal STAT3 phosphorylation was observed in TG 
neuronal cells following exposure to IL-6±IL-6Rα for 10 min.  This is in line with 
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previous studies that have shown optimal pSTAT3 levels at ≤10 min (Zhang et al., 
1995) and that tyrosine705 phosphorylation of STAT3 occurred within 5 min 
(Schuringa et al., 2000) following IL-6 exposure.  Following treatment, cells were 
rapidly fixed and immunocytochemistry was carried out and neuronal cells were 
identified by staining with β-tubulin III.  In order to quantify neuronal response to IL-
6±IL-6Rα, total neuronal cells were counted and the proportion of neurons showing 
nuclear translocation of pSTAT3 (pSTAT3+) was assessed.  Ten minutes following 
exposure to IL-6±IL-6Rα (20 ng/ml, 30 ng/ml respectively) 39.44±3.4% of neurons 
were pSTAT3+.  This was significantly different to control treatment (18.49±3.0%) 
(p=<0.01, n=3).  No significant difference was found in the proportions of pSTAT3+ 
cells between treatments with IL-6 only (38.27±4.4%) or IL-6 plus IL-6Rα 
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(40.6±3.2%).  Figure 4-3 illustrates enhanced STAT3 phosphorylation in TG neuronal 
cells following 10 min exposure to IL-6±IL-6Rα. 
4.3.4. Quantification of STAT3 phosphorylation following 
exposure to IL-6 
We have further quantified the increase in STAT3 phosphorylation observed in our 
earlier experiments by using Western blot analysis.  TG neuronal cells were cultured 
as previously described and cells were exposed to IL-6 only or IL-6+IL-6Rα for 10 
min.   Activation of STAT3 was assessed using a pSTAT3Tyr705 antibody and was 
analysed by Western blot from whole-cell lysates.  To help eliminate any variability in 
total protein levels loaded onto gels, the data for pSTAT3 was normalised against 
levels of β-Tubulin III which was used as a loading control.  The Western blot image 
in Figure 4-4A displays bands at the appropriate molecular weights for pSTAT3α (86 
kDa), pSTAT3-β (79 kDa) and β-tubulin III (50 kDa) and clearly exemplifies an 
increase in pSTAT3 following exposure of TG neuronal cells to IL-6 only and IL-6+IL-
6Rα.  Following data analysis, our results confirmed our earlier findings that there 
was no significant difference in the levels of STAT3 activation between treatments 
with IL-6 only or IL-6+IL-6Rα.  Furthermore, our results confirmed a significant 
increase in pSTAT3 following treatment with IL-6±IL-6Rα (p=<0.01) when compared 
to control.  To further quantify our results, the following fold increases were observed 
in levels of pSTAT3 when compared to control: IL-6 only, 2.6-fold increase; IL-6+IL-
6Rα, 3-fold increase; combined treatments (IL-6±IL-6Rα), 2.7-fold increase (Figure 4-
4 B).    
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4.3.5. IL-6 preferentially activates STAT3 within the NF200 
population of TG neuronal cells 
In order to determine the phenotype of activated neurons, co-staining of TG cultures 
with NF200 was performed following exposure to IL-6 only or IL-6+IL-6Rα (Figure 4-
5).  Preliminary experiments showed that as a percentage of total neurons, the 
proportion of cells which were pSTAT3+ was as follows: control, 28.14±6.4%; IL-6 
only, 60.37±4.8%; IL-6+IL-6Rα, 61.21±6.4%.  These results confirmed our earlier 
findings in that there was no significant difference between treatment groups with IL-
6 only, and IL-6+IL-6Rα and our data for these treatments were pooled.  Again, 
confirming our earlier experiments, there was a significant increase in STAT3 
phosphorylation following treatment with IL-6±IL-6Rα when compared to control 
(p=<0.01) (Figure 4-6 A).  We further analysed our data to determine phenotypic 
populations of TG neurons which were pSTAT3+.  Our data indicate that the majority 
of the increase in STAT3 phosphorylation occurs within the NF200+ population of 
neuronal cells.  Figure 4-6A illustrates that total STAT3 phosphorylation increased by 
26% within the NF200+ population but only 7% within the combined CGRP+ and 
IB4+ populations.  Furthermore, as illustrated in figure 4-6 B-D, the preferential 
increase in pSTAT3 within the NF200+ population was significant when compared to 
untreated/control cells as follows:  NF200+/pSTAT3+ co-expression increased from 
16% in control cells to 38% in IL-6±IL-6Rα treated cells (p=<0.01); the proportion of 
total NF200+ cells which were pSTAT3+ increased from 31% in control cells to 63% 
in IL-6±IL-6Rα treated cells (p=<0.01); the proportion of total pSTAT3+ cells which 
were NF200+ increased from 42% in control cells to 62% in IL-6±IL-6Rα treated cells 
(p=<0.01). 
 135 
 
 136 
 
  
 137 
4.4. Discussion 
Our previous data has shown that the gp130 signal transducing receptor component 
is ubiquitously expressed in rat TG neurons.  IL-6 is a potent activator of STAT3 
(Zhang et al., 1995), therefore, in order to test the functional competency of the 
receptor component gp130, we investigated the upregulation of pSTAT3 in cultured 
TG neurons following exposure to IL-6.  We first established the viability of TG and 
DRG neuronal cell cultures and determined that similar proportions of neurons within 
each neurochemical population were surviving in vitro as were found in our in vivo 
experiments.  We observed a similar discrepancy in proportions of neurochemical 
populations between TG and DRG in vitro that we found in vivo, in that there was a 
significantly larger population of NF200+ neurons, and significantly smaller 
populations of CGRP+ and IB4+ neurons in TG compared to DRG (Figure 4-2).  We 
are confident therefore, that all neuronal sub-populations are represented in our 
cultures in similar proportions that appear in situ.   
Our results showed a significant increase in pSTAT3 in TG cells following 10 min 
exposure to IL-6±IL-6Rα, with 39.4% of cells being pSTAT3+ compared to 18.5% in 
control cells (Figure 4-3).  Somewhat surprisingly, we found no significant difference 
in the levels of pSTAT3 between cells treated with IL-6 only and IL-6+IL6Rα (38.3% 
and 40.6% respectively).  To further quantify this increase in STAT3 phosphorylation, 
we carried out Western blot analysis on TG neuronal cells following identical 
treatment protocols as per our immunocytochemistry experiments.  Here again, we 
found that pre-treatment with IL-6±IL-6Rα led to a significant 2.7-fold increase in 
STAT3 phosphorylation.  Our Western blot analysis also confirmed our previous 
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findings of no significant difference in levels of pSTAT3 between treatments with IL-6 
alone or IL-6+IL-6Rα (Figure 4-4 B). 
As described earlier, IL-6 can signal via the classic signalling pathway, which 
requires expression on the target cell of its cognate receptor, IL-6Rα, in addition to 
the signal transducing component gp130.  However, cells which only express gp130 
but do not express IL-6Rα, are still able to be influenced by IL-6 via the trans-
signalling mechanism, using a soluble IL-6Rα which has been made available, mainly 
by the cleaving action of ADAM17 (see Gardiner et al., 2002, Chalaris et al., 2011).  
The membrane expression of IL-6Rα, is thought to be predominantly restricted to 
leukocytes and hepatocytes (see Rincon, 2012).  Therefore, for neuronal cells to be 
able to respond to IL-6, one could assume that it was a necessity for the soluble form 
of the IL-6Rα to be present within the surrounding media.  Indeed, in the in vivo state, 
this may be the case, as sIL-6Rα could be shed from surrounding non-neuronal cells.  
However, within the in vitro state, this would not occur to such an extent, of course, 
depending upon the homogeneity of the cultured cells.  Nonetheless, we are not the 
first to report such findings, indeed, Vardanyan et al. (2010), when investigating IL-6-
evoked CGRP release from rat DRG, recorded no difference in response when co-
administering IL-6+IL-6Rα than with IL-6 alone.  There is evidence to suggest that the 
classic signalling and trans-signalling pathways, activate alternative downstream 
signalling cascades (Chalaris et al., 2011, Scheller et al., 2011(a), Scheller et al., 
2011(b)).  Therefore, in order to record a difference in treatments with or without 
exogenous IL-6Rα, we may need to investigate an additional outcome to STAT3 
phosphorylation, such as the activation of ERK1/2.  We can only conclude therefore, 
that under our present culture conditions and within the confines of our experimental 
protocol, the presence of additional exogenous IL-6Rα was not required for TG 
neuronal cells to respond to IL-6. 
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In order to determine the phenotype of neurons expressing pSTAT3 we carried out 
co-staining of TG cultures for phenotypic markers.  We observed that the majority of 
the increase in STAT3 phosphorylation was occurring within the NF200+ population 
of neuronal cells.  For instance, under control (untreated) conditions, STAT3 
phosphorylation was split almost equally between the population of NF200+ cells 
(12%), and the remaining neuronal cells (16%), which were assumed to be the 
combined populations of pSTAT3+ CGRP expressing and IB4 binding cells.  
However, following exposure to IL-6±IL-6Rα, there was a significant increase in 
pSTAT3 observed only within the NF200+ population, which increased from 12% to 
38%, equivalent to a 3.2-fold increase.  The increase in pSTAT3 in the remaining 
population of neuronal cells was only a small amount, from 16% to 23%, representing 
a 1.4-fold increase (Figure 4-6A-D). 
Since we have demonstrated that gp130 appears to be ubiquitously expressed 
throughout TG neuronal cells, our results showing that STAT3 was preferentially 
activated in NF200+ cells following IL-6 exposure, is a notable finding and requires 
examination.  As far as we are aware, only one other study has investigated IL-6-
evoked STAT phosphorylation within neurochemical populations of TG neuronal 
cells, albeit, in a mouse model.  Although this study used pSTAT1 as an outcome 
measure rather than pSTAT3, they also found that the activation of STAT1 was 
preferentially within the NF200+ population of neuronal cells (Kobierski et al., 2000).  
There is the possibility that although gp130 is ubiquitously expressed, its levels of 
expression may not be uniformly distributed across all populations of neuronal cells.  
Higher levels of expression may occur within the myelinated population of cells, 
allowing for greater levels of signalling and enhanced STAT3 activation within this 
population.  Although STAT3 phosphorylation may also have been occurring to a 
lesser extent within the NF200-negative population of cells, in some of these cells, 
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activation may have been at such a low level to have been below the threshold set 
within our experimental protocol for marking cells as pSTAT3+.  Alternatively, IL-6 
may be activating other signalling cascades within the NF200-negative population, 
which we have not monitored and this would require a different outcome measure, 
such as phosphorylation of ERK1/2 or PI3K to be quantified.  However, if NF200+ 
neurons have higher levels of expression of gp130 and enhanced levels of STAT3 
activation, then IL-6 could be preferentially acting on what would traditionally be 
classified as non-nociceptors which may have important implications during 
inflammatory conditions, such as altering the phenotype and function of these cells.  
Indeed, this would have an even greater impact within the trigeminal nervous system 
due to the significantly larger population of NF200+ neurons which we have observed 
within the TG. 
There is growing evidence to support the importance of IL-6 in the development of 
chronic pain conditions and its involvement in the pathogenesis of 
temporomandibular disorder and migraine headaches (Heijmans-Antonissen et al., 
2006, Wang et al., 2009a, Wang et al., 2009c, Yan et al., 2012).  In addition, IL-6 is 
now thought to have a crucial role in the development of mechanical hyperalgesia 
and mechanical allodynia (Arruda et al., 1998, Anderson and Rao, 2001, Verri et al., 
2006a, Manjavachi et al., 2010).  In combination with the fact that myelinated 
neurons are generally thought to be either low- or high-threshold mechanoreceptors 
(see McMahon and Priestley, 2005), along with our previous results of a much larger 
population of NF200+ neurons within the TG, these additional findings may go 
towards explaining the high prevalence of mechanical hyperalgesia and allodynia 
observed in some orofacial pain conditions, in particular, temporomandibular joint 
disorders and following intradental injury and inflammation (Anderson and Rao, 2001, 
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Sessle, 2005, Takeda et al., 2005(a), Takeda et al., 2006, Morgan and Gebhart, 
2008, Takeda et al., 2008(a), Takeda et al., 2008(b), Takeda et al., 2008(c)). 
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5. Cytokine receptor-mediated sensitisation 
of thermo-transducer function in 
trigeminal neurons 
5.1. Introduction 
The binding of IL-6 to its cognate receptor, IL-6Rα, and association with its signal 
transducing receptor component gp130, triggers activation of the JAK/STAT 
signalling cascade (Zhang et al., 1995, Burton et al., 2011).  We have shown 
previously that IL-6 application to TG neurons in culture results in STAT3 
phosphorylation and translocation of this signal transducer to the nucleus.  This 
implies a potential functional outcome of exposure to IL-6 in TG neurons (see 
Chapter 4).  However, IL-6 is capable of triggering two additional signalling pathways 
namely, the Gab1/MAPK/ERK1/2 pathway and the Gab1/PI3K/Akt pathway (see 
Heinrich et al., 2003).  Given the number of signalling pathways, it is important to 
determine whether a functional response occurs within TG neurons following 
exposure to IL-6 and by which pathway.  Therefore, by using different outcome 
measures to STAT3 phosphorylation, we could investigate functional responses via 
alternative signalling pathways. 
One outcome we have used is CGRP release as a functional measure of TG neuron 
activation and subsequent sensitisation by IL-6.  Previous studies have demonstrated 
that activation of neurons by TRPV1 ligands leads to neuronal activation and the 
release of CGRP (Flores et al., 2001, Fehrenbacher et al., 2009, Meng et al., 2009, 
Loyd et al., 2012).  CGRP is a vasoactive neuropeptide, the actions of which 
increase neurotransmitter release leading to hyperalgesia and central sensitisation.  
Furthermore, CGRP can be released antidromically in the periphery where it has 
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been strongly linked with neurogenic inflammation and chronic pain conditions such 
as migraine and temporomandibular joint disorder (Sixt et al., 2009, Eftekhari et al., 
2010, Benarroch, 2011, Cady et al., 2011, Ceruti et al., 2011).  CGRP release 
therefore, is a useful indicator of functional activation of primary sensory neurons. 
Furthermore, it is also widely known that post-translational modifications of thermo-
transducer channels can significantly alter neuronal response properties.  For 
instance, phosphorylation of TRPV1 at serine or threonine amino acid residues, 
results in transducer sensitisation that leads to exaggerated responses to 
subsequent noxious stimuli (Numazaki et al., 2002, Zhang and McNaughton, 2006, 
Jeske et al., 2008, Studer and McNaughton, 2010).  Many inflammatory mediators 
such as, NGF, bradykinin, prostaglandins, brain-derived neurotrophic factor (BDNF), 
GDNF and TNFα are known to be responsible for triggering the phosphorylation and 
sensitisation of TRPV1 (Shu and Mendell, 1999, 2001, Bonnington and McNaughton, 
2003a, Price et al., 2005, Huang et al., 2006b, Zhu and Oxford, 2007, Khan et al., 
2008, Schmutzler et al., 2009).  One consequence of TRPV1 sensitisation by 
inflammatory mediators has been the demonstration of an increased release of 
CGRP following exposure of neurons to the TRPV1 agonist capsaicin.  Hence, TNFα, 
BDNF and GDNF have all been shown to increase levels of capsaicin-evoked CGRP 
release (Price et al., 2005, Khan et al., 2008, Schmutzler et al., 2009). 
Only a minority of studies have investigated the functional outcome of IL-6-receptor 
activation in sensory neurons, either in terms of direct neuronal activation or 
sensitisation to subsequent stimuli.  Using behavioural outcome measures, IL-6 has 
been shown to decrease paw withdrawal latencies to heat stimulation in mice, and to 
decrease withdrawal latencies to both mechanical and heat stimulation in rats 
(Andratsch et al., 2009, Vardanyan et al., 2010).  Furthermore, in vitro studies have 
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demonstrated that IL-6 increases thermal hyperalgesia, decreases thermal threshold 
and increases CAPS-evoked inward currents and augments CGRP release (Oprée 
and Kress, 2000, Obreja et al., 2002, Obreja et al., 2005, Andratsch et al., 2009, 
Vardanyan et al., 2010).  All these studies have addressed activation and 
sensitisation of sensory neurons in the somatosensory system.  To our knowledge, 
no studies to date have investigated the effect of IL-6 on TRPV1 sensitisation within 
the rat TG.  
The cellular mechanisms underlying TRPV1 sensitisation by inflammatory mediators 
remain unclear.  However, protein kinase C (PKC) and more particularly, PKCδ, are 
believed to have key roles in the potentiation of TRPV1 activity and in regulating the 
IL-6 signalling pathway (Jain et al., 1999, Schuringa et al., 2001, Vellani et al., 2001, 
Novotny-Diermayr et al., 2002, Bhave et al., 2003, Obreja et al., 2005, Honan and 
McNaughton, 2007, Andratsch et al., 2009, Studer and McNaughton, 2010, 
Wallerstedt et al., 2010).  We have investigated therefore, the effect of IL-6 signalling 
and possible TRPV1 sensitisation on rat TG neurons.  We have used two 
independent and distinct measures of neuronal excitation and sensitisation.  First, we 
have examined the effect of IL-6 on CAPS-evoked CGRP release by analysing cell 
supernatant using an in vitro enzyme immunoassay.  In addition, we have 
investigated potential signalling pathways involved in IL-6 mediated effects by using 
the specific PKCδ inhibitor, Rottlerin.  Second, we have performed in vitro 
electrophysiological experiments to monitor the functional outcome of capsaicin 
activation of TG neurons and the modification of responses in the presence of IL-6.  
Through specific membrane capacitance measurement, these studies have 
additionally allowed estimation of neuronal cell size and potential functional modality 
to be made. 
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5.2. Methods 
5.2.1. CGRP release Enzyme Immunoassay 
TG cells were cultured as previously described except that four animals were used 
per 8-well LabTek slide to ensure optimum protein levels.  The protein kinase 
inhibitor Rottlerin, which preferentially inhibits the PKCδ isoenzyme (Gschwendt et 
al., 1994), was used to investigate a possible role for PKCδ in the sensitisation of 
TRPV1 following IL-6-evoked downstream activation of PKCδ.  TG cells were 
cultured overnight and culture medium was aspirated and replaced with fresh pre-
warmed F12.  Different treatments were performed in each of the 8 wells as follows: 
(1) F12 only; (2) CAPS only; (3) IL-6 only; (4) IL-6+IL-6Rα; (5) CAPS+IL-6; (6) 
CAPS+IL-6+IL-6Rα; (7) CAPS+IL-6+Rottlerin; (8) CAPS+IL-6+IL-6Rα+Rottlerin 
(Figure 5-1 C).  The timeline for the treatment of cells was as follows and as 
illustrated in Figure 5-1A.  Rottlerin (6 µM, Fisher #32849-0100) was added and cells 
incubated at 37°C for 30 min.  Following this IL-6 (20 ng/ml) ±IL-6Rα (30 ng/ml) was 
added and cells were incubated at 37°C for 20 min.  Capsaicin (CAPS) (30 µM, 
Sigma #M2028) was then added and cells were incubated for a further 20 min at 
37°C.  The supernatant was collected and CGRP levels determined by carrying out 
an enzyme immunoassay (EIA) (CGRP (rat) enzyme immunoassay kit (SPI-bio), 
Bioquote Ltd #589001).  Briefly, samples, standards and controls, all in duplicate, 
were added to a 96-well plate pre-coated with mouse-anti-CGRP monoclonal 
antibody.  Following this anti-CGRP acetylcholinesterase conjugate was added to 
each well and the plate was incubated overnight at +4°C.  Following several washes, 
Ellman’s Reagent (5,5'-dithiobis-(2-nitrobenzoic acid), 2% w/v in deionized H2O and 
2% v/v wash buffer) was added to all wells and incubated on an orbital shaker for 30 
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– 60 min protected from light.  The plates were read at 405 nm in a Versa Max plate 
reader using SoftMax Pro software (Molecular Devices).  Serial dilutions of a known 
concentration of CGRP were run in duplicate and used to produce a standard curve 
for each experiment.  Polynomial regression analysis was applied to each standard 
curve and used to determine unknown concentrations of CGRP from samples.  
Control experiments were also carried out using TNFα (10 ng/ml, 50 ng/ml, 100 
ng/ml, R&D #510-RT) with and without TNFα neutralizing antibody (60 µg/ml, R&D 
#AF-510-NA) (Figure 5-1 B, C).   
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5.2.2. Electrophysiology 
TG neuronal cells were cultured as previously described except that cells were plated 
onto Melinex (Agar Scientific #L4103).  The Melinex sheeting was pre-treated as 
follows.  The Melinex was cut to size, washed X2 in 70% ethanol and rinsed with L15 
medium.  The Melinex was then pre-coated with poly-D-lysine/laminin and rinsed with 
sterile water before plating cells.  All electrophysiological recordings were carried out 
at room temperature with an Axopatch 200B amplifier (Axon CNS).  The output was 
digitized with a Digidata 1440A converter (Axon CNS) and was sampled every 5 ms.  
Data was visualised using Axoscope software.  Patch pipettes were pulled on a 
Narishige 2-stage puller from borosilicate glass capillaries (1.5 mm O.D. X 0.86 mm 
I.D., Harvard Apparatus #30-0058) and fire polished using a Microforge MF-90.  
Following overnight incubation, cells were placed into the recording chamber and 
were continuously superfused (1 ml/min) with physiological solution containing (in 
mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 D-glucose and 10 HEPES (pH adjusted 
to 7.4 with NaOH).  Single cells were patch clamped in the whole-cell configuration 
using pipettes with a resistance of 3-5 MΩ when filled with (in mM): 140 KCl, 1 
MgCl2, 1 CaCl2, 10 EGTA and 10 HEPES (pH adjusted to 7.3 with KOH).  The cells 
were voltage clamped at holding membrane potential of -60 mV.  Series resistance 
was compensated by >80%.  CAPS (10 µM) was delivered via a syringe through a 
narrow tube located close to the cell.  A pulse of solution containing CAPS (200 µl, 2 
s) was applied at 1 min intervals.  Under these conditions, an habituation of the 
response to repeated CAPS pulses (tachyphylaxis) was observed.  The effect of IL-6 
on response tachyphylaxis was examined by pre-treating cells with physiological 
solution containing IL-6 (20 ng/ml).  After 5 min, repeated CAPS pulses at 1 min 
intervals were applied as before whilst in the presence of IL-6.  Cross-sectional areas 
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of cells were calculated (area = (π)r2) following conversion of membrane capacitance 
to cell diameters using d = √[100 X Cm/π], where d (in micrometers) is cell diameter 
and Cm (in picofarads) is membrane capacitance (Akopian et al., 2008).   
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5.3. Results 
5.3.1. Effect of cytokines on CAPS-evoked CGRP release 
TNFα has previously been shown to directly enhance TRPV1 sensitivity and lead to 
an increase in CAPS-evoked CGRP release in rat TG (Khan et al., 2008).  As a 
measure of control and to verify the reliability of our assay, we have confirmed these 
data by carrying out an initial EIA using TNFα at various concentrations (10 ng/ml, 50 
ng/ml, 100 ng/ml) with and without TNFα neutralizing antibody (60 µg/ml).  Optimal 
results were achieved using TNFα at 50 ng/ml.  Baseline and evoked CGRP 
concentrations were as follows: basal, 78 pg/ml; CAPS, 140 pg/ml (180% of basal); 
TNFα, 118 pg/ml (151% of basal); TNFα+CAPS, 330 pg/ml (424% of basal); 
TNFα+CAPS + neutralising antibody, 218 pg/ml (280% of basal) (Figure 5-2 A-B).  
Our results demonstrate that exposure of TG neuronal cells to TNFα (50 ng/ml) 
increased levels of CAPS-evoked CGRP release by 236% over CAPS-only evoked 
values (n=1).  This effect was reduced by the inclusion of a TNFα neutralising 
antibody (Figure 5-2 A-B).   
Further experiments were carried out to determine the effect of IL-6 upon CAPS-
evoked CGRP release.  Experiments were performed in the presence and absence 
of the soluble receptor IL-6Rα.  Experiments were also performed in the presence 
and absence of the specific PKCδ inhibitor, Rottlerin (Gschwendt et al., 1994).  
Baseline and evoked CGRP concentrations were as follows: basal, 78±25 pg/ml; 
CAPS, 140±47 pg/ml (179±2% of basal); IL-6±IL-6Rα, 79±31 pg/ml (98±6% of basal); 
IL-6±IL-6Rα+CAPS, 143±48 pg/ml (182±3% of basal); IL-6±IL-6Rα+CAPS+Rottlerin, 
140±36 pg/ml (186±12% of basal) (Figure 5-2 C-D).  These data show that a 
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stimulated release of CGRP was detected in the presence of CAPS which was 
significant from baseline levels (p=<0.01).  IL-6±IL-6Rα did not evoke a significant 
release of CGRP above baseline in the absence of CAPS.  Furthermore, CAPS-
evoked CGRP release was not significantly altered by IL-6±IL-6Rα pre-treatment or 
following the inclusion of Rottlerin (Figure 5-2, C, D).   
These data suggest that TNFα but not IL-6 evokes a partial sensitisation of TG 
neurons in terms of the CAPS-mediated release of CGRP (Figure 5-2). 
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5.3.2. Effect of IL-6 on CAPS-evoked electrophysiological 
responses 
Dissociated TG cells were whole-cell clamped and held at a potential of -60 mV.  
Recordings were made from 31 cells from a total of 5 animals.  Membrane 
capacitance of cells ranged from 8.5 pF to 55 pF which corresponded to cell cross-
sectional areas ranging from 211 µm² to 1377 µm².   CAPS (10 µM, 2 s) exposure 
produced an inward current in 58% (18/31) of the cells studied.  The mean current 
amplitude following the first application of CAPS was 686±22 pA (n=18) in 
responding cells compared to 6.8±2.1 pA (n=13) in non-responding cells.  Although 
the amplitude of the CAPS-evoked current varied considerably among CAPS-
responsive cells (range 55 pA to 3800 pA) there was a significant difference in total 
current between responding and non-responding cells (p=<0.01) (Figure 5-3 A).  The 
mean current density following the first application of CAPS was 34.5±7 pA/pF in 
responding cells compared to 0.33±0.1 pA/pF in non-responding cells.  There was a 
significant difference in current density between responding and non-responding cells 
(p=<0.001) (Figure 5-3 B).  
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The membrane capacitance and calculated cell size areas of CAPS-responsive and 
non-responsive cells was further analysed.  Membrane capacitance for CAPS-
responsive cells ranged from 8.5 pF to 39 pF (n=18) which gave equivalent cell sizes 
ranging from 211 µm² to 975 µm².  Membrane capacitance for CAPS non-responsive 
cells ranged from 10 pF to 55 pF (n=13) which gave equivalent cell sizes ranging 
from 250 µm² to 1377 µm² (Figure 5-4 A).  There was a significant difference in mean 
cell size areas between CAPS-responding cells (491±54 µm²) and CAPS non-
responding (757±11 µm²) (p=<0.05) (Figure 5-4 B).  The proportions of cells within 
each cell size group (see section 2.3.2) for CAPS-responding and non-responding 
cells were as follows: small 59% vs. 46%, medium 41% vs. 23%, large nil vs. 31%.  
These data demonstrate that cells with the highest current density were within the 
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small and medium cell size range (Figure 5-4 A).  In addition, our data show a 
complete absence of CAPS responsive within the large cell size range whereas 
CAPS non-responsive cells were represented throughout all cell size ranges (Figure 
5-4 A).  
 
 155 
In response to repeated applications of CAPS (200 µl, 10 µM, 2 s) at 1 min intervals, 
tachyphylaxis was clearly demonstrated with a decrease in mean amplitude of the 
response from 721 pA to 8 pA over 6 successive CAPS applications.  The result of 
repeated CAPS applications to non-responsive cells is also demonstrated for 
comparison (Figure 5-5 A-C). 
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The effect of IL-6 upon CAPS-evoked tachyphylaxis was examined.  An initial 
application of CAPS (10µM, 2 s) was given to establish that the cell was CAPS-
responsive.  Cells were then superfused in physiological solution containing IL-6 (20 
ng/ml) for 5 min before repeated applications of CAPS at 1 min intervals.  Figure 5-
6A illustrates responses to successive CAPS applications in the presence or 
absence of IL-6.  Figure 5-6B illustrates these data normalised as a percentage of 
the initial CAPS current for each cell examined.  Our data show that superfusion with 
IL-6 had no significant effect upon CAPS-evoked tachyphylaxis (Figure 5-6 A-B). 
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We further analysed CAPS-evoked current kinetics in the presence or absence of IL-
6.  Mean recovery time and time-to-peak of CAPS-evoked responses were further 
analysed.  Figure 5-7(A, B) illustrates the typical responses of a cell to a single pulse 
of CAPS in the presence or absence of IL-6.  Mean recovery times were measured 
from peak current to the time taken for return to baseline current levels.  Mean 
recovery time of CAPS-evoked current was greater in IL-6 treated populations 
compared to CAPS alone (90.8±35 s vs. 22.9±2 s respectively), however, these 
values did not reach significance (Figure 5-7 C).  Mean time-to-peak of CAPS-evoked 
current was greater in IL-6 treated populations compared to CAPS alone (44.7±10 s 
vs. 2.8±0.4 s respectively).  These data show that IL-6 significantly increased time-to-
peak values of CAPS-evoked current (p=<0.05) (Figure 5-7 D).  These data indicate 
that there is a trend towards IL-6 enhancement of CAPS-evoked total current.  
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5.3.3. Summary of results 
 The levels of CAPS-evoked CGRP release were analysed in the presence or 
absence of TNFα.  TNFα was found to enhance CAPS-evoked CGRP release 
by >200% (Figure 5-2 A-B). 
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 The levels of CAPS-evoked CGRP release were analysed in the presence or 
absence of IL-6±IL-6Rα and in the presence or absence of the PKCδ inhibitor 
Rottlerin.  No effect was seen upon CAPS-evoked CGRP release (Figure 5-2 C-
D). 
 The mean cell size of CAPS-responding cells was found to be significantly smaller 
than non-responding cells (p=<0.05).  There was a complete absence of CAPS-
responding cells within the large cell size range (Figure 5-4 A-B). 
 Successive CAPS applications resulted in tachyphylaxis in CAPS-responding 
cells with a decrease in mean CAPS current from 721 pA to 8 pA over 6 
successive CAPS applications (Figure 5-5 A-C). 
 IL-6 appeared to have no significant effect on CAPS-induced tachyphylaxis 
(Figure 5-6 A-B). 
 Time-to-peak of CAPS-evoked responses were significantly extended in the 
presence of IL-6 (p=<0.05).  Furthermore, there was a trend towards prolonged 
recovery time of CAPS-evoked responses in the presence of IL-6.  Overall our 
results demonstrate a significant augmentation of CAPS-evoked current kinetics 
in the presence of IL-6 (Figure 5-7 A-D).  
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5.4. Discussion 
There is a growing body of evidence to suggest a major role for IL-6 in the 
development and maintenance of hyperalgesia and chronic pain.  Indeed, a 
correlation has been found between the up-regulation of IL-6 and rising pain intensity 
in a variety of inflammatory pain states (Verri et al., 2006a, Wang et al., 2009c, 
Rincon, 2012).  IL-6 activates cells by binding to its cognate receptor IL-6Rα and 
subsequent association with its signal transducing receptor component gp130 (see 
Heinrich et al., 1998).  We have for the first time demonstrated that gp130 receptor 
protein is ubiquitously expressed throughout the rat TG (see Chapter 3).  In addition, 
we have shown that IL-6 activates the JAK/STAT signalling pathway within 
subpopulations of TG neuronal cells.  Indeed, our data has shown that IL-6 is 
preferentially activating STAT3 within the NF200+ population of TG neurons (see 
Chapter 4).  One possibility to explain these findings is that although gp130 is 
ubiquitously expressed, its levels of expression may not be uniformly distributed 
across all populations of neuronal cells.  Alternatively, IL-6 may be activating other 
signalling cascades within the NF200-negative population, which would require a 
different outcome measure to STAT3 phosphorylation to be quantified, such as 
transducer sensitisation.   
The cellular mechanisms underlying TRPV1 sensitisation by inflammatory mediators 
remain unclear, however, a key mediator in the potentiation of TRPV1 activity is 
thought to be the phosphorylation of serines S502 and S801 on TRPV1 by protein 
kinase C (PKC) (Vellani et al., 2001, Bhave et al., 2003, Honan and McNaughton, 
2007, Studer and McNaughton, 2010).  Interestingly, a particular isoenzyme of PKC, 
PKCδ, has been demonstrated to have a regulatory role in IL-6 signalling via the 
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JAK/STAT pathway.  For instance, PKCδ has been shown to enhance STAT3 
dimerisation and nuclear translocation and to maximise transcriptional activity 
(Schuringa et al., 2001, Novotny-Diermayr et al., 2002, Wallerstedt et al., 2010).  
Although, one study has suggested a negative regulatory role for PKCδ in inhibiting 
STAT3 DNA binding and transcriptional activity (Jain et al., 1999).  Furthermore, 
there is evidence to suggest a link between IL-6 evoked activation of PKCδ and 
sensitisation of TRPV1.  For instance, PKCδ was demonstrated to have a key role in 
enhancing heat hyperalgesia (Obreja et al., 2005).  Moreover, a further study has 
suggested a novel pathway for TRPV1 sensitisation by IL-6 signalling, via cross-talk 
between PI3K and PKCδ and subsequent phosphorylation of TRPV1 (Andratsch et 
al., 2009).   
We have previously shown that IL-6 is preferentially activating the JAK/STAT 
signalling pathway in the NF200+ population of TG neurons.  Furthermore, we have 
previously shown that in the TG, TRPV1 expressing neurons are almost entirely 
NF200-negative (see Chapter 3).  Therefore, by investigating the sensitisation of 
TRPV1 responses, this permits us to analyse functional activation of other signalling 
pathways by IL-6 in the TRPV1+ (NF200-negative) cell population.  We have 
therefore analysed two potential outcome measurements of the sensitisation of the 
TRPV1 transducer following cytokine application in vitro.  First, we have investigated 
the effect of IL-6 on CAPS-evoked CGRP release as a measure of TRPV1 
sensitisation by analysing CGRP levels in supernatant by enzyme immunoassay.  In 
addition, we have investigated a possible role for PKCδ in TRPV1 sensitisation, by 
including in our experimental protocol the PKCδ inhibitor, Rottlerin.  Previous in vitro 
studies have determined TRPV1 sensitisation by inflammatory mediators such as 
TNFα, BDNF and GDNF, by demonstrating increased release of CGRP following 
exposure of neurons to the TRPV1 agonist CAPS (Price et al., 2005, Khan et al., 
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2008, Schmutzler et al., 2009).  To our knowledge, only one previous study has 
investigated the in vitro effects of IL-6 on CAPS-evoked CGRP release in neuronal 
cells.  Their results demonstrated a significant augmentation of CAPS-evoked CGRP 
release in the presence of IL-6 in rat DRG (Vardanyan et al., 2010).   Therefore, as 
far as we are aware, ours is the first study to investigate the effect of IL-6 on CAPS-
evoked CGRP release within the rat TG.   
Second, we have performed electrophysiological studies to examine the effect of IL-6 
on CAPS-evoked responses in rat TG neuronal cells.  These studies enabled us 
examine a further outcome measure and in addition, to incorporate the majority of the 
TRPV1+ population of TG neuronal cells in our investigation, including those which 
were CGRP-negative.  Previous electrophysiological studies on rat and mice DRG 
neuronal cells have demonstrated that the presence of IL-6 resulted in the 
potentiation of heat-evoked and CAPS-evoked inward currents and led to a shift in 
activation thresholds towards lower temperatures (Obreja et al., 2005, Andratsch et 
al., 2009).  Therefore, to our knowledge, ours is the first electrophysiological study to 
investigate the effect of IL-6 on CAPS-evoked responses within the rat TG.  
Our study on the effect of IL-6 on CAPS-evoked CGRP release, showed that 
treatment of neuronal cells with CAPS alone resulted in a significant increase in 
CGRP release above basal levels.  However, CAPS-evoked CGRP release was not 
significantly altered in the presence of IL-6±IL-6Rα or following the inclusion of 
Rottlerin (Figure 5-2, C, D).   IL-6 has been shown previously to augment CAPS-
evoked CGRP release in vitro in rat DRG (Vardanyan et al., 2010).  One hypothesis 
from our findings is that IL-6 may be activating alternative signalling pathways within 
the trigeminal nervous system.  However, a further possibility to explain the 
contrasting results could be that in the study on rat DRG, the neuronal cells were 
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cultured for 4 days as opposed to <24 hours in our study.  This may have led to an 
alteration in neuronal phenotype and possibly an up-regulation of TRPV1 expression 
due to the presence of growth factors within the media (Bonnington and 
McNaughton, 2003b) resulting in enhanced CGRP-release.  Of interest to our study 
was their finding that the enhanced release of CGRP by IL-6 did not require the 
presence of the soluble IL-6Rα (Vardanyan et al., 2010).  This is in line with the 
results from our in vitro experiments and would suggest that the soluble receptor was 
already present under our experimental conditions.  This could possibly be due to 
shedding of the soluble IL-6Rα from satellite glial cells present in the culture (Dubovy 
et al., 2010).  Interestingly, a previous in vitro study in mice DRG investigating the 
effect of IL-6 on CAPS-evoked inward current, also found that the soluble IL-6Rα was 
not required for the sensitisation of TRPV1 to occur.   This is in contrast however, to 
other behavioural and in vitro studies in rat, again using different methodologies to 
those performed here, which have shown that the presence of the soluble IL-6Rα 
was required for the TRPV1 sensitisation effects of IL-6 to occur (Oprée and Kress, 
2000, Obreja et al., 2005).  However, somewhat surprisingly, one study showed that 
IL-6Rα alone significantly augmented heat-induced CGRP release to the same level 
as when IL-6 was included in the treatment (Obreja et al., 2002).  As mentioned 
previously, to our knowledge, ours is the first in vitro study to investigate the effect of 
IL-6 on CAPS-evoked CGRP release on rat TG neurons.  Clearly more studies need 
to be undertaken to elucidate the underlying mechanisms by which IL-6 influences 
neuronal cells both within the somatosensory system and within the trigeminal 
nervous system.  Taken together with previous data, our results suggest an 
hypothesis, that the effects of inflammatory mediators may differ between the TG and 
DRG.  
 165 
Indeed, the results from our electrophysiological experiments go some way towards 
supporting this hypothesis.  As a measure of control, cell size areas were calculated 
from membrane capacitance values and confirmed the findings of our in vivo TRPV1 
expression data, in that those cells responding to CAPS, and presumably expressing 
TRPV1, were limited to the small to medium cell size ranges (see Chapter 3).  
Furthermore, when analysing mean cell size areas, we found that non-responding 
cells were significantly larger.  Although we were unable to show any significant 
effect of IL-6 on CAPS-evoked tachyphylaxis, our results do suggest a trend towards 
unusual tachyphylaxis in the presence of IL-6.   We have further examined the effect 
of IL-6 on CAPS-evoked current kinetics.  Interestingly, we found that in the presence 
of IL-6, CAPS-evoked inward current was significantly prolonged.  Whilst previous 
electrophysiological studies on somatosensory neurons have shown transient 
potentiation of CAPS-evoked currents (Obreja et al., 2005, Andratsch et al., 2009), 
our data appear to suggest that within the trigeminal nervous system, IL-6 leads to 
sensitisation of TRPV1 in a manner that alters the gating properties of this 
transducer, prolonging the opening time of the channel.  These results give weight to 
our hypothesis that the effects of IL-6 may differ between the somatosensory and 
trigeminal nervous systems.  Indeed, in their behavioural studies, Cuellar and 
colleagues (2010) found that trigeminal thermonociceptors were distinct from somatic 
thermonociceptors both in their conduction velocities and thresholds.   
There is now a consensus regarding the central role of TRPV1 in mediating thermal 
hyperalgesia (Rueff and Mendell, 1996, Bennett et al., 1998(a), Caterina et al., 2000, 
Shu and Mendell, 2001, Bonnington and McNaughton, 2003b, Lewin et al., 2004, 
Woodbury et al., 2004, Pogatzki-Zahn et al., 2005, Zhang et al., 2005, Yu et al., 
2008, Walder et al., 2012, Barcena de Arellano et al., 2013).  With this in mind, our 
data would suggest that IL-6 may be influencing TRPV1+ TG neuronal cells via 
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alternative signalling pathways to the JAK/STAT pathway such as the MAPK/ERK1/2 
or PI3K/Akt pathways.  The outcome of which is the sensitisation of TRPV1, 
enhancing the ability of TG neurons to respond to thermal stimuli.  Indeed, an 
increase in thermal sensitivity has been shown in patients with pulpitis and oral 
cancer (Hahn et al., 1993, Khabbaz et al., 2000, Nagamine et al., 2006).  
Furthermore, an upregulation in the expression of TRPV1 has been demonstrated 
during pulpitis, which would have the effect of exacerbating thermal hyperalgesia 
(Chung et al., 2011).  In addition, the potentiation of TRPV1 activation by IL-6 which 
we have demonstrated, may contribute to central sensitisation and the development 
of allodynia. 
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6. Discussion 
The question of how the sensory nervous system interprets the constant barrage of 
diverse stimuli into clear and discriminatory percepts, has long captivated the interest 
of many scientific disciplines (Romo and de Lafuente, 2013).  In an attempt to help 
clarify this question, two main theories have been proposed.  The specificity theory, 
originating from studies by German neurophysiologists in the 19th century, suggests 
that a percept is generated by the activation of specific neuronal pathways, with each 
sensory modality being processed along fixed specific labelled lines from the 
periphery to the brain (see Belmonte and Viana, 2008, Ma, 2010).  The pattern 
theory, as exemplified in the gate control theory of pain (Melzack and Wall, 1962, 
1965), advocates against specific labelled lines, and in contrast suggests that the 
ultimate percept results from modulation within the brain of input from a variety of 
afferent neurons which respond to a multitude of different stimuli (see Ma, 2010).  
In an attempt to specify a line-labelled system in primary afferent neurons, it has 
been the tradition in the field of sensory neurobiology, to classify sensory neurons 
into functional sub-populations using certain neurochemical, physiological and 
phenotypic characteristics (see Priestley, 2009).  More recently, molecular and 
transgenic studies have aided in the process of classifying sensory neurons into 
functionally distinct sub-populations.  However, it is now recognised that the use of 
these classifications as a way of conferring modality specificity is an 
oversimplification and that the classification of sensory neurons is far more complex 
than previously thought.  Evidence now suggests that a specific repertoire of 
characteristics and receptor expression patterns, may be a more accurate method of 
describing modality specificity and to predicting expected percepts following 
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activation of sensory neurons.  Indeed, considering the labile nature of the sensory 
nervous system, and the formation of transduction complexes which confer 
considerable plasticity to the sensory neuron (see Frings, 2009), one may question 
the motivation behind attempting to classify sensory neurons to a specific modality.   
Furthermore, large variations between species have been observed in many of the 
characteristics used to define sensory neuron modality (see Ringkamp and Meyer, 
2009).  This may have a bigger impact on our understanding of pain mechanisms, 
since the majority of our knowledge has been derived from studies on the spinal 
sensory system in rat models.  However, an increasing number of studies are using 
transgenic mice models to investigate mRNA or genes related to pain mechanisms.  
This will obviously have implications as to the applicability of findings from these 
studies to those of previous and current studies in rat models.  In addition, it has 
recently been hypothesised that neuronal phenotype and modality may be regulated 
by the type of tissue being targeted, an hypothesis supported by studies which have 
observed phenotypic differences in sensory neurons depending on their target 
innervation (see Frings, 2009, Kiasalari et al., 2010, Hargreaves, 2011). 
However, notwithstanding these considerations, and in an attempt to expand the 
knowledge-base on sensory neurons within the rat trigeminal nervous system, we 
have carried out an in-depth in vivo study investigating neurochemical populations 
and cell size distributions of sensory neurons within the TG and compared our 
findings to those within the DRG.  In addition, we have carried out a detailed in vivo 
analysis of expression patterns for receptor components of three important 
inflammatory mediators, NGF, TNFα and IL-6, along with the thermo-transducers 
TRPV1 and TRPM8.  Here again, we have compared our findings from the TG to 
those from the DRG.  Furthermore, we have performed several in vitro studies to 
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investigate the functional implications of IL-6-receptor-activated signalling in TG 
neuronal cells and the possible sensitisation of TRPV1 in these cells. 
6.1. Defining neurochemical properties and functions of TG 
neurons 
The neurofilament NF200 has traditionally been used to define a population of 
neurons which conduct in the Aα/β fibre range, have large cell bodies and function as 
non-nociceptors (Michael and Priestley, 1999).  The results from our study on NF200 
expression within the DRG concur with these accepted classifications.  However, our 
results from the TG have questioned the applicability of these classifications to the 
trigeminal nervous system.  Within the TG we have observed a significantly larger 
population of NF200+ neurons, and most interestingly, these neurons are enriched in 
the medium cell size range.  The conclusions we can draw from these results are that 
within the TG, the majority of NF200+ neurons conduct in the Aδ fibre range and 
therefore, have a higher probability of functioning as nociceptors.   
By way of explanation, we know that the tooth pulp is richly innervated in 
unmyelinated nerve fibres, and that pain is the predominant sensation evoked by 
pulpal stimuli (Brashear, 1935, Anderson et al., 1970, Mumford and Bowsher, 1976, 
Johnsen and Johns, 1978, McGrath et al., 1983, Sessle, 1986, Narhi et al., 1994, 
Nair, 1995, Orchardson and Cadden, 2001, Narhi, 2005).  Thus, tooth pulp was 
thought to be innervated by C fibre nociceptors.  However, increasing evidence is 
suggesting that pulpal afferents originate from myelinated parent axons which taper 
and lose their myelination as they enter the pulp (Orchardson and Cadden, 2001).  
This hypothesis is supported by several in vivo and in vitro studies which have shown 
pulpal afferents to have larger cells bodies than expected and which are within the 
medium cell size range, that the parent axons are thinly myelinated Aδ fibres, and 
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that the conduction velocity of pulpal neurons increases as they leave the pulp and 
enter the alveolar nerve (Sugimoto et al., 1988, Hildebrand et al., 1995, Lazarov, 
2002, Ichikawa et al., 2006, Paik et al., 2009, Fried et al., 2011).  Taken together with 
our results, we have described a novel population of NF200 expressing, Aδ fibre, 
possibly nociceptive neurons which are enriched within the TG.  A proportion of this 
population may be those neurons with tapering axons and which are functionally 
adapted to the innervation of tooth pulp.  In addition, this enriched population of TG 
neurons which display an unusual phenotype, may contribute to the distinct response 
patterns to tissue injury observed within the trigeminal nervous system (see 
Hargreaves, 2011).  
The impact of these findings is even greater when considering our in vitro studies.  
We have shown that IL-6 is preferentially activating TG neuronal cells within the 
NF200+ population.    In addition, we have shown a significantly larger population of 
NF200+ neurons in the TG compared to the DRG.  Since IL-6 is now thought to have 
a crucial role in the development of mechanical hyperalgesia (Arruda et al., 1998, 
Anderson and Rao, 2001, Verri et al., 2006b, Manjavachi et al., 2010), and that 
NF200+ neurons are generally thought to be mechanoreceptors (see McMahon and 
Priestley, 2005), these findings may in some way explain the prevalence of 
mechanical hyperalgesia and allodynia occurring in many orofacial pain conditions 
such as temporomandibular disorders (Anderson and Rao, 2001, Sessle, 2005, 
Takeda et al., 2005(a), Takeda et al., 2006, Morgan and Gebhart, 2008, Takeda et 
al., 2008(a), Takeda et al., 2008(b), Takeda et al., 2008(c), Saloman et al., 2013).   
Another distinctive feature we have identified within the TG, is the unusual lack of co-
expression of CGRP and TrkA.  Within the DRG, TrkA and CGRP are almost 
exclusively co-expressed (Averill et al., 1995, McMahon, 1996).  Furthermore, 
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activation of TrkA by NGF is known to regulate the expression of neuropeptides 
(Pezet and McMahon, 2006).  We have observed within the TG, that <50% of TrkA 
expressing neurons co-expressed CGRP and conversely, around 40% of CGRP+ 
neurons were TrkA-negative.  These findings suggest that the pro-inflammatory 
effects following injury-induced upregulation of NGF and subsequent release of 
CGRP, would be significantly reduced within the trigeminal nervous system.   
In addition, our observations would suggest that within the trigeminal nervous 
system, since we have shown that around half of the neurons expressing TrkA were 
CGRP-negative, that these neurons may be expressing other neuropeptides such as 
substance P (SP), somatostatin, vasoactive intestinal polypeptide and galanin (see 
Priestley, 2009).  Possibly, these neuropeptides have a more important role during 
inflammatory conditions within the trigeminal nervous system than they do in the 
somatosensory system.  Indeed, it has been shown that inflammation within the 
temporomandibular joint potentiates the excitability of Aβ-fibre neurons and that the 
resulting allodynia is dependent on the release of SP by TG neurons (Takeda et al., 
2005(a), Takeda et al., 2005(b)).  Furthermore, activation of TG nociceptors and 
subsequent release of SP within the VBSNC, has been shown to produce sustained 
excitation of VBSNC nociceptor terminals (see Sessle, 2000).  This may possibly be 
a result of SP-induced glial cell activation within the VBSNC, which has been 
demonstrated to facilitate neuronal plasticity (Guo et al., 2007).  Further studies 
investigating co-expression of neurotrophin receptors and neuropeptides such as SP 
within the trigeminal nervous system, may help to elucidate the neuromodulatory role 
these molecules have in mediating persistent pain. 
Furthermore, the lack of TrkA expression in a substantial proportion of CGRP+ 
neurons in the TG, seems to suggest that the expression of neuropeptides may be 
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regulated by a neurotrophin other than NGF in these neurons.  One possible 
candidate would be the regulation of neuropeptide expression by GDNF.  The 
findings from a previous in vivo study on rat molar pulp would support this proposal 
since the majority of pulpal TrkA+ neurons co-expressed GFRα1 (Yang et al., 2006).  
Within the somatosensory system the populations of nociceptors which respond to 
NGF and GDNF (TrkA+ and GFRα1/Ret+ respectively) are thought to be distinct 
populations with different functional properties (Priestley et al., 2002).  Our results 
would suggest that within the trigeminal nervous system, these distinctions are less 
clear-cut, the functional consequences of which will require further investigation. 
This lack of distinction in functional properties between peptidergic and non-
peptidergic nociceptors within the TG, may have wider impact on the sensitisation of 
nociceptors within the trigeminal nervous system.  Both NGF and GDNF have been 
shown to sensitise and increase expression of TRPV1 (see Priestley et al., 2002, 
Priestley, 2009).  In addition, CAPS-evoked responses in IB4+, presumably GDNF 
responsive neurons, are significantly larger, suggesting that TRPV1 has distinct 
functional properties within the IB4+ and IB4- populations of nociceptors in DRG 
(Priestley et al., 2002).  Therefore, if IB4+ and IB4- populations are less clearly 
defined within the TG, it would follow that the distinct functional properties of TRPV1 
between neuronal populations observed in the DRG, would also be less clearly 
defined within the trigeminal nervous system.   
These differences may have functional implications and lead to unusual response 
mechanisms following activation of these neurons by inflammatory mediators within 
the trigeminal nervous system.  Indeed, since we have shown that within the TG a 
large proportion of neurons express p55 and all neurons express gp130, the 
downstream sensitisation of TRPV1 by TNFα and IL-6 might result in atypical 
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responses and pain perception.  Furthermore, activation of TRPV1 has been shown 
to result in the increased release of both TNFα and IL-6 (Sooampon et al., 2013, 
Yang et al., 2013).   
These findings pose an interesting scenario.  TRPV1 has recently been shown to be 
intrinsically heat sensitive (Cao et al., 2013), and is known to play a major role in the 
mediation of thermal hyperalgesia (Caterina et al., 2000, Bonnington and 
McNaughton, 2003b).  Furthermore, the oral cavity is frequently exposed to a 
barrage of thermal stressors recently shown to activate TRPV1 (Sooampon et al., 
2013).  We could hypothesise therefore, that within the oral cavity there is an on-
going thermally-induced activation of TRPV1 leading to an increase in the release of 
potent pro-inflammatory mediators, which in turn, further sensitise TRPV1, possibly 
via atypical mechanisms.  Hence, thermal hyperalgesia within the oral cavity would 
be potentiated, possibly explaining the increase in thermal sensitivity in patients with 
conditions such as pulpitis and oral cancer (Hahn et al., 1993, Khabbaz et al., 2000, 
Nagamine et al., 2006).   
The concept of unusual TRPV1 response mechanisms occurring within the trigeminal 
nervous system, is supported by our in vitro investigations on IL-6 mediated TRPV1 
sensitisation within TG neuronal cells.  We observed significant effects mediated by 
IL-6 on CAPS-evoked current kinetics.  Previous studies on somatosensory neurons 
observed a transient potentiation of CAPS-evoked currents in DRG cells when in the 
presence of IL-6 (Obreja et al., 2005, Andratsch et al., 2009).  However, we found 
CAPS-evoked currents to be significantly prolonged, suggesting IL-6 sensitises 
TRPV1 in a manner that effects the gating properties and kinetics of this thermo-
transducer within the trigeminal nervous system. 
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Taken together, our findings give weight to the recently emerging hypothesis of 
peripheral regulation of neuronal phenotype (see Hargreaves, 2011), since we have 
shown several significant differences in neuronal phenotype and function between 
the TG and DRG in a manner that may reflect the unique areas of innervation found 
within the orofacial region.  The information obtained from our present study, may 
help to further elucidate the peripheral mechanisms of sensory integration and 
interpretation within the trigeminal nervous system and may help in the long-term 
development of more targeted and effective therapeutics for managing orofacial pain.   
6.2. Future research plans 
6.2.1. Characterisation of changes in neurochemical phenotype 
and nociceptive marker expression in a model of chronic 
orofacial hyperalgesia 
Several animal models are now available for use in research studies investigating 
orofacial pain mechanisms.  One frequently used orofacial neuropathic pain model is 
that of chronic constriction injury (CCI) to the infraorbital nerve.  This involves tying a 
single or double ligature of chromic gut loosely around the superior branches of the 
infraorbital nerve, a procedure which mimics that of CCI to the sciatic nerve for 
somatosensory studies (Anderson and Rao, 2001, Shubayev and Myers, 2001, 
Latremoliere et al., 2008).  A model of injury to the dentin and pulp cavity allows for 
the investigation of response mechanisms in a specific subpopulation of trigeminal 
sensory neurons (Wheeler et al., 1998, Yang et al., 2006).  Several inflammatory 
orofacial pain models have been developed which involve the injection of various 
agents to induce an inflammatory response such as formalin (Lu et al., 2009), 
turpentine oil (Neubert et al., 2000) and IL-6 (Yan et al., 2012).  However, the 
majority of studies investigating chronic inflammatory mechanisms use complete 
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Freund’s adjuvant (CFA) as a vehicle for inducing chronic inflammatory hyperalgesia.  
For example, CFA can be injected into the TMJ space (Takeda et al., 2006, Wang et 
al., 2009), facial skin (Takeda et al., 2008(b)) or right upper lip/whisker pad (Morgan 
and Gebhart, 2008) depending on the orofacial pain condition being studied. Since 
we wish to investigate the response mechanisms of trigeminal neurons to chronic 
inflammation, we have decided upon the latter model of CFA-induced chronic 
orofacial hyperalgesia. 
All experiments would be carried out on adult male Sprague Dawley rats.  Following 
sedation, rats would receive an injection of CFA or saline into the right upper 
lip/whisker pad, lateral to the nostrils (Morgan and Gebhart, 2008) or into the right 
hind paws (Amaya et al., 2003).  Twenty-four hours, 72 hours, 1 week and 2 weeks 
following treatment, 8 animals would be killed and transcardially perfused and fixed.  
TG and DRG would be rapidly dissected and prepared for cryosectioning.  Indirect 
dual immunofluorescence to be carried out to investigate changes in expression and 
binding patterns of neurochemical markers NF200, CGRP and IB4 in TG and DRG in 
both CFA treated and sham treated animals.  For the TG, expression data would be 
collected from each of the somatotopic areas within the TG corresponding to the 
ophthalmic, maxillary and mandibular branches of the trigeminal nerve.  Following 
this, indirect dual or triple immunofluorescence would be used to determine changes 
in expression and co-expression levels of TrkA, p55, TRPV1 and TRPM8 within 
neurochemically defined neuronal subpopulations of TG and DRG in both CFA 
treated and sham treated animals.  Data analysis would be performed to investigate 
whether chronic hyperalgesia alters neurochemical phenotype and/or increases or 
decreases expression levels of nociceptive markers.  Comparisons in the responses 
to CFA would be made between TG and DRG to determine whether sensory neurons 
within the orofacial region respond differently to those of somatosensory neurons.  
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The findings from previous studies would suggest increases in expression of TrkA, 
p55 and TRPV1 may be observed following inflammation.  Of particular interest to us 
in relation to the findings from our current study, is a significant increase observed in 
TRPV1 expression within the NF200+ subpopulation of DRG neurons following 
inflammation (Wheeler et al., 1998, Amaya et al., 2003, Sakuma et al., 2007). 
6.2.2. The role of neurotrophins NGF and GDNF in regulating 
neuropeptide expression within the trigeminal and 
somatosensory nervous systems  
We have shown a lack of correlation in the co-expression of TrkA and CGRP in TG 
neurons.  In order to investigate this further, we would carry out indirect dual 
immunofluorescence on adult male Sprague Dawley rats to analyse expression of 
the GDNF receptor components GFRα1/2 and Ret along with neuropeptides CGRP 
and SP within neurochemically defined subpopulations of both TG and DRG.  
Analysis would be undertaken in the naïve state and following induction of chronic 
hyperalgesia using CFA as described earlier.  
To further analyse the regulation of neuropeptide expression within TG and DRG, 
primary cell culture of TG and DRG neuronal cells would be carried.  Cells would be 
immunolabelled and sorted by fluorescence-activated cell sorting (FACS) into 
neurochemically defined subpopulations of NF200+, CGRP+ and IB4+ cells.  
Following this, cells would be treated with NGF or GDNF for 18 h, 1 day and 2 days 
post-plating.  Analysis of neuropeptide synthesis would be investigated using RT-
PCR to determine the regulatory effects of these neurotrophins on expression of 
CGRP and/or SP mRNA in TG and DRG neuronal cells.  In addition, we could 
determine differential regulatory effects within each neurochemically defined 
subpopulation of neuronal cells. 
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In addition, NGF and GDNF have previously been shown to differentially regulate 
TRPV1 within TrkA+ and IB4+ subpopulations of DRG neuronal cells (Amaya et al., 
2004).  We would extend this to the TG using FACS to sort primary cell cultures of 
TG and DRG neuronal cells into TrkA+, IB4+ and NF200+ populations.  Following 
treatment of cells with NGF or GDNF, immunocytochemistry would be carried out to 
investigate whether exposure of neuronal cells to neurotrophins, changes the 
expression of TRPV1 preferentially within a particular subpopulation.  Amaya et al. 
(2004) showed in DRG an upregulation in expression of TRPV1 by NGF in TrkA+ 
cells and by GDNF in IB4+ cells.  However, since we have shown a lack of 
correlation of TrkA and neuropeptide expression in the TG, we could hypothesise 
that the effects of NGF and GDNF may be less clear cut within the trigeminal nervous 
system.   
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